UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 10-K


ANNUAL REPORT PURSUANT TO SECTION

pursuant to Section 13 OR 15(D) OFor 15(d)

of the Securities Exchange Act of 1934

FOR THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended JuneFISCAL YEAR ENDED JUNE 30, 20022005

000-15701

(Commission file number 0-15701number)


NATURAL ALTERNATIVES INTERNATIONAL, INC.

(Exact name of registrant as specified in its charter)


Delaware 
84-1007839
(State or other jurisdiction of incorporation)
incorporation or organization)
 
(I.R.S.IRS Employer Identification No.)

1185 Linda Vista Drive

San Marcos, California 9206992078

 
(760) 744-7340
(Address of principal executive offices,offices)
including zip code)
 
(Registrant’s telephone number,number)
including area code)

Securities registered pursuant to Section 12(b) of the Act:

Common Stock—$.01 par valueNone

Securities registered pursuant to Section 12(g) of the Act:

NoneCommon Stock, $0.01 par value per share


Indicate by check mark whether the RegistrantNatural Alternatives International, Inc. (NAI) (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrantNAI was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes    x  NoYes    ¨
  No

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of the Registrant’sNAI’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.  ¨

Indicate by check mark whether NAI is an accelerated filer (as defined in Rule 12b-2 of the Act).    ¨  Yes    x  No

Indicate by check mark whether NAI is a shell company (as defined in Rule 12b-2 of the Exchange Act.):    Yes  ¨    No  x

The aggregate market value of the votingNAI’s common stock held by non-affiliates (assuming for this purpose that all officers and directors, and affiliates of officers and directors, are affiliates)NAI as of the Registrant, aslast business day of September 4, 2002NAI’s most recently completed second fiscal quarter (December 31, 2004) was approximately $15.5 million based$41,243,757 (based on the closing sale price asof $9.23 reported for such date by NASDAQ.

AtNasdaq on December 31, 2004). For this purpose, all of NAI’s officers and directors and their affiliates were assumed to be affiliates of NAI.

As of September 4, 2002, the Registrant had 5,855,426 outstanding8, 2005, 6,032,367 shares of NAI’s common stock $.01 par value,were outstanding, net of 272,40061,000 treasury shares.

DOCUMENTS INCORPORATED BY REFERENCE

Registrant’s Proxy Statement

Part III (Items 10, 11, 12, 13 and 14) of this Form 10-K incorporates by reference portions of NAI’s definitive proxy statement for the 2003its Annual Meeting of Stockholders to be held December 2, 2005, to be filed within 120 days from June 30, 2002, ison or before October 28, 2005.



TABLE OF CONTENTS

Page

SPECIAL NOTE ABOUT FORWARD-LOOKING STATEMENTS

1

PART I

Item 1.Business2
Item 2.Properties8
Item 3.Legal Proceedings9
Item 4.Submission of Matters to a Vote of Security Holders9

PART II

Item 5.Market for Our Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities10
Item 6.Selected Financial Data10
Item 7.Management’s Discussion and Analysis of Financial Condition and Results of Operation13
Item 7A.Quantitative and Qualitative Disclosures About Market Risk27
Item 8.Financial Statements and Supplementary Data28
Item 9.Changes in and Disagreements with Accountants on Accounting and Financial Disclosure46
Item 9A.Controls and Procedures46
Item 9B.Other Information46

PART III

Item 10.Directors and Executive Officers47
Item 11.Executive Compensation47
Item 12.Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters47
Item 13.Certain Relationships and Related Transactions47
Item 14.Principal Accounting Fees and Services47

PART IV

Item 15.Exhibits and Financial Statement Schedules48

SIGNATURES

52

(i)


SPECIAL NOTE ABOUT FORWARD-LOOKING STATEMENTS

Certain statements in this report, including information incorporated by reference, are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect current views about future events and financial performance based on certain assumptions. They include opinions, forecasts, intentions, plans, goals, projections, guidance, expectations, beliefs or other statements that are not statements of historical fact. Words such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “believes,” “anticipates,” “intends,” “estimates,” “approximates,” “predicts,” or “projects,” or the negative or other variation of such words, and similar expressions may identify a statement as a forward-looking statement. Any statements that refer to projections of our future financial performance, our anticipated growth and trends in Part III, Items 10, 11, 12our business, our goals, strategies, focus and 13.plans, and other characterizations of future events or circumstances, including statements expressing general optimism about future operating results, are forward-looking statements. Forward-looking statements in this report may include statements about:

future financial and operating results, including projections of net sales, revenue, income, net income per share, profit margins, expenditures, liquidity and other financial items;

inventories and the adequacy and intended use of our facilities;


the adequacy of reserves and allowances;

sources and availability of raw materials;

personnel;

operations outside the United States;

overall industry and market performance;

competition;

current and future economic and political conditions;

development of new products, brands and marketing strategies;

distribution channels and product sales and performance;

growth, expansion and acquisition strategies;

the outcome of regulatory, tax and litigation matters;

our ability to develop relationships with new customers and maintain or improve existing customer relationships;

the impact of accounting pronouncements;

management’s goals and plans for future operations; and

other assumptions described in this report underlying or relating to any forward-looking statements.

The forward-looking statements in this report speak only as of the date of this report and caution should be taken not to place undue reliance on any such forward-looking statements. Forward-looking statements are subject to certain events, risks, and uncertainties that may be outside of our control. When considering forward-looking statements, you should carefully review the risks, uncertainties and other cautionary statements in this report as they identify certain important factors that could cause actual results to differ materially from those expressed in or implied by the forward-looking statements. These factors include, among others, the risks described under Item 7 and elsewhere in this report, as well as in other reports and documents we file with the SEC.

PART I

ITEM 1. BUSINESS

Natural Alternatives International, Inc. and its subsidiaries (referred

Overview

Our vision is to collectively herein as “Natural Alternatives”, “NAI”, orenrich the “Company”) are engaged inworld through the formulation, manufacturing and packagingbest of encapsulated and compressed tablets and powder blended vitamins and related nutritional supplements including phytochemicals derived from botanicals and foods. The Company has for many years providednutrition.

As our primary business activity, we provide private label contract manufacturing services to various companies engaged in the marketingthat market and distribution ofdistribute vitamins, mineral supplements,minerals, herbs, and other nutritional supplements, as well as other health care products, to consumers both within and nutrition consumer products (“core business” or “core products”). The Company seeks to further its customers’ objectives by assisting them in expanding their market share through a variety of special marketing and research programs including customer-specific nutritional product formulation; clinical studies assessment; product development; assistance with international product registration; and packaging and delivery system design. Revenues are not specifically derived from these activities, but are a component ofoutside the sales price for the core products delivered to the customer. Marketing, research and other services are provided to the customer prior to manufacturing the products.

The Company’s strategy is to increase its revenues by capitalizing on key customer relationships through new product introductions, developing new customer relationships in its core business both internationally and domestically, expanding itsUnited States. Additionally, under our direct-to-consumer (“DTC”) marketing program, by increasing existing product lines, marketing through additional mediawe develop, manufacture and securing new highly targeted DTC brands. The Company also intends to strengthen its financial position by effectively managing its cost structure. The Company believes it can successfully implement its strategy by continuing to capitalize on its core product developmentmarket our own products and manufacturing strengths; its abilitywork with nationally recognized physicians to develop innovative science-based products; adherencebrand name products that reflect their individual approaches to stringent quality control and assurance standards; the utilization of fully integratedrestoring, maintaining or improving health.

Our U.S.-based manufacturing and distribution; and the leadership of an experienced management team.

The Company’s long-term growth strategiesfacilities are focused on geographic diversification through its European manufacturing facility and Asian sales presence, introduction of additional branded DTC product lines and development of strategic alliances with health companies focused on consumer sales.
RECENT MANAGEMENT CHANGES
In March 2002, Mark Zimmerman was appointed Interim Vice President of Manufacturing. In May 2002, Tim Belanger and John Reaves joined NAI as Senior Vice President of Sales & Marketing and Vice President of Finance, respectively. In August 2002, Mark Zimmerman was promoted to Vice President of Manufacturing and Randy Weaver was promoted to Executive Vice President and Chief Operating Officer.
PRODUCTS AND MANUFACTURING
The Company is engagedlocated in the research, design and manufacture of private label customized nutritional supplements for domestic and international personal care and health product companies engagedVista, California. These facilities were recertified in marketing and distribution in a variety of sales channels. The Company purchases raw materials in bulk from qualified vendors, and, after quality control testing and release, weighs and blends these materials and then either encapsulates them, processes the powder blends into jars, or compresses them into solid dosage forms of either chewable wafers or tablets. These materials are packagedJune 2005 by the Company and delivered to its customers.
The Therapeutic Goods Administration (“TGA”) of Australia has certified the Company’s operations. Theafter their audit of our Good Manufacturing Practices (“GMP”). TGA evaluates new therapeutic products, prepares standards, develops testing methods and conducts testing programs to ensure that products are of high in quality, safe and effective. The TGA also conducts a range of assessment and monitoring activities including audits of the manufacturing practices of companies who export and sell products to Australia. TGA certification also enables the Companyus to manufacture products for export into countries that have signed the Pharmaceutical Inspection Convention, which includesinclude most European countries as well as several Pacific Rim countries.
The United States Food TGA certifications are generally reviewed every eighteen months.

Our California facilities also have been awarded GMP registration annually by NSF International (NSF) through the NSF Dietary Supplements Certification Program since October 2002.

GMP requirements are regulatory standards and Drug Administration (“FDA”) has proposed detailed Good Manufacturing Practices (“GMP”)guidelines establishing necessary processes, procedures and documentation for nutritional supplements but has not yet adopted final regulations. The Company believes it complies with GMP as proposedmanufacturers in an effort to assure the products produced by that manufacturer have the FDA.

2
identity, strength, composition, quality and purity they are represented to possess.


INTERNATIONAL OPERATIONS

Natural Alternatives International Europe S.A. (“NAIE”)(NAIE), a wholly-ownedour wholly owned subsidiary existing under the laws of the Company,Switzerland, also operates a manufacturing, warehousing, packaging and distribution facility in Manno, Switzerland. In January 2004, NAIE obtained a pharmaceutical license to process pharmaceuticals for packaging, importation, export and sale within Switzerland whichand other countries from the Swissmedic Authority of Bern, Switzerland. We believe the license can help improve our ability to develop relationships with new customers. The license is adjacentvalid until January 2009.

In addition to our operations in the United States and Switzerland, we have a full-time representative in Japan who provides a range of services to our customers seeking to expand into the Japanese market and other markets in the Pacific Rim. These services include regulatory and marketing assistance along with guidance and support in adapting products to these markets.

Originally founded in 1980, Natural Alternatives International, Inc. reorganized as a Delaware corporation in 1989. Unless the context requires otherwise, all references in this report to the city“Company,” “NAI,” “we,” “our,” and “us” refer to Natural Alternatives International, Inc. and, as applicable, NAIE and our other wholly owned subsidiaries. Our principal executive offices are located at 1185 Linda Vista Drive, San Marcos, California, 92078.

Business Strategy

Our goals are to increase and diversify our net sales while improving our overall financial results. To achieve these goals, we intend to:

capitalize on the strength of Lugano.our existing customer relationships through new product introductions;

develop new customer relationships both within and outside the United States;

continue to develop new products, marketing strategies and brands within our direct-to-consumer marketing programs, which we believe could improve our operating margins over the long term due to generally higher gross margins than those derived from products sold to private label contract manufacturing customers;

improve brand awareness;

further diversify by entering new markets outside the United States and/or expanding our presence in existing markets;

strengthen our offering of customized services including product formulation, clinical studies, regulatory assistance and product registration;

evaluate acquisition opportunities; and

improve efficiencies and manage costs.

Overall, we believe there is an opportunity to enhance consumer confidence in the quality of our nutritional supplements and their adherence to label claims through the education provided by direct sales and direct-to-consumer marketing programs. We believe our GMP certified manufacturing operations, science based product formulation, clinical studies and regulatory expertise provide us with a sustainable competitive advantage by providing our customers with a high degree of confidence in our products.

We believe the lack of relevant and reliable consumer education about nutrition and nutritional supplementation combined with the duplication of brands and products in the retail sales channel create a significant opportunity for the direct sales marketing channel. The direct sales marketing channel has proved, and we believe will continue to prove, to be a highly effective method for marketing high quality nutritional supplements as associates or other personalities educate consumers on the benefits of science based nutritional supplements. We believe this education process can lead to premium product pricing and avoid competing with brands of inferior quality and lower pricing in other distribution channels. Our two largest customers operate in the direct sales marketing channel. Thus, our growth has been fueled by the effectiveness of this marketing channel.

We believe our comprehensive approach to customer service is unique within our industry. We believe this approach, together with our commitment to high quality, innovative products and the leadership of our experienced management team, will provide the means to implement our strategies and achieve our goals. There can be no assurance, however, that we will successfully implement any of our business strategies or that we will increase or diversify our net sales or improve our overall financial results.

Products, Principal Markets and Methods of Distribution

Our primary business activity is to provide private label contract manufacturing facility providesservices to companies that market and distribute vitamins, minerals, herbs, and other nutritional supplements, as well as other health care products, to consumers both within and outside the United States. Our private label contract manufacturing capabilitycustomers include companies that market nutritional supplements through direct sales marketing channels, direct response television and retail stores. We manufacture products in a variety of forms, including capsules, tablets, chewable wafers and powders to accommodate a variety of consumer preferences.

We provide strategic partnering services to our private label contract manufacturing customers, including the following:

customized product formulation;

clinical studies;

manufacturing;

marketing support;

international regulatory and label law compliance;

international product registration; and

package and labeling design.

Additionally, under our direct-to-consumer marketing program, we develop, manufacture and market our own products. Under the direct-to-consumer marketing program, we work with nationally recognized physicians to develop brand name products that reflect their individual approaches to restoring, maintaining or improving health. Direct-to-consumer marketing program products are sold through a variety of distribution channels including television programs, print media and the internet.

We believe the direct-to-consumer marketing program can be an effective method for encapsulation and tableting, finished goods packaging,marketing our high quality control laboratory testing, warehousing, distribution and administration. NAIE is operating undernutritional supplements. In March 2000, we launched Dr. Cherry’s Pathway to HealingTM product line. As of June 30, 2005, the product line included nineteen condition specific, custom formulated products. The products are primarily marketed through a five-year Swiss federal and local income tax holiday ending in fiscal 2005.

weekly television program.

For the last three fiscal years, ended June 30, 2002, 2001 and 2000, the percentage of the Company’s net sales from our private label contract manufacturing and direct-to-consumer marketing program were as follows (dollars in thousands):

   Fiscal
2005


  Fiscal
2004


  Fiscal
2003


Private Label Contract Manufacturing

  $83,382  $68,493  $45,768

Direct-to-Consumer Marketing Program

   8,110   10,041   10,194
   

  

  

Total Net Sales

  $91,492  $78,534  $55,962
   

  

  

Research and Development

We are committed to customers in international markets was approximately 31%, 29% and 32%, respectively. Approximately 16%, 18% and 8% of the Company’s net sales for the same fiscal years, respectively, were manufactured by NAIE for customers with sales in the European marketplace.

RESEARCH AND DEVELOPMENT
The primary emphasis of the Company’squality research and development activities isdevelopment. We focus on the development of new science based products and enhancementthe improvement of existing products. In addition, the Company continuously produces pilot or sample runs of product formulation prototypesWe periodically test and validate our products to help ensure their stability, and/orpotency, efficacy and to determine ingredient interaction and prospective customer acceptance of the final product. The Company maintainssafety. We maintain quality control procedures to verify that allour products comply with establishedapplicable specifications and standards in compliance with both United States Pharmacopoeia and Good Manufacturing Practices promulgatedestablished by the Food and Drug Administration. The CompanyAdministration and other regulatory agencies. We also directsdirect and participatesparticipate in clinical research studies, for measuringoften in collaboration with scientists and research institutions, to validate the efficacybenefits of certain products and/or formulations. These studies are conducted to establish consumer benefitsa product and provide scientific efficacy supporting bothsupport for product claims and marketing initiatives. The Company often collaboratesWe believe our research and development team of experienced personnel, as well as our facilities and strategic alliances with scientistsour suppliers and institutions,customers, allow us to effectively identify, develop and market high-quality and innovative products.

As part of the study resultsservices we provide to our private label contract manufacturing customers, we may perform, but are generally presented at various scientific meetingsnot required to perform, certain research and symposia,development activities related to the development or improvement of their products. While our customers typically do not pay directly for this service, the cost of this service is included as a component of the price we charge to manufacture and generally also published in peer reviewed scientific journals.deliver their products. Research and development costs, which include costs associated with international regulatory compliance services we provide to our customers, are expensed when incurredas incurred.

Our research and were $821,000, $718,000 and $774,000development expenses for the last three fiscal years ended June 30 2002, 2001were $3.5 million for 2005, $2.8 million for 2004 and 2000, respectively.

$1.7 million for 2003.

SOURCES AND AVAILABILITY OF RAW MATERIALS

Sources and Availability of Raw Materials

We use raw materials used in the Company’s products consist of nutrientour operations including powders, excipients, empty gelatin capsules, and necessary components for packaging and distribution ofdistributing our finished vitamin and nutritional supplement products. The nutrient powders and the empty gelatin capsules are purchased from manufacturers in the United States and foreign countries. To date, the Company has not experienced any difficulty in obtaining adequate sources of supply. Although there can be no assurance the Company will continue to be able to obtain adequate sources of theseWe typically buy raw materials in bulk from a limited number of qualified vendors located both within and outside the future,United States. During fiscal 2005, Carrington Laboratories Incorporated was our largest supplier, accounting for 35% of our total raw material purchases.

We test the Company believes it will be ableraw materials we buy to do so.

MAJOR CUSTOMERS
NSA International, Inc. (“NSA”)ensure their quality, purity and Mannatech Incorporated (“Mannatech”) comprised 69% of the Company’s net sales forpotency before we use them in our products. During the fiscal year ended June 30, 2002. No other customers comprised 10%2005, we did not experience any significant shortages or moredifficulties obtaining adequate supplies of raw materials and we do not anticipate any significant shortages or difficulties in the Company’s net sales fornear term.

Major Customers

NSA International, Inc. has been our largest customer over the past several years. During the fiscal year ended June 30, 2002. For2005, NSA International, Inc. accounted for approximately 40% of our net sales. Our second largest customer was Mannatech, Incorporated, which accounted for approximately 39% of our net sales during fiscal 2005. Both NSA International, Inc. and Mannatech, Incorporated are private label contract manufacturing customers. No other customer accounted for 10% or more of our net sales during fiscal 2005. Our sales and marketing team is focused on obtaining new private label contract manufacturing customers and developing new direct-to-consumer marketing programs to reduce the year ended June 30, 2001,risks associated with deriving a significant portion of our net sales to NSA, Mannatechfrom a limited number of customers.

Competition

We compete with other manufacturers and Nikken USA, Ltd. (“Nikken”) comprised 72%distributors of vitamins, minerals, herbs, and other nutritional supplements both within and outside the Company’s net sales.

United States. The majority ofnutritional supplement industry is highly fragmented and competition for the Company’s existing customers are marketing organizations who distribute a varietysale of nutritional and health related products throughout the United States, Europe and the Pacific Rim.
The Company’s sales backlog was approximately $10.1 million and $10.7 million as of August 31, 2002 and 2001, respectively.

3


COMPETITION
The Company’ssupplements comes from many sources. These products are sold primarily through retailers (drug store chains, supermarkets, and mass market discount retailers), health and natural food stores, and direct sales channels (mail order, network marketing and e-marketing companies). The products we produce for our private label contract manufacturing customers may compete with our direct-to-consumer products, although we believe such competition is limited.

We believe competition in domesticour industry is based on, among other things, customized services offered, product quality and foreign markets in competitionsafety, innovation, price and customer service. We believe we compete favorably with other private labelcompanies because of our ability to provide comprehensive turn key solutions for customers, our certified manufacturing operations and marketing companies. our commitment to quality and safety through our research and development activities. Our future position in the industry will likely depend on, but not be limited to, the following:

the continued acceptance of our products by our customers and consumers;

our ability to continue to develop high quality, innovative products;

our ability to attract and retain qualified personnel;

the effect of any future governmental regulations on our products and business;

the results of, and publicity from, product safety and performance studies performed by governments and other research institutions;

the continued growth of the global nutrition industry; and

our ability to respond to changes within the industry and consumer demand, financially and otherwise.

The vitamin and nutritional supplement industry is highly competitive and we expect the level of competition continues to increase. The nutritional supplements category includes vitamins, minerals, herbs, botanicals, sports supplements, food supplements and homeopathic supplements. Competition forremain high over the sale of vitamins and supplements comes from many sources, including companies that sell supplements to supermarkets, large chain discount retailers, drug store chains and independent drug stores, health food stores, pharmaceutical companies and others who sell to wholesalers, as well as mail order vendors, eCommerce and network marketing companies. The Company doesnear term. We do not believe it is possible to accurately estimate the number or size of its many competitors sinceour competitors. The industry has undergone consolidation in the recent past and we expect that trend to continue in the near term.

Government Regulation

Our business is subject to varying degrees of regulation by a number of government authorities in the United States, including the United States Food and Drug Administration (FDA), the Federal Trade Commission (FTC), the Consumer Product Safety Commission, the United States Department of Agriculture, and the Environmental

Protection Agency. Various agencies of the states and localities in which we operate and in which our products are sold also regulate our business, such as the California Department of Health Services, Food and Drug Branch. The areas of our business that these and other authorities regulate include, among others:

product claims and advertising;

product labels;

product ingredients; and

how we manufacture, package, distribute, import, export, sell and store our products.

The FDA, in particular, regulates the formulation, manufacturing, packaging, storage, labeling, promotion, distribution and sale of vitamin and other nutritional supplements in the United States, while the FTC regulates marketing and advertising claims. The FDA issued a final rule called “Statements Made for Dietary Supplements Concerning the Effect of the Product on the Structure or Function of the Body,” which includes regulations requiring companies, their suppliers and manufacturers to meet GMP in the preparation, packaging, storage and shipment of their products. The FDA also published a Notice of Advance Rule Making for Good Manufacturing Practices that would require manufacturing of dietary supplements to follow GMP. While the final regulations are subject to revision, we are committed to meeting or exceeding the standards set by the FDA.

The FDA has also issued regulations governing the labeling and marketing of dietary supplements and nutritional products. They include:

the identification of dietary supplements or nutritional products and their nutrition and ingredient labeling;

requirements related to the wording used for claims about nutrients, health claims, and statements of nutritional support;

labeling requirements for dietary supplements or nutritional products for which “high potency” and “antioxidant” claims are made;

notification procedures for statements on dietary supplements or nutritional products; and

premarket notification procedures for new dietary ingredients in nutritional supplements.

The Dietary Supplement Health and Education Act of 1994 (DSHEA) revised the provisions of the Federal Food, Drug and Cosmetic Act concerning the composition and labeling of dietary supplements and defined dietary supplements to include vitamins, minerals, herbs, amino acids and other dietary substances used to supplement industrydiets. DSHEA generally provides a regulatory framework to help ensure safe, quality dietary supplements and the dissemination of accurate information about such products. The FDA is largely privately heldgenerally prohibited from regulating active ingredients in dietary supplements as drugs unless product claims, such as claims that a product may heal, mitigate, cure or prevent an illness, disease or malady, trigger drug status.

We are also subject to a variety of other regulations in the United States, including those relating to bioterrorism, taxes, labor and highly fragmented.

employment, import and export, the environment and intellectual property.

Our operations outside the United States are similarly regulated by various agencies and entities in the countries in which we operate and in which our products are sold. The Company believesregulations of these countries may conflict with those in the industryUnited States and may vary from country to country. The sale of our products in certain European countries is subject to the rules and regulations of the European Union, which may be interpreted differently among the countries within the Union. In markets outside the United States, we may be required to obtain approvals, licenses or certifications from a country’s ministry of health or comparable agency before we begin operations or the marketing of products in that country. Approvals or licenses may be conditioned on reformulation of our products for a particular market or may be unavailable for certain products or product ingredients. These regulations may limit our ability to enter certain markets outside the United States.

Intellectual Property

Trademarks. We have developed and use registered trademarks in our business, particularly relating to corporate and product names. We own 21 trademark registrations in the United States and have six trademark applications pending with the United States Patent and Trademark Office. Federal registration of a trademark enables the registered owner of the mark to bar the unauthorized use of the registered mark in connection with a similar product in the same channels of trade by any third party anywhere in the United States, regardless of whether the registered owner has ever used the trademark in the area where the unauthorized use occurs.

We have filed applications and own trademark registrations and intend to register additional trademarks in foreign countries where products are or may be sold in the future. We have one trademark application filed with the Japan Trademark Office.

We also claim ownership and protection of certain product names, unregistered trademarks and service marks under common law. Common law trademark rights do not provide the same level of protection afforded by registration of a trademark. In addition, common law trademark rights are limited to the geographic area in which the trademark is actually used. We believe these trademarks, whether registered or claimed under common law, constitute valuable assets, adding to our recognition and the marketing of our products and that these proprietary rights have been and will continue to undergo significant consolidationbe important in enabling us to compete.

Trade Secrets. We own certain intellectual property, including trade secrets that we seek to protect, in part, through confidentiality agreements with mergeremployees and acquisition activityother parties. Although we regard our proprietary technology, trade secrets, trademarks and similar intellectual property as critical to our success, we rely on a combination of trade secrets, contract, patent, copyright and trademark law to establish and protect our rights in our products and technology. In addition, the near-term. Most industry experts expect consolidation activitylaws of certain foreign countries may not protect our intellectual property rights to continuethe same extent as the laws of the United States.

Patents and Patent Licenses. We own certain United States patents. In addition, we have licensed exclusive worldwide rights to four certain United States patents, and each patent’s corresponding foreign patent application, and are currently involved in research and development of products employing the licensed inventions. These patents relate to the ingredient formerly known as “Oxford Factor”. We are currently selling this ingredient to a customer for use in a limited market under the name of Beta-AlanineTM.

Backlogs

Our backlog was approximately $16.0 million at September 2, 2005 and $15.8 million at September 2, 2004. Our sales are made primarily pursuant to standard purchase orders for the foreseeable futuredelivery of products. Quantities of our products to be delivered and delivery schedules are frequently revised to reflect changes in food and nutrition companies, multilevel marketing organizations and eCommerce internet firms.

The Company believes competition among manufacturers of vitamin and supplement products is based, among other things, on price, timely delivery, product quality, safety, availability, product innovation, marketing assistance and customer service. The competitive position of the Company will likely depend upon continued acceptance of its products, its ability to attract and retain qualified personnel, future governmental regulations affecting vitamins and nutritional supplements, and publication of vitamin product safety and efficacy studies by the government and authoritative health and medical authorities.
The Company’s operations are subjectour customers’ needs. Customer orders generally can be cancelled or rescheduled without significant penalty to the risks normally associated with manufacturing vitaminscustomer. For these reasons, our backlog as of any particular date is not representative of actual sales for any succeeding period, and nutritionaltherefore, we believe that backlog is not necessarily a good indicator of future revenue.

Working Capital Practices

We manufacture products including shortagefollowing receipt of certaincustomer specific purchase orders and as a result our inventory primarily consists of raw materials and damagework in process. Our raw material purchases are made primarily pursuant to property or injurystandard purchase orders for the delivery of raw materials based upon anticipated demand. Customer specific delivery requirements combined with raw material lead times impact the amount of inventory on hand at any given time. We typically purchase raw materials on 30-day payment terms. Discounts are taken periodically for early payment.

Sales are typically made based upon 30-day terms. A 2% discount is provided to persons.

customers that pay within 10 days of invoice date.

EMPLOYEESEmployees

As of June 30, 2002, the Company2005, we employed 208 full-time employees in the United States, 134six of whom held executive management positions. Of the remaining full-time employees, with six32 were employed in executive management positions, 18 in the area of research, laboratory and quality control, eight11 in sales and marketing, while the remaining employees are engagedand 159 in productionmanufacturing and administration. The Company uses in its normal course of operationsFrom time to time we use temporary personnel to help us meet short-term operating requirements primarilyrequirements. These positions typically are in manufacturing and manufacturing support. As of June 30, 2002, approximately 35 individuals were employed as2005, we had 50 temporary personnel.

As of June 30, 2002, the Company’s Swiss subsidiary2005, NAIE employed 2625 full-time employees and two temporary personnel in Switzerland.employees. Most of these employees were engagedpositions are in the areas of manufacturing and manufacturing support.

The Company has never experienced a work stoppage. None of its

Our employees are currentlynot represented by a union or any other form of collective bargaining unit. The Company believes its relationsagreement and we have not experienced any work stoppages as a result of labor disputes. We believe our relationship with itsour employees areis good.

GOVERNMENT REGULATIONSeasonality

The formulation,

We believe there is no material impact on our business or results of operations from seasonal factors.

Financial Information about Our Business Segment and Geographic Areas

Our business consists of one industry segment, the development, manufacturing, packaging, labeling, advertisingmarketing and distribution of the Company’snutritional supplements. Our products are subject to regulation by one or more federal agencies, includingsold both within the United States Food and Drug Administration (“FDA”), the Federal Trade Commission (“FTC”), the Consumer Product Safety Commission (“CPSC”),in markets outside the United States, Departmentincluding Europe, Australia and Japan. Our primary market outside the United States is Europe.

For the last three fiscal years, net sales by geographic region were as follows (dollars in thousands):

   Fiscal
2005


  Fiscal
2004


  Fiscal
2003


Net Sales

            

United States

  $67,784  $56,350  $41,838

Markets Outside the United States

   23,708   22,184   14,124
   

  

  

Total Net Sales

  $91,492  $78,534  $55,962
   

  

  

The allocation of Agriculture (“USDA”)net sales between the United States and markets outside the Environmental Protection Agency (“EPA”). The Company’s activities are also regulated by various agenciesUnited States is based on the location of the statescustomers. Products manufactured by NAIE accounted for 46% of net sales in markets outside the United States in fiscal 2005, 42% in fiscal 2004 and localities51% in fiscal 2003. No products manufactured by NAIE were sold in the United States during the last three fiscal years.

For additional financial information, including financial information about our business segment and geographic areas, please see the consolidated financial statements and accompanying notes to the consolidated financial statements included under Item 8 of this report.

As we continue to expand into markets outside the United States, we will become increasingly subject to political, economic and other risks in the countries in which the Company’s products are sold including without limitation the California Department of Health Services, Food and Drug branch. The FDA in particular regulates the advertising, labelingwhich we operate. For more information about these and sales of vitaminother risks, please see Items 7 and mineral supplements and may take regulatory action concerning medical claims, misleading or untruthful advertising, and product safety issues. These regulations include the FDA’s Good Manufacturing Practices (“GMP”) for foods. Detailed dietary supplement GMPs have been proposed but no regulations have been adopted. Additional dietary supplement regulations were adopted by the FDA pursuant to the implementation of the Dietary Supplement Health and Education Act of 1994 (“DSHEA”).

4


The Company may be subject, from time to time, to additional laws or regulations administered by the FDA or other Federal, state or foreign regulatory authorities, or to revised interpretations of current laws or regulations. The Company is unable to predict the nature of such future laws, regulations, interpretations or their application to the Company, nor can it predict what effect additional governmental regulations or administrative orders, when and if promulgated, would have on its business7A in the future. They could, however, by way of illustration and without limitation, require the Company to: reformulate certain products to meet new standards; recall or discontinue certain products not able to be reformulated; expand documentation of the properties of certain products; expand or provide different labeling and scientific substantiation; or, impose additional record keeping requirements. Any or all such requirements could have a material adverse effect on the Company’s results of operations and financial position.
this report.

ITEM 2. PROPERTIES

The Company’s U.S. corporate and manufacturing

This table summarizes our facilities consistas of approximately 123,000 square feet and are located in San Marcos and Vista, California. Of this space, the Company owns approximately 29,500 square feet and leases the remaining space. Approximately 68,000 square feet is used for production related activities, 35,000 square feet is used for warehousing, 5,000 square feet is used for laboratory and product development, and 15,000 square feet is used for offices.

The Company’s Swiss subsidiary leases approximately 22,000 square feet in Manno, Switzerland. The facilities are used primarily for the manufacturing, packaging and distribution of nutritional supplement products for the European marketplace.
The Company expects to renew its leases in the normal course of business. The Company is presently expanding its Swiss facilities. The Company believes that itsJune 30, 2005. We believe our facilities are adequate to meet itsour operating requirements for the foreseeable future.

Location


Nature of Use


Square
Feet


How Held


Lease Expiration
Date(2)


San Marcos, CA USACorporate headquarters49,000Owned/leased(4)Various(4)
Vista, CA USAManufacturing, warehousing, packaging and distribution(3)162,000LeasedMarch 2014
Manno, Switzerland(1)Manufacturing, warehousing, packaging and distribution38,000LeasedDecember 2015

(1)This facility is used by NAIE, our Swiss subsidiary.
(2)We expect to renew our leases in the normal course of business.
(3)We use approximately 93,000 square feet for production; 60,000 square feet for warehousing and 9,000 square feet for administrative functions.
(4)We own approximately 29,500 square feet and lease the remaining space with various expiration dates through 2007.

ITEM 3. LEGAL PROCEEDINGS

Over the past several years, the Company was a plaintiff in an anti-trust lawsuit against several manufacturers of vitamins and other raw materials purchased by the Company. Other similarly situated companies filed a number of similar lawsuits against some or all of the same manufacturers. The Company’s lawsuit was consolidated with some of the others and captionedIn re: Vitamin Antitrust Litigation. Settlement payments received by the Company of $3,410,000, $298,000 and $116,000 are included in proceeds fromVitamin Antitrust Litigation for fiscal 2002, 2001 and 2000, respectively, in the accompanying statements of operations. Subsequent

From time to June 30, 2002, the Company received a final settlement payment of $225,000 as all of its claims under theVitamin Antitrust Litigation were settled.

The Company was a party to a lawsuit filed in January 2000 against its former President, Director and Chief Financial Officer and others. In November 2001, the parties mutually resolved their disputes with each other, dismissed all pending claims against one another and entered into a confidential settlement agreement.
The Company istime, we become involved in various investigations, claims and legal actions arisingproceedings that arise in the ordinary course of our business. In the opinion of management, after consultation with its legal counsel, the ultimate dispositionThese matters may relate to product liability, employment, intellectual property, tax, regulation, contract or other matters. The resolution of these matters as they arise will be subject to various uncertainties and, even if such claims are without merit, could result in the expenditure of significant financial and managerial resources. While unfavorable outcomes are possible, based on available information, we generally do not havebelieve the resolution of these matters, including that discussed below, will result in a material adverse effect on the Company’sour business, consolidated financial position,condition, or results of operationsoperation. However, a settlement payment or liquidity.
unfavorable outcome could adversely impact our results of operation. Our evaluation of the likely impact of these actions, including that discussed below, could change in the future and we could have unfavorable outcomes that we do not expect.

On February 10, 2005, a complaint was filed against NAI on behalf of Novogen Research Pty. Ltd. in the United States District Court, Southern District of New York alleging a cause of action for patent infringement of a Novogen patent by products manufactured by NAI. The parties are attempting to resolve the matter in an out-of-court settlement but if we are unable to do so we intend to vigorously defend the action.

As of September 8, 2005, other than as set forth above, neither NAI nor its subsidiaries were a party to any material pending legal proceeding nor was any of their property the subject of any material pending legal proceeding.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

None.

5


We did not submit any matters to our stockholders for a vote during the fourth quarter ended June 30, 2005.

PART II

ITEM 5. MARKET FOR REGISTRANT’SOUR COMMON EQUITY, AND RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

The Company’s

Market Information

Our common stock trades on Thethe Nasdaq StockNational Market under the Symbol: NAII. The table below sets forthsymbol “NAII.” Below are the high and low salesclosing prices of our common stock as reported on the Company’s stockNasdaq National Market for each quarter of the fiscal years ended June 30, 20022005 and 2001.

     
High

  
Low

FY 2002
 
          
Fourth Quarter
 
    $3.10  $1.58
Third Quarter
 
    $2.45  $1.60
Second Quarter
 
    $2.25  $1.08
First Quarter
 
    $2.10  $1.24
FY 2001
 
          
Fourth Quarter
 
    $2.78  $1.94
Third Quarter
 
    $3.00  $2.09
Second Quarter
 
    $3.63  $1.66
First Quarter    $2.31  $1.38
2004:

   Fiscal 2005

  Fiscal 2004

   High

  Low

  High

  Low

First Quarter

  $9.65  $6.32  $5.47  $4.68

Second Quarter

  $11.46  $7.88  $6.41  $4.70

Third Quarter

  $9.85  $6.37  $9.60  $6.20

Fourth Quarter

  $8.21  $6.75  $13.80  $7.27

In addition to the Nasdaq National Market, our shares are also listed for trading on the Berlin-Bremen Stock Exchange, the Frankfurt Stock Exchange, and the XETRA Stock Exchange, each of which is a foreign exchange located in Germany. We are not aware of any other exchanges on which our shares are traded.

Holders

As of June 30, 2002,September 8, 2005, there were approximately 418360 stockholders of record of NAIIour common stock.

The Company has

Dividends

We have never paid a dividend on itsour common stock. Itstock and we do not intend to pay a dividend in the foreseeable future. Our current policy is the Company’s present policy to retain all earnings to help provide funds for future growth. Additionally, under the future growthterms of our credit facility, we are precluded from paying a dividend.

Recent Sales of Unregistered Securities

During the Company.

6
fiscal year ended June 30, 2005, we did not sell any unregistered securities.


Repurchases

During fiscal 2005, we did not repurchase any shares of our common stock, nor were any repurchases made on our behalf.

ITEM 6. SELECTED FINANCIAL DATA

The following table sets forth selectedtables contain certain financial data forinformation about NAI, including its subsidiaries. When you review this information, you should keep in mind that it is historical. Our future financial condition and results of operations will vary based on a variety of factors. You should carefully review the Company. The selected financial datafollowing information together with the information on risks under Item 7 and elsewhere in the table are derived from thethis report, and our consolidated financial statements of the Company. The following data should be readincluded in conjunction with, and is qualified in its entirety by, the Company’s consolidated financial statements and related notes and with “Management’s Discussion and Analysis of Financial Condition and Results of Operations” includedthis report under Item 7 of this Form 10-K.

   
Year Ended June 30

 
   
2002

   
2001

   
2000

   
1999

   
1998

 
   
(Dollars in thousands, except per share amounts)
 
Net sales  $50,037   $42,158   $47,827   $57,430   $67,894 
Cost of goods sold   39,068    33,970    44,152    45,010    49,158 
   


  


  


  


  


Gross profit   10,969    8,188    3,675    12,420    18,736 
Selling, general & administrative expenses   10,684    8,848    8,670    11,965    9,114 
Loss on abandonment of leased facility   —      —      1,729    5,392    —   
Loss on impairment of intangible assets acquired   —      1,544    —      —      —   
   


  


  


  


  


Income (loss) from operations   285    (2,204)   (6,724)   (4,937)   9,622 
   


  


  


  


  


Other income (expense):                         
Interest income   16    92    139    185    195 
Interest expense   (665)   (755)   (399)   (85)   (110)
Equity in loss of unconsolidated joint venture   —      (38)   (62)   —      —   
Foreign exchange gain (loss)   (68)   15    74    —      —   
Proceeds from vitamin antitrust litigation   3,410    298    116    —      —   
Other, net   259    73    (45)   15    (40)
   


  


  


  


  


Total other income (expense)   2,952    (315)   (177)   115    45 
   


  


  


  


  


Income (loss) before income taxes   3,237    (2,519)   (6,901)   (4,822)   9,667 
Provision (benefit) for income taxes   (642)   2,370    (2,429)   (1,899)   3,795 
   


  


  


  


  


Net income (loss)  $3,879   $(4,889)  $(4,472)  $(2,923)  $5,872 
   


  


  


  


  


Net income (loss) per common share:                         
Basic  $0.67   $(0.85)  $(0.78)  $(0.50)  $1.06 
Diluted  $0.67   $(0.85)  $(0.78)  $(0.50)  $1.00 
Weighted average common shares:                         
Basic   5,788    5,770    5,757    5,868    5,544 
Diluted   5,798    5,770    5,757    5,868    5,867 
Balance sheet data at end of period:                         
Total assets  $27,510   $25,068   $34,109   $38,596   $42,987 
Working capital   8,725    5,045    7,639    14,098    17,454 
Long-term debt and capital lease obligations, net of current portion   1,576    3,567    3,345    927    977 
Total stockholders’ equity   19,608    15,604    20,486    25,091    27,659 

8.

7


Annual Financial Data

   

Annual Financial Information for Years Ended June 30

(Amounts in thousands, except per share amounts)


 
   2005

  2004

  2003

  2002

  2001

 

Net sales

  $91,492  $78,534  $55,962  $50,037  $42,158 

Cost of goods sold

   73,095   59,964   42,781   39,068   33,970 
   


 


 


 


 


Gross profit

   18,397   18,570   13,181   10,969   8,188 

Selling, general & administrative expenses

   14,605   15,188   12,012   10,684   8,848 

Loss on impairment of intangible assets acquired

   —     —     —     —     1,544 
   


 


 


 


 


Income (loss) from operations

   3,792   3,382   1,169   285   (2,204)
   


 


 


 


 


Other income (expense):

                     

Interest income

   21   24   57   16   92 

Interest expense

   (280)  (274)  (252)  (665)  (755)

Foreign exchange gain (loss)

   (137)  57   12   (68)  15 

Proceeds from vitamin antitrust litigation

   —     —     225   3,410   298 

Other, net

   13   (165)  (59)  259   35 
   


 


 


 


 


Total other income (expense)

   (383)  (358)  (17)  2,952   (315)
   


 


 


 


 


Income (loss) before income taxes

   3,409   3,024   1,152   3,237   (2,519)

Provision for (benefit from) income taxes

   1,210   24   47   (642)  2,370 
   


 


 


 


 


Net income (loss)

  $2,199  $3,000  $1,105  $3,879  $(4,889)
   


 


 


 


 


Net income (loss) per common share:

                     

Basic

  $0.37  $0.51  $0.19  $0.67  $(0.85)

Diluted

  $0.34  $0.48  $0.18  $0.67  $(0.85)

Weighted average common shares:

                     

Basic

   5,949   5,843   5,809   5,788   5,770 

Diluted

   6,465   6,304   6,021   5,798   5,770 

Balance sheet data at end of period:

                     

Total assets

  $44,138  $42,468  $30,724  $27,510  $25,068 

Working capital

  $14,398  $17,468  $12,321  $8,725  $5,045 

Long-term debt and capital lease obligations, net of current portion

  $2,979  $3,841  $2,386  $1,576  $3,567 

Total stockholders’ equity

  $26,917  $24,128  $20,777  $19,608  $15,604 

Quarterly Financial Data - Unaudited

   

Quarterly Financial Information for Fiscal 2005 and Fiscal 2004

(Amounts in thousands, except per share amounts)


 
   Fiscal 2005

  Fiscal 2004

 
   Q4

  Q3

  Q2

  Q1

  Q4

  Q3

  Q2

  Q1

 

Net sales

  $24,730  $22,490  $21,545  $22,727  $23,350  $21,268  $17,195  $16,721 

Cost of goods sold

   20,456   18,277   16,953   17,409   17,874   16,215   13,300   12,575 
   


 


 


 


 


 


 


 


Gross profit

   4,274   4,213   4,592   5,318   5,476   5,053   3,895   4,146 

Selling, general & administrative expenses

   3,433   3,538   3,710   3,924   4,279   4,047   3,346   3,516 
   


 


 


 


 


 


 


 


Income from operations

   841   675   882   1,394   1,197   1,006   549   630 
   


 


 


 


 


 


 


 


Other income (expense):

                                 

Interest income

   6   5   6   4   3   3   9   9 

Interest expense

   (89)  (86)  (54)  (51)  (111)  (69)  (51)  (43)

Foreign exchange gain (loss)

   (115)  (188)  168   (2)  (38)  (50)  130   15 

Other, net

   (3)  (8)  25   (1)  (96)  (22)  (25)  (22)
   


 


 


 


 


 


 


 


Total other income (expense)

   (201)  (277)  145   (50)  (242)  (138)  63   (41)
   


 


 


 


 


 


 


 


Income before income taxes

   640   398   1,027   1,344   955   868   612   589 

Provision for (benefit from) income taxes

   355   121   242   492   (47)  13   36   22 
   


 


 


 


 


 


 


 


Net income

  $285  $277  $785  $852  $1,002  $855  $576  $567 
   


 


 


 


 


 


 


 


Net income per common share:

                                 

Basic

  $0.05  $0.05  $0.13  $0.14  $0.17  $0.15  $0.10  $0.10 

Diluted

  $0.04  $0.04  $0.12  $0.13  $0.15  $0.13  $0.09  $0.09 

Weighted average common shares:

                                 

Basic

   5,982   5,958   5,929   5,924   5,881   5,849   5,822   5,821 

Diluted

   6,414   6,421   6,572   6,448   6,606   6,335   6,162   6,107 

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND

RESULTS OF OPERATIONSOPERATION
Certain Forward-Looking Information
This Form 10-K contains certain “forward-looking statements” as such term is defined in the Private Securities Litigation Reform Act of 1995 or by the Securities and Exchange Commission in its rules, regulations and releases. These statements represent the Company’s expectations or beliefs, including, but not limited to, statements concerning future financial and operating results, anticipated growth in revenues and profit margins, improvements in management personnel, the impact of European operations, the utilization of inventories and facilities, statements concerning industry performance, the Company’s operations, economic performance, financial condition, growth and acquisition strategies, margins and growth in sales of the Company’s products. For this purpose, any statements contained in this Report that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “expect”, “believe”, “anticipate”, “intend”, “could”, “estimate” or “continue” or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. These statements by their nature involve substantial risks and uncertainties, certain of which are beyond the Company’s control, and actual results may differ materially depending on a variety of important factors, including without limitation uncertainty related to government regulation, the effect of adverse publicity, litigation, the centralized location of the Company’s manufacturing operations, availability of raw materials, risks associated with international operations, competition, product liability claims, volatility of stock price and those factors described in this and other Company filings with the Securities and Exchange Commission.
Critical Accounting Policies and Estimates

The Company’sfollowing discussion and analysis of itsis intended to help you understand our financial condition and results of operations are based upon itsfor the last three fiscal years ended June 30, 2005. You should read the following discussion and analysis together with our audited consolidated financial statements and the notes to the consolidated financial statements included under Item 8 in this report. Our future financial condition and results of operations will vary from our historical financial condition and results of operations described below. You should carefully review the risks described under this Item 7 and elsewhere in this report, which identify certain important factors that could cause our future financial condition and results of operations to vary.

Executive Overview

The following overview does not address all of the matters covered in the other sections of this Item 7 or other items in this report or contain all of the information that may be important to our stockholders or the investing public. This overview should be read in conjunction with the other sections of this Item 7 and this report.

Major business developments of fiscal 2005 included the following:

Completed our fourth year of net sales and operating income growth. Achieved record-breaking net sales in fiscal 2005.

Net sales to our two largest customers grew 32% and comprised 79% of total net sales in fiscal 2005.

Gross profit margin declined to 20.1% in fiscal 2005 from 23.6%. Sales from powder products in fiscal 2005 increased to 31% of our total net sales compared to 20% last year. Powder products typically include higher material cost as a percentage of selling price as compared to capsule or tablet products, contributing to a lower gross profit margin.

Achieved a $385,000 improvement in income before income taxes over last year despite incurring increased regulatory costs of $706,000 related to the TGA certification review of our U.S.-based manufacturing facilities and $323,000 related to public company compliance matters.

We extended our relationship with one of our largest customers, NSA International, Inc.

Obtained GMP recertification by the TGA for our recently expanded U.S.-based manufacturing facilities.

Funded $7.7 million of capital expenditures from available cash on hand and reduced our outstanding debt by $832,000, or 18%. The capital expenditures were invested primarily in the build out of our Vista, California facility, which included the acquisition of additional manufacturing equipment.

Our focus for fiscal 2006 includes the following:

Leverage our new facility and TGA recertification to:

Increase the value of the goods and services we provide to our highly valued customers; and

Assist us in developing relationships with additional quality oriented customers;

Implement focused initiatives to market our own branded products through new distribution channels;

Improve operational efficiency and manage costs and business risks to improve profitability; and

Identify and evaluate acquisition opportunities that could increase product lines, expand distribution channels, enhance manufacturing capabilities or reduce risks associated with a variety of factors.

Looking forward, we expect to continue our trend of annual revenue growth. We anticipate quarterly revenue fluctuations due to, among other things, the timing of customer orders that are impacted by marketing programs, supply chain management, entry into new markets and new product introductions.

We also expect our long-term trend of growth in annual operating income to continue, however; there may be periodic quarterly declines in operating income due to revenue fluctuations, regulatory compliance costs and investments in new marketing, brand development and channel diversification initiatives. Regulatory compliance costs related to our TGA recertification are largely complete. We anticipate the reduction in regulatory compliance costs to be offset by incremental costs for implementing focused initiatives to establish our own branded products through new distribution channels.

Critical Accounting Policies and Estimates

Our consolidated financial statements included under Item 8 in this report have been prepared in accordance with United States generally accepted accounting principles generally accepted(GAAP). Our significant accounting policies are described in the United States.notes to our consolidated financial statements. The preparation of these financial statements in accordance with GAAP requires the Company tothat we make estimates and judgmentsassumptions that affect the amounts reported amountsin our financial statements and their accompanying notes. We have identified certain policies that we believe are important to the portrayal of assets, liabilities, revenuesour financial condition and expenses, and related disclosureresults of contingent assets and liabilities. On an on-going basis,operations. These policies require the Company evaluates the estimates including those related to bad debts and inventories. The Company bases itsapplication of significant judgment by our management. We base our estimates on our historical experience, industry standards, and on various other assumptions that we believe are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.circumstances. Actual results maycould differ from these estimates.

The Company believesestimates under different assumptions or conditions. An adverse effect on our financial condition, changes in financial condition, and results of operations could occur if circumstances change that alter the followingvarious assumptions or conditions used in such estimates or assumptions. Our critical accounting policies affectinclude those listed below.

Revenue Recognition

We recognize revenue in accordance with SEC Staff Accounting Bulletin No. 101, “Revenue Recognition in Financial Statements” (SAB 101). SAB 101 requires that four basic criteria be met before revenue can be recognized: 1) there is evidence that an arrangement exists; 2) delivery has occurred; 3) the more significant judgmentsfee is fixed or determinable; and estimates used in4) collectibility is reasonably assured. We recognize revenue upon determination that all criteria for revenue recognition have been met. The criteria are usually met at the preparationtime title passes to the customer, which usually occurs upon shipment. Revenue from shipments where title passes upon delivery is deferred until the shipment has been delivered.

As part of the consolidated financial statements:

Allowance for Doubtful Accounts—services we provide to our private label contract manufacturing customers, we may perform, but are not required to perform, certain research and development activities related to the Company maintains an allowance for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments. If the financial condition of the Company’s customers were to deteriorate, resulting in an impairmentdevelopment or improvement of their ability to make payments, additional allowance may be required.
Reserveproducts. While our customers typically do not pay directly for Inventory—the Company records valuation reserves on its inventory for estimated excess and obsolete inventory equal to the difference betweenthis service, the cost of inventorythis service is included as a component of the price we charge to manufacture and thedeliver their products.

Additionally, we record reductions to gross revenue for estimated market valuereturns of private label contract manufacturing products and direct-to-consumer products. The estimated returns are based upon assumptions about futurethe trailing six months of private label contract manufacturing gross sales and our historical experience for both private label contract manufacturing and direct-to-consumer product returns. However, the estimate for product returns does not reflect the impact of a large product recall resulting from product nonconformance or other factors as such events are not predictable nor is the related economic impact estimable.

Inventory Reserve

We operate primarily as a private label contract manufacturer that builds products following receipt of customer specific purchase orders. As a result, we have limited realization risk in finished goods and work-in-process inventories. Our inventory reserve primarily relates to, but is not necessarily limited to, realization risk for raw materials. Our estimate to reduce inventory to net realizable value is based upon expiration of the raw materials’ efficacy, foreseeable demand of raw materials, market conditions and market conditions.specific factors that arise from time to time related to regulatory and other factors. The reserve level reflects our historical experience. If future product demand and/or market conditions are less favorable than those projected by management,we estimate, additional inventory reserves may be required.

Depreciation of Long-Lived Assets—the Company assigns useful lives for long-lived assets based on periodic studies of actual asset lives and the intended use for those assets. Any change in these asset lives would be reported in the statement of operations as soon as any change in estimate is determined.

8


Accounting for Income Taxes—the Company is required toTaxes

We estimate income taxes in each of the jurisdictions in which it operates.we operate. This process involves estimating our actual current tax exposure, for the Company together with assessing temporary differences resulting from differing treatment of items, such as property plant and equipment depreciation, for tax and accountingfinancial reporting purposes. Actual income taxes could vary from these estimates due to future changes in income tax law or results from final tax examexamination reviews. At June 30, 2002, the Company assessed

We record valuation allowances to reduce our deferred tax assets to an amount that we believe is more likely than not to be realized. We consider estimated future taxable income and ongoing prudent and feasible tax planning strategies in assessing the need for a valuation allowance on its deferred tax assets. A valuation allowance is provided when it is more likely than notallowance. If we determine that some portion or all of the deferred tax assetswe will not be realized. Based upon the historical operating losses and the uncertainty regarding sufficient near term taxable income, management believes that this evidence creates sufficient uncertainty regarding the realizability of the net deferred tax assets. Therefore, a full valuation allowance of $1,097,000 is recorded at June 30, 2002. Should the Company determine that it would be able to realize all or part of itsour deferred tax assets in the future, we will record an adjustment to the carrying value of the deferred tax asset, which

would be reflected as income tax expense. Conversely, if we determine that we will realize a deferred tax asset, which currently has a valuation allowance, we would reverse the valuation allowance, which would be reflected as income tax benefit.

Additionally, we have not recorded U.S. income tax expense for NAIE’s retained earnings that we have declared as indefinitely reinvested offshore, thus reducing our overall income tax expense. The earnings designated as indefinitely reinvested in NAIE are based upon the actual deployment of such earnings in NAIE’s assets and our expectations of the future cash needs of NAIE and NAI. Income tax laws are also a factor in determining the amount of foreign earnings to be indefinitely reinvested offshore.

We carefully review several factors that influence the ultimate disposition of NAIE’s retained earnings declared as reinvested offshore, and apply stringent standards to overcoming the presumption of repatriation. Despite this approach, because the determination involves our future plans and expectations of future events, the possibility exists that amounts declared as indefinitely reinvested offshore may ultimately be repatriated. For instance, NAI’s actual cash needs may exceed our current expectations or NAIE’s actual cash needs may be less than our current expectations. Additionally, changes may occur in tax laws and or accounting standards that could change our conclusion about the status of NAIE’s retained earnings. This would result in additional income tax expense in the fiscal year we determine that amounts are no longer indefinitely reinvested offshore.

On an interim basis, we estimate what our effective tax rate will be for the full fiscal year and record a quarterly income tax provision in accordance with the anticipated annual rate. As the fiscal year progresses, we continually refine our estimate based upon actual events and earnings by jurisdiction during the year. This continual estimation process periodically results in a change to our expected effective tax rate for the fiscal year. When this occurs, we adjust the income tax provision during the quarter in which the change in estimate occurs so that the year-to-date provision equals the expected annual rate.

It is our policy to establish reserves based upon management’s assessment of exposure for certain positions taken in previously filed tax returns that may become payable upon audit by tax authorities. The tax reserves are analyzed at least annually, generally in the fourth quarter of each year, and adjustments are made as events occur which warrant adjustments to the reserve.

Derivative Financial Instruments

We use derivative financial instruments in the management of our foreign currency exchange risk inherent in our forecasted transactions denominated in Euros. We may hedge our foreign currency exposures by entering into offsetting forward exchange contracts and currency options. We account for derivative financial instruments using the deferral method under FAS 133, “Accounting for Derivatives and Related Hedging Activity,” when such instruments are intended to hedge identifiable, firm foreign currency commitments or anticipated transactions and are designated as, and effective as, hedges. Foreign exchange exposures arising from certain transactions that do not meet the criteria for the deferral method are marked-to-market.

We recognize any unrealized gains and losses associated with derivative instruments in income in the period in which the underlying hedged transaction is realized. In the event the derivative instrument is deemed ineffective or sold prior to maturity, we would recognize the resulting gain or loss in income at that time.

Allowance for Doubtful Accounts

We maintain an allowance for doubtful accounts to reflect our estimate of current and past due receivable balances that may not be collected. The allowance for doubtful accounts is based upon our assessment of the collectibility of specific customer accounts, the aging of accounts receivable and our history of bad debts. We believe that the allowance for doubtful accounts is adequate to cover anticipated losses in the receivable balance under current conditions; however, significant deterioration in the financial condition of our customers, resulting in an impairment of their ability to make payments, could materially change these expectations and additional allowance may be required.

Defined benefit pension plan

The plan obligation and related assets of the defined benefit pension plan are presented in the notes to the consolidated financial statements. Plan assets, which consist primarily of marketable equity and debt instruments, are valued based upon third party market quotations. Independent actuaries through the use of a number of assumptions determine plan obligation and annual pension expense. Key assumptions in measuring the plan obligation include the discount rate and estimated future return on plan assets. In determining the discount rate, we use an average long-term bond yield. Asset returns are based upon the historical returns of multiple asset classes to develop a risk free rate of return and risk premiums for each asset class. The overall rate for each asset class was developed by combining a long-term inflation component, the risk free rate of return and the associated risk premium. A weighted average rate is developed based on the overall rates and the plan’s asset allocation.

We have discussed the development and selection of these critical accounting policies with the Audit Committee of our Board of Directors and the Audit Committee has reviewed our disclosure relating to these policies.

Results of Operations

The results of operations for the fiscal years ended June 30 were as follows (dollars in thousands, except per share amounts):

   2005

  2004

  Percent
Change
(2005-
2004)


  2003

  Percent
Change
(2004-
2003)


 

Private label contract manufacturing

  $83,382  $68,493  22% $45,768  50%

Direct-to-consumer marketing program

   8,110   10,041  (19)%  10,194  (2)%
   


 


 

 


 

Total net sales

   91,492   78,534  16%  55,962  40%

Cost of goods sold

   73,095   59,964  22%  42,781  40%
   


 


 

 


 

Gross profit

   18,397   18,570  (1)%  13,181  41%

Gross profit %

   20.1%  23.6%     23.6%   

Selling, general & administrative expenses

   14,605   15,188  (4)%  12,012  26%
   


 


 

 


 

% of net sales

   16.0%  19.3%     21.5%   

Other expenses, net

   383   358  7%  17  2006%
   


 


 

 


 

Income before income taxes

   3,409   3,024  13%  1,152  163%

% of net sales

   3.7%  3.9%     2.1%   

Net income

  $2,199  $3,000  (27)% $1,105  171%
   


 


 

 


 

% of net sales

   2.4%  3.8%     2.0%   

Diluted net income per common share

  $0.34  $0.48  (29)% $0.18  167%

Fiscal 2005 Compared to Fiscal 2004

The percentage increase in private label contract manufacturing net sales was attributed to the following:

Strengthening of the Euro against the U.S dollar

1%

NSA International, Inc. net sales growth

8%

Mannatech, Incorporated net sales growth

17%

Discontinuation of two customer relationships

(7)%

Other customers net sales growth

3%


Total

22%


Net sales growth from NSA International, Inc over the prior year resulted primarily from higher volumes of established products in existing markets.

Net sales growth from Mannatech, Incorporated over the prior year resulted primarily from the following:

Higher volumes of established products in existing markets contributed 16 percentage points; and

Introduction of existing products into new markets contributed one percentage point.

We discontinued relationships with two of our customers due to the disproportionate risks related to inventory levels and accounts receivable required to continue serving these customers.

The remaining increase in private label contract manufacturing net sales was from growth in sales to newer customers, partially offset by decreased volumes with existing customers.

The increase in our private label contract manufacturing net sales was partially offset by the decrease in our direct-to-consumer net sales. This decrease was a continuation of the decline in sales for the Dr. Cherry Pathway to HealingTM product line due to our prior reduction in media spending investment in new television markets for the product line and a reduction in new customer acquisitions from our primary television market. We market our Dr. Cherry Pathway to HealingTM product line primarily through weekly television programming. During the third quarter we completed what we believe are improvements to the content and style of several of the programs. The new programming was introduced in the beginning of April 2005. The initial impact of the new programming appears to be positive as fourth quarter net sales improved 5% over the third quarter of fiscal 2005. In addition, we terminated the Chopra Center EssentialsTM product line in June 2005.

Gross profit margin decreased to 20.1% in fiscal 2005 from 23.6%, or 3.5 percentage points, from fiscal 2004. The decrease in gross profit margin was primarily due to the following:

Percentage
Points


Shift in sales mix

(4.0)

Incremental inventory reserves

(0.5)

Incremental overhead expenses

(0.6)

Reduction in royalties paid to third parties

0.6

Reduction in direct and indirect labor

1.0


Total

(3.5)


The shift in sales mix resulted from selling higher volumes of established powder products to one of our largest customers. Powder products typically include higher material cost as a percentage of selling price compared to capsule or tablet products, resulting in lower gross profit margins;

Overhead expenses as a percentage of net sales increased 0.6 percentage points or $1.6 million, from the prior year primarily due to the following:

Incremental outsourced lab testing of $756,000 in conjunction with the preparation for our TGA audit; and

Incremental rent and maintenance expense of $545,000 related to our facility expansion in Vista, California.

Reduction in direct-to-consumer marketing program royalties resulted from lower net sales; and

Reduction in direct and indirect labor was primarily due to improved operational efficiencies and fixed cost leverage.

Selling, general and administrative expenses decreased $583,000, or 4%, from the prior year primarily attributable to the following:

Incremental Sarbanes-Oxley (SOX) compliance costs of $323,000.

Incremental costs of $706,000 due to increased regulatory certification requirements to improve service to our customers selling products in international markets.

Incremental personnel costs of $844,000 primarily due to changes in personnel to strengthen quality assurance, regulatory compliance, product formulation and sales and marketing.

Incremental non-cash charge of $131,000 associated with the acceleration of vesting of all outstanding and unvested stock options.

Reduced clinical study costs of $398,000 as a result of lowering our level of participation in certain clinical studies.

Reduced compensation costs under our Management Cash Incentive Plan of $1.2 million.

Reduced direct-to-consumer marketing brand development spending of $324,000 and call center costs of $411,000 associated with lower direct-to-consumer net sales.

Other expense, net, increased $25,000 over the prior year primarily attributable to the following:

Net loss associated with derivative financial instruments to manage our foreign currency exchange risks of $109,000.

Incremental net loss on translation of Euro denominated cash and receivables of $28,000.

A gain of $47,000 on the sale of a previously written-off investment.

Fiscal 2004 included a $61,000 charge in conjunction with refinancing our credit facility in May 2004. The charge related to a prepayment penalty and the write-off of capitalized issuance costs.

Our effective tax rate for fiscal 2005 was 35.5% compared to 1% in fiscal 2004. The increase in our effective rate is primarily attributable to the reduction in our valuation allowance on our net deferred tax assets in the future,prior year. Income taxes for fiscal 2005 differed from statutory rates primarily due to our Swiss federal and cantonal income tax holiday and the utilization of certain federal and state tax credits. Our Swiss tax holiday ended on June 30, 2005. We anticipate NAIE’s effective tax rate for Swiss federal, cantonal and communal taxes will be approximately 23% in fiscal 2006 compared to our fiscal 2005 effective rate of 5%.

During the fourth quarter of fiscal 2005 we repatriated $2.0 million of NAIE’s foreign earnings under the American Jobs Creation Act (the “Act”), which was signed into law by the President on October 22, 2004. The Act creates a temporary incentive for U.S. multinational corporations to repatriate accumulated income earned outside the U.S. by providing an adjustment85% dividend received deduction for certain dividends from controlled foreign corporations. The $2.0 million repatriation resulted in an increase of $232,000 in our tax provision for fiscal 2005. NAIE’s repatriated foreign earnings previously had been designated as permanently reinvested and the remaining undistributed retained earnings continue to be designated as such subsequent to the deferred tax assets would be recorded to operations in the period such determination was made.

one-time repatriation.

RESULTS OF OPERATIONS

Fiscal 20022004 Compared to Fiscal 20012003
In fiscal 2002, the Company’s net sales were $50.0 million, an increase from fiscal 2001 of $7.8 million, or 19%. Net sales for fiscal 2002 were comprised of $41.6 million from our core business and $8.4 million from DTC products versus $36.5 million and $5.7 million for the same products in fiscal 2001, respectively. Of the core business for fiscal 2002, $8.2 million was produced by NAIE with NAI

Consolidated private label contract manufacturing the remainder of $33.4 million. NAIE produced $7.5 million of the core business sales in fiscal 2001.

Total net sales for all core business customers achieving individualthe fiscal year ended June 30, 2004, increased $22.7 million, or 50%, over the prior year. Changes in currency exchange rates, namely the strengthening of the Euro, contributed $1.1 million dollars, or 2%, of this growth. Excluding the impact of changes in currency exchange rates, the remaining increase was due primarily to additional net sales of $14.1 million, or 31%, to our two largest customers. Net sales to our largest customer increased $6.0 million due to higher volumes of at least $1.0established products in existing markets. Net sales to our second largest customer increased $3.7 million from new products in existing markets and $4.4 million from established products in existing markets. Additionally, net sales increased $4.9 million from net sales to new customers and $3.4 million due to incremental volumes sold to customers obtained in the fourth quarter of fiscal 2003.

The Dr. Cherry Pathway to HealingTM product line comprised 100% of our direct-to-consumer net sales for the fiscal years ended June 30, 2004 and 2003. Direct-to-consumer net sales remained consistent due to a reduction in our media spending investment in new television markets for the Dr. Cherry Pathway to HealingTM product line, as the investment did not produce what we considered to be adequate results. Additionally, we experienced a reduction in new customer acquisitions from our primary television market, while the average order value remained consistent. We have identified opportunities to improve the content and style of the television programs and anticipate introducing the upgraded television programs in the third quarter of fiscal 2005.

Gross profit margin remained consistent despite a 1.4 percentage point increase in material cost as a percentage of net sales, due to a 1.5 percentage point decrease in labor and overhead as a percentage of net sales.

Our material cost as a percentage of net sales was $39.2 million (four customers) and $34.4 million (six customers)54.4% ($42.7 million) for fiscal years 20022004 and 2001, respectively, an53.0% ($29.6 million) in the prior year. The increase in material cost as a percentage of $4.8 million. Thenet sales increase was primarily due to new productan increase in inventory reserves of $854,000 for specific inventory realization risks and $111,000 for products as a result of terminating the Jennifer O’Neill Signature LineTM brand. The inventory allowance as a percentage of gross inventory at June 30, 2004 remained consistent with June 30, 2003. Additionally, 0.5 percentage points of the increase related to a shift in our sales combined with increasedmix to higher volume, of established products to the first and second largest customers of $2.1 million and $6.2 million, respectively. These increases were partially offset by decreased orders from smaller customers.

As noted above, DTC sales increased $2.7 million or 47%, from $5.7 million in fiscal 2001 to $8.4 million in fiscal 2002. This increase is primarily due to the introduction of eight new DTClower margin products in fiscal 2002.
Gross profit for fiscal 2002 increased to $11.0 million, or 22% of net sales, from $8.2 million, or 19% of net sales, for fiscal 2001. Gross profit for fiscal 2002 was favorably impacted by sales increases from core business2004. Our labor and DTC business and improved manufacturing yields partially offset by higher royaltyoverhead expenses related to the DTC products.
Material costs as a percentage of net sales were 52%22.0% ($26.2 million) and 53% ($22.217.2 million) for fiscal years 20022004 compared to 23.5% ($13.1 million) in the prior year. The decrease in labor and 2001, respectively. Material contribution margins decreased due to material costs for the new packaged powder products sales. Excluding the packaged powder products, the material costsoverhead as a percentage of net sales would have improved 4% due to the Company’s efforts to reduce costs.
Direct and indirect manufacturing expenses were 24% and 28%, as a percentage of net sales for fiscal 2002 and 2001, respectively. The reduction in manufacturing expenses as a percent of net sales is due to improved internal process controls and increased efficiency.
Selling, general and administrative expenses (“SG&A”) for fiscal 2002 and 2001 was $10.7 million (21% of net sales) and $8.8 million (21% of net sales), respectively. The increase in fiscal 2002 is primarily attributable to incremental spending for DTC of $1.7 million and $350,000 related to reorganizing of the Company’s manufacturing and sales organizations. Additionally, inadequate performance by the Company’s former 3rd party DTC call and fulfillment center provider resulted in significantly higher processing and customer services costs. The Company replaced the former DTC call and fulfillment center in December 2001 and began an aggressive campaign to resolve the customer service issues resulting in additional charges of approximately $500,000. The start up costs associated with the new DTC call and fulfillment center were approximately $267,000.

9


Fiscal 2001 operating expenses included a charge of $1.5 million reflecting the write down of intangible assets acquired and additional expenses associated with the attempted commercialization of the underlying software obtained from the FitnessAge and Custom Nutrition ventures.
Proceeds from vitamin antitrust litigation for fiscal 2002 and 2001 includes receipts of $3.4 million and $298,000, respectively, obtained in settlement of claims associated with theVitamin Antitrust Litigation.
The Company’s income from operations was $285,000 for fiscal 2002 compared to a loss of $2.2 million for fiscal 2001. The improvement in income from operations was due primarily to the increase in gross profit of $2.8 million and the intangible asset impairment charge of $1.5 million recorded in 2001. Operating expenses for both fiscal 2002 and fiscal 2001 were comparable in absolute dollars at approximately $10.7 million and $10.4 million, respectively.
Income tax expense for fiscal 2001 was $2.4 million resulting from the establishment of a valuation allowance on the net deferred tax assets. In fiscal 2002, Federal tax legislation was passed allowing companies to carryback NOLs for five years. This resulted in recognition of a $701,000 income tax refund receivable which was included as an income tax benefit in the accompanying consolidated statement of operations for the year ended June 30, 2002.
The Company recorded net income for fiscal 2002 of $3.9 million ($0.67 per share) compared to a net loss for fiscal 2001 of $4.9 million ($0.85 per share). The improvement in net income from fiscal 2002 to fiscal 2001 results from improved operating results, the Vitamin Antitrust settlement and the income tax benefit as described above.
Fiscal 2001 Compared to Fiscal 2000
Fiscal 2001’s net sales were $42.2 million, a decrease from fiscal 2000 of $5.6 million, or 12%. Net sales for fiscal 2001 were comprised of $36.5 million from our core business and $5.7 million from our DTC products versus $46.9 million and $875,000, for the same products in fiscal 2000, respectively. Of the core business for fiscal 2001, $7.5 million was produced by NAIE with NAI manufacturing the remainder of $29.0 million. NAIE produced approximately $3.4 million of the core business sales in fiscal 2000.
DTC products were first shipped in March 2000 and included only a single product offering. Sales for fiscal 2000 were $875,000. During fiscal 2001, three additional products were introduced and as a result sales increased approximately $4.8 million.
Total net sales for all core business customers achieving individual volumes of at least $1.0 million was $34.4 million (six customers) and $45.1 million (eight customers) for fiscal years 2001 and 2000, respectively, a decrease of $10.7 million. The sales decline was primarily due to improved leverage of fixed costs on higher net sales.

In June 2004, we began the lossbuild out of three customers, which represented combined net salestenant improvements for approximately 46,000 square feet at our Vista facility. We anticipate the build out will be completed by the end of $9.9 millionour second quarter in fiscal 2000 versus $238,000 for fiscal 2001. Loss of these three customers reflects the risk associated with our core business where price/cost is a prime driver. Sales2005. We anticipate being able to our second largest customer declined in 2001 by 53% to $4.2 million from $9.0 million for fiscal 2000. Fiscal 2000 sales were higher as this customer purchased large quantities of product from the Company to support a major product introduction, while fiscal 2001 sales volumes have stabilized at lower levels. The sales decreases associated with these customers were offset by increases with other existing customers. Sales to our largest customer during fiscal 2001 increased by $1.1 million to $21.9 million as a result of increased product shipped. Sales increased by $1.1 million in 2001 to our third largest customer as a result of increased volume of established products coupled with additional new products introduced during the 2001 fiscal year.

Gross profit for fiscal 2001 increased to $8.2 million, 19% of net sales, from $3.7 million, or 8% of net sales, for fiscal 2000. Gross profit for fiscal 2001 was favorably impacted primarily by: savings obtained by bringing in-house the Company’s packaging operations (gross savings of $4.6 million), the favorable material contribution margins generated by DTC product sales (approximately $1.1 million) and the $2.0 million inventory write-off in fiscal 2000, partially offset by increases to material costs associated with our core business ($520,000) and the additional manufacturing, fulfillment, and royalty expenses required to support in-house packaging and the DTC products ($2.5 million). Cost of goods sold for fiscal 2000 included an inventory write-off of $2.0 million, which represents approximately 4% of net sales. Excluding this charge, gross profit would have been 12% for fiscal 2000.

10


Cost of goods sold, excluding the inventory write-off of $2.0 million, decreased by $8.2 million, or 19%, to $34.0 million from $42.2 million in fiscal 2000. The decreaseinitiate production activities in the absolute dollar amount of the cost of goods sold resulted from the decrease in sales in fiscal 2001 versus fiscal 2000.
Material costs, including outside packaging costs, as a percentage of net sales, excluding the inventory write-off, were 53% ($22.2 million) and 63% ($30.2 million) for fiscal 2001 and 2000, respectively. The decrease is primarily due to savings in packaging costs coupled with the effect of higher gross margins generated by our direct-to-consumer (“DTC”) business, offset by some higher material costs affecting our core products. During the fourththird quarter of fiscal 2000,2005. If we are unable to complete the Company began packaging most of its finished goods internally. Priorbuild out and transition our operating activities as planned, we could experience a disruption in our manufacturing capabilities and incur additional costs to this period, independent third-party vendors performed all packaging of the Company’s products. Cost of outside packaging during fiscal 2001 amounted to approximately $700,000, or 2% of sales, versus $5.4 million (11% of sales) for fiscal 2000. Material costs, as a percentage of sales, are approximately 55%fulfill customer orders.

Selling, general and 36% for our core and DTC businesses, respectively.

Direct and indirect manufacturing expenses were, 28% and 25%, as a percentage of sales, for fiscal years 2001 and 2000, respectively. In absolute dollars, the expenses decreased to $11.7 million in 2001 from $12.0 million in 2000. The reduction was primarily due to a cost containment program established previously in fiscal 2000, offset by additional expenses to support in-house packaging and fulfillment expenses required by the DTC business.
SG&A for fiscal 2001 and 2000 was $8.8 million (21% of net sales) and $8.7 million (18% of net sales), respectively. The increase of fiscal 2001’s SG&Aadministrative expenses as a percentage of net sales reflected incremental expenditures for legal expenses ($851,000), and selling and promotional expenses associated with DTC sales increases, ($712,000), offset by savings in bad debts, and costs to support our Swiss subsidiary. Legal expense incurreddecreased 2.2 percentage points in fiscal 2001 is net2004 compared to fiscal 2003. In absolute dollars, however, selling, general and administrative expenses increased $3.2 million in fiscal 2004. The increase was primarily attributable to compensation payments under our fiscal 2004 Management Incentive Plan of $1.2 million, higher property, product liability and general liability insurance proceeds received fromcosts of $457,000 and research and development initiatives of $948,000.

During fiscal 2004, we made significant investments in our insurance carriersresearch and development initiatives primarily in the areas of $312,000.

Fiscal 2000 operating expenses includedclinical studies, regulatory assistance and personnel. Clinical studies increased $168,000 over the prior year primarily for efficacy validation of products in production and development stages. Regulatory related costs increased $381,000 over the prior year for services provided to current and prospective customers for international product registration, international and domestic product compliance and other services. Personnel costs increased $369,000 over the prior year to strengthen our team in the areas of regulatory and product formulation along with the hiring of our new Vice President of Science and Technology.

Other expense increased over the prior year primarily due to a $1.7 million$61,000 charge for loss on leased facility. Fiscal 2001 operating expenses includedin conjunction with refinancing our credit facility in May 2004. The charge related to a charge of $1.5 million reflectingprepayment penalty and the write downoff of intangible assets acquiredcapitalized issuance costs and additional expenses associated with the attempted commercializationis included in interest expense in our consolidated statements of the underlying software obtainedincome. Additionally, we received proceeds from the FitnessAge and Custom Nutrition ventures.

Proceeds from vitamin antitrust litigation for fiscal 2001 and 2000 includes receipts of $298,000 and $116,000, respectively obtained in settlement of claims associated with theVitamin Antitrust Litigation.
The Company’s loss from operations was $2.2 million for fiscal 2001 compared to a loss vitamin antitrust litigation of $6.7 million for fiscal 2000. The decrease in loss from operations of $4.5 million in 2001 was due primarily to an increase in gross profit of $4.5 million. Operating expenses for both fiscal 2001 and fiscal 2000 were comparable in absolute dollars at approximately $10.4 million.
Income tax expense for fiscal 2001 was $2.4 million, while fiscal 2000 reflected a benefit of $2.4 million, a change of $4.8 million. The income tax benefit recorded$225,000 in fiscal 2000 gave rise to net2003.

At June 30, 2004, we reduced our valuation allowance on our deferred tax assets based on historical operating profits. The effective tax rate for fiscal 2004 was 1% compared to 4% in fiscal 2003. NAIE operates under a five-year Swiss federal and cantonal income tax holiday that ends June 30, 2005. Following the expiration of $2.3 million. Atour tax holiday, we anticipate NAIE’s effective tax rate for Swiss federal, cantonal and communal taxes will be approximately 23% compared to our current effective rate of approximately 5%.

Our net income was $3.0 million ($0.48 per diluted share) in fiscal 2004 and $1.1 million ($0.18 per diluted share) in fiscal 2003. Excluding the endeffect of fiscal 2001, changes in underlying estimates and assumptions as to the ultimate recoverylitigation settlement proceeds of these assets required management to establish a valuation reserve of $2.3 million thereon, resulting$225,000 in the charge toprior year, net income taxes, for the current year, of the same amount.

The Company recorded a net loss for fiscal 2001 of $4.9increased $2.1 million ($0.85 per share) compared to a net loss$880,000 ($0.15 per diluted share).

Liquidity and Capital Resources

Our primary sources of $4.5 million ($0.78 per share) for fiscal 2000. The change in net loss from fiscal 2000 to fiscal 2001 reflected a favorable change in operations offsetliquidity and capital resources are cash flows provided by operating activities and the significant charge to income taxes as described above.

LIQUIDITY AND CAPITAL RESOURCES
The Company has historically financed its operations throughavailability of borrowings under our credit facility. Net cash flow from operations, capital and operating lease transactions, working capital credit facilities and equipment financing arrangements.

11


At June 30, 2002, the Company had cash of approximately $640,000, an increase from approximately $499,000 at June 30, 2001. Cash provided by operating activities was approximately $4.8 million. Proceeds$2.5 million in fiscal 2005, compared to $3.3 million in fiscal 2004 and $3.3 million in fiscal 2003. Our operating cash flow in fiscal 2005 was impacted by the following:

Net income of $2.2 million;

Receipt of $960,000 from theVitamin Antitrust Litigationour landlord to fund tenant improvements; and

Payments of approximately $3.4$1.6 million under our fiscal 2004 Management Cash Incentive Plan.

Approximately $1.0 million of our operating cash flow was generated by NAIE in fiscal 2005. In June 2005, we repatriated $2.0 million of NAIE retained earnings under the American Jobs Creation Act. As of June 30, 2005, NAIE’s undistributed retained earnings are included in cash provided by operating activities. The Companyconsidered indefinitely reinvested.

Cash used approximately $681,000 in investing activities primarily onin fiscal 2005 was $7.7 million compared to $3.3 million in fiscal 2004 and $779,000 in fiscal 2003. Capital expenditures were $7.7 million in fiscal 2005 compared to $3.3 million in fiscal 2004 and $977,000 in fiscal 2003. Fiscal 2005 capital expenditures were primarily for the expansion of our Vista, California production facility, which included the acquisition of additional manufacturing equipment. The expanded facility should help us improve operational efficiency, increase manufacturing capacity and reduce business risk. On February 1, 2005, we amended our credit facility to increase the limitation on our capital expenditures for the fiscal year ended June 30, 2005 from $6.5 million to $8.0 million. All other terms and conditions of our credit facility remain in full force and effect. Capital expenditures included $960,000 of tenant improvements that were partially offsetfunded by the repaymentlandlord allowances.

Our consolidated debt decreased to $3.8 million at June 30, 2005 from $4.7 million at June 30, 2004. Our $12.0 million credit facility is comprised of notes receivable. The Company used approximately $4.0an $8.0 million in financing activities to pay down debt by approximately $2.5 million and place a $1.5 million cash deposit as collateral for the Company’s amended working capital line of credit agreement.

Capital expenditures for fiscal 2002 were approximately $1,076,000. These expenditures relate primarily to the continuing development of the Swiss manufacturing facility of approximately $356,000 and domestic manufacturing and information system improvements of approximately $720,000. The domestic capital expenditures for manufacturing were spent on the acquisition of equipment primarily for our finished goods packaging operation. Additional expenditures were made to improve the Company’s management information system as well as to improve speed and security of the Company’s local-area and web-based networks. These expenditures were funded primarily from cash provided by operations.
At June 30, 2002, the Company had working capital of approximately $8.7$4.0 million compared to approximately $5.0 million at June 30, 2001. The $3.7 million increase in working capital was primarily the result of an increase in current assets of $4.1 million offset by an increase in current liabilities of $0.4 million. The change in current assets was primarily due to an increase in inventories of approximately $1.6 million, an income tax receivable of $0.7 million and cash and restricted cash of $2.1 million. Current liabilities declined primarily as cash was used to pay-down debt of $2.5 million of which $889,000 was current.
For fiscal 2002, the Company’s consolidated outstanding debt decreased to approximately $2.2 million from approximately $4.7 million at June 30, 2001. The decrease of $2.5 million reflects the pay-down of debt discussed in the previous paragraph. The composite interest rate on all outstanding debt as of June 30, 2002 was approximately 8.84%.
The Company has access to funds from the existing working capital credit facility to support future ongoing operating requirements of approximately $2.5 million, net of borrowings outstanding under these facilities as of June 30, 2002 of approximately $-0-.term loans. The working capital line of credit facilitiesexpires in November 2006, is secured by our accounts receivable and other rights to payment, general intangibles, inventory and equipment, has an interest rate of Prime Rate or LIBOR plus 1.75%, as elected by the Company from time to time, and borrowings are subject to eligibility requirements for current accounts receivable and inventory balances. The term loans consist of a $700,000 ten year term loan with a twenty year amortization, secured by our San Marcos building, at an interest rate of LIBOR plus 2.25%; a $1.8 million four year term loan, secured by our accounts receivable and other rights to payment, general intangibles, inventory and equipment, at an interest rate of LIBOR plus 2.10%; and a $1.5 million five year term loan, secured by equipment, at an interest rate of LIBOR plus 2.10%. Monthly payments on the term loans are approximately $63,000 plus interest. As of June 30, 2002 total excess borrowing capacity based on eligible working capital balances was approximately $2.5 million.
Effective July 1, 2002, the Company and lender amended the working capital line of credit agreement. Under the terms of the amended agreement, maximum borrowings remain at $2.52005, we had $7.7 million the interest rate was decreased to prime plus 0.5% and existing financial covenants were removed. The amended agreement requires the Company to maintain a minimum cash balance of $1.5 million with the secured creditor. The amount outstandingavailable under the working capital line of credit, agreementnet of a $270,000 outstanding letter of credit issued to our landlord. Under our credit facility, we may not create, incur or assume additional indebtedness without the approval of our lender.

On May 13, 2005, we purchased seven option contracts designated and effective as cash flow hedges to protect against the foreign currency exchange risk inherent in a portion of our forecasted transactions denominated in Euros. The seven options expire monthly beginning June 2005 and ending December 2005. The option contracts had a notional amount of $4.2 million, a weighted average strike price of $1.19, and a purchase price of $21,000. The risk of loss associated with the options is limited to bepremium amounts paid upon expirationfor the option contracts. As of June 30, 2005, we had not exercised any of the agreementoptions and one of the options had expired.

On July 7, 2005, we purchased 12 option contracts designated and effective as cash flow hedges to protect against the foreign currency exchange risk inherent in a portion of our forecasted transactions denominated in Euros. The 12 options expire monthly beginning January 2006 and ending December 2006. The option contracts had a notional amount of $7.0 million, a weighted average strike price of $1.16, and a purchase price of $152,000. The risk of loss associated with the options is limited to premium amounts paid for the option contracts.

There are no other derivative financial instruments at June 30, 2005.

As of June 30, 2005, we had $1.9 million in cash and cash equivalents. We plan on October 31, 2002. The Company is working with prospective lenders to replace thefunding our current working capital line of credit facility.

The Company believes that itsneeds, capital expenditures and debt payments using available cash, and existing credit facility should be sufficient to fund near-term operating activities. However, the Company’s ability to fund futurecash flow from operations and meetour credit facility.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet debt nor do we have any transactions, arrangements, obligations (including contingent obligations) or other relationships with any unconsolidated entities or other persons that may have a material current or future effect on financial condition, changes in financial condition, results of operations, liquidity, capital requirements will depend on many factors, including but not limited to: continued profitability from operations, the ability to seek additional financing; the effectivenessexpenditures, capital resources, or significant components of the Company’s diversified growth strategy; the effectiveness of the expansion of European operations and the ability to establish additional customersrevenue or changes to existing customer’s business.

12
expenses.


CONTRACTUAL OBLIGATIONS AND COMMITMENTSContractual Obligations

The following

This table summarizes the Company’sour known contractual obligations and estimated cash requirements as ofcommercial commitments at June 30, 2002. This table should be read in conjunction with the footnotes in the accompanying consolidated financial statements2005 (dollars in thousands):

Fiscal Year

  
Operating Leases

  
Term Notes

  
Total

2003  $906  $587  $1,493
2004   375   642   1,017
2005   241   332   573
2006   108   83   191
2007   -0-   90   90
Thereafter   -0-   429   429
   

  

  

Total  $1,630  $2,163  $3,793
   

  

  

.

   Payments Due By Period

Contractual Obligations


  Total

  Less Than 1
Year


  1 –3 Years

  3 –5 Years

  More Than 5
Years


Long-Term Debt

  $3,840  $861  $1,783  $596  $600

Operating Leases

   18,605   1,872   3,856   3,916   8,961
   

  

  

  

  

Total Obligations

  $22,445  $2,733  $5,639  $4,512  $9,561
   

  

  

  

  

RECENT ACCOUNTING PRONOUNCEMENTSInflation

We do not believe that inflation or changing prices have had a material impact on our historical operations or profitability.

Recent Accounting Pronouncements

In August 2001,November 2004, the Financial Accounting Standards Board (the “FASB”)FASB issued Statement of Financial Accounting Standards (“SFAS”) No. 143, “Accounting for Asset Retirement Obligations.” This statement addresses financial accounting151, “Inventory Costs, an amendment of APB No. 43, Chapter 4” (SFAS 151). SFAS 151 clarifies that abnormal inventory costs such as costs of idle facilities, excess freight and reporting for obligations associated with the retirementhandling costs, and wasted materials (spoilage) are required to be recognized as current period charges. The provisions of tangible long-lived assets and the associated asset retirement costs. It applies to (a) all entities and (b) legal obligations associated with the retirement of long-lived assets that result from the acquisition, construction, development and/or normal operation of long-lived assets, except for certain obligations of lessees. This statement isSFAS 151 are effective for financial statements issued forour fiscal yearsyear beginning after June 15, 2002. The Company doesJuly 1, 2006. We do not believeexpect that the adoption of this statementSFAS 151 will have a material impact on itsour consolidated financial position or results of operations.

Also

On December 16, 2004, the FASB finalized SFAS 123R, “Share Based Payment” (SFAS 123R), which will be effective for our interim and annual reporting periods beginning after June 15, 2005. SFAS 123R will require that we expense stock options and employee stock purchase plan shares using a binomial lattice valuation model that the FASB believes is capable of more fully reflecting certain characteristics of employee stock options. The effect of expensing stock options and employee stock purchase plan shares on our reported results of operations using the Black-Scholes model is presented in August 2001,the notes to our consolidated financial statements under Item 8 of this report.

In May 2005, the FASB issued Statement No. 154, “Accounting Changes and Error Corrections” (SFAS 154). SFAS No. 144, “Accounting for the Impairment or Disposal of Long-Lived Assets,” which establishes one accounting model to be used for long-lived assets to be disposed of by sale and broadens the presentation of discontinued operations to include more disposal transactions. SFAS No. 144 supersedes SFAS No. 121, “Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to Be Disposed Of” and the accounting and reporting provisions of154 replaces APB Opinion No. 30,20, “Accounting Changes” and FASB Statement No. 3, “Reporting Accounting Changes in Interim Financial Statements.” SFAS 154 requires that a voluntary change in accounting principle be applied retrospectively with all prior period financial statements presented on the Resultsnew accounting principle, unless it is impracticable to do so. SFAS 154 also provides that a correction of Operations—Reporting the Effects of Disposal oferrors in previously issued financial statements should be termed a Segment of a Business, and Extraordinary, Unusual and Infrequently Occurring Events and Transactions” for the disposal of a segment of a business (as previously defined in that Opinion).“restatement.” The provisions of SFAS No. 144 arenew standard is effective for financial statements issued for fiscal yearsaccounting changes and correction of errors beginning after December 15, 2001. TheJuly 1, 2005. We do not expect that the adoption of SFAS No. 144 had no154 will have a material impact on the Company’sour consolidated financial position or results of operations.

In April 2002,

Risks

You should carefully consider the FASB issued SFAS No. 145, “Rescission of FASB Statements No. 4, 44, and 64, Amendment of FASB Statement No. 13, and Technical Corrections,” which rescinds SFAS No. 4, “Reporting Gains and Losses from Extinguishment of Debt” and an amendment of that Statement, and SFAS No. 64, “Extinguishments of Debt Made to Satisfy Sinking-Fund Requirements.” SFAS No. 145 also rescinds SFAS No. 44, “Accounting for Intangible Assets of Motor Carriers.” SFAS No. 145 amends SFAS No. 13, “Accounting for Leases,” to eliminate an inconsistency between the required accounting for sale-leaseback transactions and the required accounting for certain lease modifications that have economic effects that are similar to sale-leaseback transactions. SFAS No. 145 also amends other existing authoritative pronouncements to make various technical corrections, clarify meanings, or describe their applicability under changed conditions. SFAS No. 145 is effective for fiscal years beginning after May 15, 2002. The Company does not expect the adoption of this statement will have a material impact on its results of operations or financial position.

13


In June 2002, the FASB issued SFAS No. 146, “Accounting for Costs Associated with Exit or Disposal Activities,” which addresses significant issues regarding the recognition, measurement, and reporting of costs associated with exit and disposal activities, including restructuring activities. This statement requires that costs associated with exit or disposal activities be recognized when they are incurred rather than at the date of a commitment to an exit or disposal plan. SFAS No. 146 is effective for all exit or disposal activities initiated after December 31, 2002. The Company does not expect the adoption of this statement will have a material impact on its results of operations or financial position.
ITEM 7A.    QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
The Company is exposed to market risks from adverse changes in interest rates, and foreign exchange rates affecting the return on its investments and the cost of its debt. The Company does not use derivative financial instruments to reduce the impact of changes in interest or foreign exchange rates.
At June 30, 2002, the Company’s cash equivalents consisted of financial instruments with original maturities of three months or less.
The Company’s debtdescribed below, as of June 30, 2002 totaled $2.2 million of fixed rate loans. The average composite interest rate at June 30, 2002 for fixed rate loans was 8.84%.
The Company is exposed to movements in the exchange rate between the Swiss Franc and the U.S. Dollar. On June 30, 2002, the Swiss Franc closed at 1.48 to 1.00 U.S. dollar. The same rate was 1.79 Swiss Francs to 1.00 U.S. dollar at June 30, 2001. Foreign exchange losses for the year-ended June 30, 2002 were $68,000.
An immediate adverse change of one hundred basis points in interest rates would increase interest expense on an annual basis by $25,000. A 10% adverse change to the Swiss Franc exchange rate would decrease earnings by $31,000.
RISK FACTORS THAT MAY AFFECT FUTURE OPERATING RESULTS
In addition towell as the other information included in this Report, the following factors should be considered inreport, when evaluating the Company’sour business and future prospects. The Company’sIf any of the following risks actually occur, our business, financial condition and results of operations could be seriously harmed by any of the following risks.harmed. In addition,that event, the market price of our common stock could decline dueand you could lose all or a portion of the value of your investment in our common stock.

Because we derive a significant portion of our revenues from a limited number of customers, our revenues would be adversely affected by the loss of a major customer or a significant change in its business or personnel.

We have in the past, and expect to anycontinue, to derive a significant portion of these risks.

Recent Operating Income; Increasing Sales
The Company’s incomeour revenues from operations was $285,000 fora relatively limited number of customers. During the fiscal year ended June 30, 2002, compared2005, sales to one customer, NSA International, Inc., were approximately 40% of our total net sales. Our second largest customer was Mannatech, Incorporated, which accounted for approximately 39% of our net sales. The loss of either of these customers or other major customers, a loss from operationssignificant decrease in sales or the growth rate of $2.2 million for fiscal 2001. Sales for thesales to these customers, or a significant change in their business or personnel, would materially affect our financial condition and results of operations. Based on press releases issued by Mannatech, Incorporated, Mannatech achieved record net sales in its fiscal year ended June 30, 2002 increased to approximately $50.0 million, compared to approximately $42.2 million forDecember 31, 2004 and in the first two quarters of its fiscal year ended June 30, 2001.2005. There can be no assurance that such results will continue. A significant decline in Mannatech’s net sales or the growth rate of such sales could materially affect our financial condition and results of operations.

Our future growth and stability depends, in part, on our ability to diversify our net sales. Our efforts to establish new products, brands, markets and customers could require significant initial investments, which may or may not result in higher net sales and improved financial results.

Our business strategy depends in large part on our ability to develop new products, marketing strategies, brands and customer relationships. These activities often require a significant up-front investment including, among others, customized formulations, regulatory compliance, product registrations, package design, product testing, pilot production runs, marketing and the build up of initial inventory. We may experience significant delays from the time we increase our operating expenses and make investments in inventory until the time we generate net sales from new products or customers, and it is possible that we may never generate any revenue from new products or customers after incurring such expenditures. If we incur significant expenses and investments in inventory that we are not able to recover, and we are not able to compensate for those expenses, our operating results could be adversely affected.

Our operating results will vary and there is no guarantee that we will earn a profit. Fluctuations in our operating results may adversely affect the share price of our common stock.

While our net sales and income from operations have both improved during the past three fiscal years, there can be no assurance that they will continue. The Company expectscontinue to improve, or that we will earn a profit in any given year. We have experienced losses in the past and may incur losses in the future. Our operating results may further fluctuate from periodyear to period as a resultyear due to various factors including differences related to the timing of differencesrevenues and expenses for financial reporting purposes and other factors described in when it incurs expenses and recognizes revenues from product sales. Some ofthis report. At times, these fluctuations may be significant.

Fluctuations in our operating results may adversely affect the share price of our common stock.

RelianceA significant or prolonged economic downturn could have a material adverse effect on Limited Numberour results of Customersoperations.

Our results of operations are affected by the level of business activity of our customers, which in turn is affected by the level of consumer demand for their products. A significant or prolonged economic downturn may adversely affect the disposable income of many consumers and may lower demand for the products we produce for our private label contract manufacturing customers, as well as for our direct-to-consumer products. A decline in consumer demand and the level of business activity of our customers due to economic conditions could have a material adverse effect on our revenues and profit margins.

Because our direct-to-consumer sales rely on the marketability of key personalities, the inability of a key personality to perform his or her role or the existence of negative publicity surrounding a key personality may adversely affect our revenues.

For the fiscal year ended June 30, 2002, the Company had two major customers, which together2005, our direct-to-consumer products accounted for approximately 69%9% of the Company’sour net sales. The loss of any of these major customers, or any substantial reduction of their purchases from the Company, would have a material adverse impact on the business, operations and financial condition of the Company.

14


Reliance on a Key Personality
For the fiscal year ended June 30, 2002, the Company’s DTC product line was approximately 17% of the Company’s net sales. DTCThese products are marketed with a key personality through a variety of distribution channels including weekly television programming, internet and a monthly newsletter.channels. The inability or failure of thea key personality to fulfill his currentor her role, the reduction of television exposure or the ineffectiveness of a key personality as a spokesperson for a product, a reduction in the exposure of interneta key personality or mailing capabilitiesnegative publicity about a key personality may adversely affect the sales of our product associated with that personality and could affect the sale of other products. A decline in sales would negatively affect our results of operations and financial condition.

Our industry is highly competitive and we may be unable to compete effectively. Increased competition could adversely affect our financial condition.

The market for our products is highly competitive. Many of our competitors are substantially larger and have greater financial resources and broader name recognition than we do. Our larger competitors may be able to devote greater resources to research and development, marketing and other activities that could provide them with a competitive advantage. Our market has relatively low entry barriers and is highly sensitive to the introduction of new products that may rapidly capture a significant market share. Increased competition could result in price reductions, reduced gross profit margins or loss of market share, any of which could have a material adverse impacteffect on the business, operations andour financial condition and results of the Company.

Potential for Increased Competition
The market for the Company’s products is highly competitive. The Company competes with other dietary supplement products and over-the-counter pharmaceutical manufacturers. Among other factors, competition among these manufacturers is based upon price. If one or more manufacturers significantly reduce their prices in an effort to gain market share, the Company’s business, operations and financial condition could be adversely affected. Many of the Company’s competitors, particularly manufacturers of nationally advertised brand name products, are larger and have resources substantially greater than those of the Company. There has been speculation about the potential for increased participation in these markets by major international pharmaceutical companies. In the future, if not already, one or more of these companies could seek to compete more directly with the Company by manufacturing and distributing their own or others’ products, or by significantly lowering the prices of existing national brand products. The Company sells substantially all of its supplement products to customers who re-sell and distribute the products. Although the Company does not currently participate significantly in other channels such as health food stores, direct mail, and internet sales, the Company is expanding its operations and its products, including direct mail and internet sales, and will likely face increased competition in such distribution and sales channels as more vendors and customers utilize them.
Availability of Line of Credit
The Company’s current $2.5 million line of credit expires on October 31, 2002. The lender has not committed to extend the facility and is not planning to renew it. The liquidity provided by a line of credit is an important component of a sound financial management plan. The Company is in negotiations with other lenders for a replacement line of credit.operations. There can be no assurance that we will be able to compete in this intensely competitive environment.

We may not be able to raise additional capital or obtain additional financing if needed.

Our cash from operations may not be sufficient to meet our working capital needs and/or to implement our business strategies. Although we obtained an $8.0 million line of credit in May 2004, there can be no assurance that this line of credit will be sufficient to meet our needs. Furthermore, if we fail to maintain certain loan covenants we will no longer have access to the current lender will extend the existingcredit line. The credit line has a 2.5 year term and will terminate in November 2006. As a result, we may need to raise additional capital or obtain additional financing.

In recent years, it has been difficult for companies to raise capital due to a variety of factors including the Companyoverall poor performance of the stock markets and the economic slowdown in the United States and other countries. Thus, there is no assurance we would be able to raise additional capital if needed. To the extent we do raise additional capital, the ownership position of existing stockholders could be diluted. Similarly, there can be no assurance that additional financing will obtain a replacement credit facilitybe available if needed or ifthat it does, thatwill be available on favorable terms. Under the terms of our

credit facility, we may not create, incur or assume additional indebtedness without the new facility will be as favorableapproval of our lender. Our inability to raise additional capital or better than those of the current credit line. Failure to obtain a new line of credit could materially impair the Company’sadditional financing if needed would negatively affect our ability to fund growthimplement our business strategies and meet our goals. This, in operations or meet other working capital needsturn, would adversely affect our financial condition and results of operations.

The failure of our suppliers to supply quality materials in sufficient quantities, at a favorable price, and in a timely fashion could adversely affect the future.

Reliance on Limited Numberresults of Suppliers; Availability and Cost of Purchased Materialsour operations.
The Company purchases certain products it does not manufacture

We buy our raw materials from a limited number of raw material suppliers. Mannatech comprised 29%During fiscal 2005, Carrington Laboratories Incorporated was our largest supplier, accounting for 35% of the Company’sour total raw material purchasespurchases. The loss of Carrington Laboratories Incorporated or other major supplier could adversely affect our business operations. Although we believe that we could establish alternate sources for the year ended June 30, 2002. No other supplier represented more than 10%most of total raw material purchases for the year ended June 30, 2002. Although the Company currently has supply arrangements with several suppliers of theseour raw materials, any delay in locating and suchestablishing relationships with other sources could result in product shortages, with a resulting loss of sales and customers. In certain situations we may be required to alter our products or to substitute different materials are generally available from numerous sources,alternative sources.

We rely solely on one supplier to process certain raw materials that we use in the terminationproduct line of the supply relationship by any material supplierour largest customer. The loss of or unexpected interruption in this service would materially adversely affect our results of operations and financial condition.

A shortage of raw materials or an unexpected interruption of supply could materially adversely affectalso result in higher prices for those materials. Although we may be able to raise our prices in response to significant increases in the Company’s business, operations and financial condition.

The Company relies on a single supplier to process certaincost of raw materials, for a product linewe may not be able to raise prices sufficiently or quickly enough to offset the negative effects of the Company’s largest customer. An unexpected interruptioncost increases on our results of supply of this service would materially adversely affect the Company’s business, operations and financial condition.

15
operations.


Decline in Stock Price
The Company’s stock price has experienced volatility, has generally declined during the past few years and is currently near historic lows. In view of the Company’s recent results and the fact there can be no assurances of future profitability, there

There can be no assurance that suppliers will provide the stock price will not decline. Market conditionsquality raw materials needed by us in the vitaminquantities requested or at a price we are willing to pay. Because we do not control the actual production of these raw materials, we are also subject to delays caused by interruption in production of materials based on conditions outside of our control, including weather, transportation interruptions, strikes and nutritional supplement industry, such as increased price competition, consolidation, oversupplynatural disasters or other catastrophic events.

Our business is subject to the effects of vitamin and supplement products, operating results of competitors, adverse publicity, which could negatively affect our sales and other factors such as customer and product announcements by the Company and operating results which are lower than the expectations of analysts and our investors, may have a continuing adverse effect on the price of the Company’s stock.

Effect of Adverse Publicityrevenues.
The Company’s products consist primarily of dietary

Our business can be affected by adverse publicity or negative public perception about our industry, our competitors, or our business generally. This adverse publicity may include publicity about the nutritional supplements (vitamins, minerals, herbs and other ingredients). The Company regards these products as safe when taken as suggested byindustry generally, the Company. In addition, various scientific studies have suggested the ingredients in some of the Company’s products may involve health benefits. The Company believes the growth in the dietary supplements business of the last several years may, in part, be based on significant media attention and various scientific research suggesting potential health benefits from the consumption of certain vitamin products. The Company is indirectly dependent upon its customers’ perception of the overall integrity of its business, as well as theefficacy, safety and quality of itsnutritional supplements and other health care products or ingredients in general or our products or ingredients specifically, and similarregulatory investigations, regardless of whether these investigations involve us or the business practices or products distributed by other companies which may not adhereof our competitors. There can be no assurance that we will be able to avoid any adverse publicity or negative public perception in the same quality standards as the Company. Thefuture. Any adverse publicity or negative public perception will likely have a material adverse effect on our business, operations, and financial condition and results of the Companyoperations. Our business, financial condition and results of operations also could be adversely affected if any of the Company’sour products or any similar products distributed by other companies should proveare alleged to be or be assertedare proved to be harmful to consumers or should scientific studies provide unfavorable findings regarding the effect of products similar to those produced by the Company.

have unanticipated health consequences.

Exposure to Product Liability Claims

The Company, like other retailers, distributors and manufacturers of products that are ingested, faces a risk of exposureWe could be exposed to product liability claims in the event that, amongor other things,litigation, which may be costly and could materially adversely affect our operations.

We could face financial liability due to product liability claims if the use of itsour products allegedly results in significant loss or injury. The Company maintainsAdditionally, the manufacture and sale of our products involves the risk of injury to consumers from tampering by unauthorized third parties or product contamination. We could be exposed to future product liability claims that, among others: our products contain contaminants; we provide consumers with inadequate instructions about product use; or we provide inadequate warning about side effects or interactions of our products with other substances.

We maintain product liability insurance coverage, including primary product liability and excess liability coverage. The cost of suchthis coverage has increased dramatically in the last year andrecent years, while the availability of adequate insurance coverage has decreased. There can be no assurance that adequate product liability insurance will continue to be available at an economically reasonable cost or that the Company’sour insurance will be adequate to cover any liability the Company incurs in respect to allwe may incur.

Additionally, it is possible product liability claims. In addition, some of the ingredients included inthat one or more of the products manufactured by the Company are subject to controversy involving potential negative side effects or questionable health benefits. Someour insurers including some providingcould exclude from our coverage to the Company, have recently excluded certain of these ingredients from their product liability coverage. Although the Company’s product liability insurance does not presently have any such limitations, the Company’s insurer could require such exclusions or limitations on coverageused in the future.our products. In such event, the Companywe may have to cease utilizing thestop using those ingredients or may have to rely on indemnification or similar arrangements with itsour customers who wish to continue to include suchthose ingredients in their products. In such an event, the consequentialA substantial increase in our product liability risk or the loss of customers or product lines could have a material adverse impacteffect on the Company’s business,our results of operations and financial condition.

Risks Associated with International MarketsAs we continue to expand into markets outside the United States our business becomes increasingly subject to political and economic risks in those markets, which could adversely affect our business.

The Company’s

Our future growth may be dependentdepend, in part, upon itson our ability to continue to expand its operations and those of its customers into markets outside the United States. There can be no assurance that we will be able to expand our presence in our existing markets outside the United States, enter new markets on a timely basis, or that new markets outside the United States will be profitable. There are significant regulatory and legal barriers in markets outside the United States that we must overcome. We will be subject to the burden of complying with a wide variety of national and local laws, including international markets. For the fiscal year ended June 30, 2002multiple and 2001, the percentage of the Company’s net sales to customers in international markets was approximately 31%possibly overlapping and 29%, respectively. NAIE operates a manufacturing facility in Switzerland, which is intended to facilitate an

16


increase in sales of the Company’s products overseas and which contributed approximately 16% and 18% of the Company’s net sales for the fiscal years ended June 30, 2002 and 2001, respectively. The Companyconflicting laws. We also may experience difficulty expanding in international markets due to regulatory barriers, the necessity ofdifficulties adapting to new regulatory systems,cultures, business customs and problems relatedlegal systems. Our sales and operations outside the United States are subject to entering new markets with different cultural basespolitical, economic and social uncertainties including, among others:

changes and limits in import and export controls;

increases in custom duties and tariffs;

changes in government regulations and laws;

coordination of geographically separated locations;

absence in some jurisdictions of effective laws to protect our intellectual property rights;

changes in currency exchange rates;

economic and political systems. Operating in international markets exposes the Company to certain risks, including, among other things, (1) changes in or interpretations of foreign import, instability; and

currency transfer and other restrictions and regulations that among other things may limit the Company’sour ability to sell certain products or repatriate profits to the United States, (2) exposureStates.

Any changes related to currency fluctuations, (3) the potential imposition of trade or foreign exchange restrictions or increased tariffs,these and (4) economicother factors could adversely affect our business, profitability and political instability.growth prospects. As the Company continueswe continue to expand its international operations,into markets outside the United States, these and other risks associated with international operations outside the United States are likely to increase.

Government RegulationOur products and manufacturing activities are subject to extensive government regulation, which could limit or prevent the sale of our products in some markets and could increase our costs.

The manufacturing, processing, formulation, packaging, labeling, advertising, promotion, distribution, and advertisingsale of the Company’sour products are subject to regulation by one or more federalnumerous national and local governmental agencies includingin the United States Food and Drug Administration (“FDA”)in other countries. Failure to comply with governmental regulations may result in, among other things, injunctions, product withdrawals, recalls, product seizures, fines, and criminal prosecutions. Any action of this type by a governmental agency could materially adversely affect our ability to successfully market our products. In addition, if the governmental agency has reason to believe the law is being violated (for example, if it believes we do not possess adequate substantiation for product claims), it can initiate an enforcement action. Governmental agency enforcement could result in orders requiring, among other things, limits on advertising, consumer redress, divestiture of assets, rescission of contracts, and such other relief as may be deemed necessary. Violation of these orders could result in substantial financial or other penalties. Any action by the Federal Trade Commission (“FTC”), the Consumer Product Safety Commission,governmental agency could materially adversely affect our ability and our customers’ ability to successfully market those products.

In markets outside the United States, Departmentbefore commencing operations or marketing our products, we may be required to obtain approvals, licenses, or certifications from a country’s ministry of Agriculture,health or comparable agency. Approvals or licensing may be conditioned on reformulation of products or may be unavailable with respect to certain products or product ingredients. We must also comply with product labeling and packaging regulations that vary from country to country. Furthermore, the regulations of these countries may conflict with those in the United States Postal Service,and with each other. The sale of our products in certain European countries is subject to the United States Environmental Protection Agency,rules and the Occupational Safety and Health Administration. The Company’s activities are also regulated by various agenciesregulations of the statesEuropean Union, which may be interpreted differently among the countries within the Union. The cost of complying with these various and localities in whichpotentially conflicting regulations can be substantial and can adversely affect our results of operations.

We cannot predict the Company’s products are sold. In particular, the FDA regulates the safety, labeling and distributionnature of dietary supplements, including vitamins, minerals, herbs, food, and over-the-counter and prescription drugs and cosmetics. In addition, the FTC has overlapping jurisdiction with the FDA to regulate the labeling, promotion and advertising of vitamins, over-the-counter drugs, cosmetics and foods.

The Dietary Supplement Health and Education Act of 1994 (“DSHEA”) was enacted on October 25, 1994. DSHEA amends the Federal Food, Drug and Cosmetic Act by defining dietary supplements, which include vitamins, minerals, nutritional supplements and herbs as a new category of food separate from conventional food. DSHEA provides a regulatory framework to ensure safe, quality dietary supplements and the dissemination of accurate information about such products. Under DSHEA, the FDA is generally prohibited from regulating the active ingredients in dietary supplements as drugs unless product claims, such as claims that a product may heal, mitigate, cureany future laws, regulations, interpretations, or prevent an illness, disease or malady, trigger drug status.
DSHEA provides for specific nutritional labeling requirements for dietary supplements. DSHEA permits substantiated, truthful and non-misleading statements of nutritional support to be made in labeling, such as statements describing general well being resulting from consumption of a dietary ingredient or the role of a nutrient or dietary ingredient in affecting or maintaining a structure or function of the body. The Company anticipates the FDA will finalize manufacturing process regulations that are specific to dietary supplements and require at least some of the quality control provisions applicable to drugs. The Company currently manufactures its vitamins and nutritional supplement products in compliance with the food good manufacturing processes.
The FDA is developing additional regulations to implement DSHEA. Labeling regulations may require expanded or different labeling for the Company’s vitamin and nutritional products. The Company cannotapplications, nor can we determine what effect suchadditional governmental regulations, when fully implemented, willand if adopted, would have on its business inour business. They could include requirements for the future. Such regulations could, among other things, requirereformulation of certain products to meet new standards, the recall reformulation or discontinuance of certain products, additional record keeping, warnings, notification proceduresexpanded or different labeling, and expanded documentationadditional scientific substantiation. Any or all of the properties of certain products or scientific substantiation regarding ingredients, product claims, safety or efficacy. Failure to comply with applicable FDAthese requirements could result in sanctions being imposed on the Company or the manufacturers of its products, including warning letters, fines, product recalls and seizures.
Governmental regulations in foreign countries where the Company plans to commence or expand sales may prevent or delay entry into a market or prevent or delay the introduction, or require the reformulation of, certain of the Company’s products. In addition, the Company cannot predict whether new domestic or foreign legislation regulating its activities will be enacted. Such new legislation could have a material adverse effect on theour operations.

If we are unable to attract and retain qualified management personnel, our business operationswill suffer.

Our executive officers and financial condition of the Company.

17


Failure to Attract and Retain Management Could Harm Our Ability to Maintain Profitability
The Company’sother management personnel are primarily responsible for our day-to-day operations. We believe our success is dependent in large part upon its continueddepends largely on our ability to identify, hire, retain,attract, maintain and motivate highly skilledqualified management employees.personnel. Competition for these employees isqualified individuals can be intense, and the Companywe may not be able to hire additional qualified personnel in a timely manner and on reasonable terms. The majority of the Company’s current corporate officers began their employment with the Company in fiscal years 2002 and 2001. TheOur inability of the Company to retain competenta skilled professional management team could adversely effect itsaffect our ability to successfully execute itsour business strategy.
strategies and achieve our goals.

Centralized Location of Manufacturing OperationsOur manufacturing activity is subject to certain risks.

The Company

We currently manufacturesmanufacture the vast majority of itsour products at itsour manufacturing facility in California. As a result, we are dependent on the uninterrupted and efficient operation of that facility. Our manufacturing operations are subject to power failures, the breakdown, failure or substandard performance of equipment, the improper installation or operation of equipment, natural or other disasters, and the need to comply with the requirements or directives of governmental agencies, including the FDA. In addition, we may in the future determine to expand or relocate our manufacturing facilities, which may result in Southern California. Accordingly,slow downs or delays in our manufacturing operations. While we maintain business interruption insurance, there can be no assurance that the occurrence of these or any event resultingother operational problems at our facility in the slowdownCalifornia or stoppage of the Company’s manufacturing operations or distribution facilitiesat NAIE’s facility in Southern California couldSwitzerland would not have a material adverse affecteffect on the Company. The Company maintainsour business, interruption insurance. Therefinancial condition and results of operations. Furthermore, there can be no assurance however, that suchour insurance will continue to be available at a reasonable cost or, if available, will be adequate to cover any losses that we may be incurredincur from an interruption in the Company’sour manufacturing and distribution operations.

ConcentrationWe may be unable to protect our intellectual property rights or may inadvertently infringe on the intellectual property rights of Ownership; Certain Anti-Takeover Considerationsothers.

The Company’s directors

We possess and executive officers beneficially ownmay possess in excessthe future certain proprietary technology, trade secrets, trademarks, tradenames and similar intellectual property. There can be no assurance that we will be able to protect our intellectual property adequately. In addition, the laws of 22.7%certain foreign countries may not protect our intellectual property rights to the same extent as the laws of the United States. Litigation in the United States or abroad may be necessary to enforce our intellectual property rights, to determine the validity and scope of the proprietary rights of others or to defend against claims of infringement. This litigation, even if successful, could result in substantial costs and diversion of resources and could have a material adverse effect on our business, results of operation and financial condition. If any such claims are asserted against us, we may seek to obtain a license under the third party’s intellectual property rights. There can be no assurance, however, that a license would be available on terms acceptable or favorable to us, if at all.

Collectively, our officers and directors own a significant amount of our common stock, giving them influence over corporate transactions and other matters and potentially limiting the influence of other stockholders on important policy and management issues.

Our officers and directors, together with their families and affiliates, beneficially owned approximately 25% of our outstanding Common Stockshares of common stock as of June 30, 2002. Accordingly, these shareholders2005. As a result, our officers and directors could influence such business matters as the election of directors and approval of significant corporate transactions.

Various transactions could be delayed, deferred or prevented without the approval of stockholders, including:

transactions resulting in a change in control;

mergers and acquisitions;

tender offers;

election of directors; and

proxy contests.

There can be no assurance that conflicts of interest will continuenot arise with respect to have the officers and directors who own shares of our common stock or that conflicts will be resolved in a manner favorable to us or our other stockholders.

If our information technology system fails, our operations could suffer.

Our business depends to a large extent on our information technology infrastructure to effectively manage and operate many of our key business functions, including order processing, customer service, product manufacturing and distribution, cash receipts and payments and financial reporting. A long term failure or impairment of any of our information technology systems could adversely affect our ability to substantially influenceconduct day-to-day business.

If certain provisions of our Certificate of Incorporation, Bylaws and Delaware law are triggered, the management, policies,future price investors might be willing to pay for our common stock could be limited.

Certain provisions in our Certificate of Incorporation, Bylaws and Delaware corporate law help discourage unsolicited proposals to acquire our business, operations ofeven if the Company. The Company’sproposal benefits our stockholders. Our Board of Directors has the authorityis authorized, without stockholder approval, to approve the issuance ofissue up to 500,000 shares of preferred stock and to fix thehaving such rights, preferences, privileges and restrictions,privileges, including voting rights, of those shares without any further vote or action byas the Company’s shareholders.board designates. The rights of the holders of Common Stockour common stockholders will be subject to, and may be adversely affected by, the rights of holders of any preferred stock that may be issued in the future. CertainAny or all of these provisions of Delaware law, as well as the issuance of preferred stock, and other “anti-takeover” provisions in the Company’s Articles and Bylaws, could delay, or inhibit the removal of incumbent directors and could delay, defer, make more difficultdeter or prevent a merger, tender offer or proxy content, or any change in control involving the Company, as well as the removaltakeover of management, even if such events would be beneficial to the interests of the Company’s shareholders,our company and maycould limit the price certain investors may beare willing to pay for our common stock.

Our stock price could fluctuate significantly.

Our stock price has been volatile in recent years. The trading price of our stock could fluctuate in response to:

broad market fluctuations and general economic conditions;

fluctuations in our financial results;

future offerings of our common stock or other securities;

the general condition of the nutritional supplement industry;

increased competition;

regulatory action;

adverse publicity;

manipulative or illegal trading practices by third parties; and

product and other public announcements.

The stock market has historically experienced significant price and volume fluctuations. There can be no assurance that an active market in our stock will continue to exist or that the price of our common stock will not decline. Our future operating results may be below the expectations of securities analysts and investors. If this were to occur, the price of our common stock would likely decline, perhaps substantially.

From time to time our shares may be listed for trading on one or more foreign exchanges, with or without our prior knowledge or consent. Certain foreign exchanges may have less stringent listing requirements, rules and enforcement procedures than the Nasdaq Stock Market or other markets in the United States, which may increase the potential for manipulative trading practices to occur. These practices, or the perception by investors that such practices could occur, may increase the volatility of our stock price or result in a decline in our stock price, which in some cases could be significant.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to market risk, which is the potential loss arising from adverse changes in market rates and prices, such as interest and foreign currency exchange rates. We generally do not enter into derivatives or other financial instruments for trading or speculative purposes. We may, however, enter into financial instruments to try to manage and reduce the impact of changes in foreign currency exchange rates. We cannot predict with any certainty our future for sharesexposure to fluctuations in interest and foreign currency exchange rates or other market risks or the impact, if any, such fluctuations may have on our future business, product pricing, consolidated financial condition, results of Common Stock.

ITEM 8.    FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
operations or cash flows. The financial statementsactual impact of any fluctuations in interest or foreign currency exchange rates may differ significantly from those discussed below.

Interest Rates

At June 30, 2005, we had fixed rate debt of $602,000 and supplementary data as requiredvariable rate debt of approximately $3.2 million. The interest rates on our variable rate debt range from LIBOR plus 1.75% to LIBOR plus 2.25%. As of June 30, 2005, the weighted average effective interest rate on our variable rate debt was 4.50%. An immediate one hundred basis point (1.0%) increase in the interest rates on our variable rate debt, holding other variables constant, would have increased our interest expense by this item are set forth on pages 25 through 45.

ITEM 9.    CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND    FINANCIAL DISCLOSURE
Form 8-K filed May 24, 2001, and amended June 12, 2001
Item 4.    Changes in Registrant’s Certifying Accountant
(b)On May 16, 2001, the Board of Directors of the Company notified KPMG LLP (“KPMG”) that their appointment as independent auditors was terminated effective May 16, 2001.
The reports of KPMG on the Company’s financial statements$48,000 for the fiscal year ended June 30, 2000 did2005. Interest rates have been at or near historic lows in recent years. There can be no guarantee that interest rates will not contain any adverse opinionrise. Any increase in interest rates may adversely affect our results of operations and financial condition.

Foreign Currencies

To the extent our business continues to expand outside the United States, an increasing share of our net sales and cost of sales will be transacted in currencies other than the United States dollar. Accounting practices require that our non-United States dollar-denominated transactions be converted to United States dollars for reporting purposes. Consequently, our reported net income may be significantly affected by fluctuations in currency exchange rates. When the United States dollar strengthens against currencies in which products are sold or disclaimer of opinionweakens against currencies in which we incur costs, net sales and were not qualified or modified as to uncertainty, audit scope or accounting principles.

18
costs could be adversely affected.


In connection

Our main exchange rate exposures are with the auditSwiss Franc and the Euro against the United States dollar. This is due to NAIE’s operations in Switzerland and the payment in Euros by our largest customer for finished goods. Additionally, we pay our NAIE employees and certain operating expenses in Swiss Francs. We may enter into forward exchange contracts, foreign currency borrowings and option contracts to hedge our foreign currency risk. Our goal in seeking to manage foreign currency risk is to provide reasonable certainty to the functional currency value of foreign currency cash flows and to help stabilize the value of non-United States dollar-denominated earnings.

On May 13, 2005, we purchased seven option contracts designated and effective as cash flow hedges to protect against the foreign currency exchange risk inherent in a portion of our forecasted transactions denominated in Euros. The seven options expire monthly beginning June 2005 and ending December 2005. The option contracts had a notional amount of $4.2 million, a weighted average strike price of $1.19, and a purchase price of $21,000. The risk of loss associated with the options is limited to premium amounts paid for the option contracts. As of June 30, 2005, we had not exercised any of the Company’s financial statementsoptions and one of the options had expired.

On July 7, 2005, we purchased 12 option contracts designated and effective as cash flow hedges to protect against the foreign currency exchange risk inherent in a portion of our forecasted transactions denominated in Euros. The 12 options expire monthly beginning January 2006 and ending December 2006. The option contracts had a notional amount of $7.0 million, a weighted average strike price of $1.16, and a purchase price of $152,000. The risk of loss associated with the options is limited to premium amounts paid for the option contracts.

On June 30, 2005, the Swiss Franc closed at 1.28 to 1.00 United States dollar and the Euro closed at 0.83 to 1.00 United States dollar. A 10% adverse change to the exchange rates between the Swiss Franc and the Euro against the United States dollar, holding other variables constant, would have decreased our net income for the fiscal yearsyear ended June 30, 2000, and in the subsequent interim period through March 31, 2001, there were no disagreements with KPMG on any matter2005 by $762,000.

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

Report of accounting principles or practices, financial statement disclosure, or auditing scope and procedures, which disagreements if not resolved to their satisfaction would have caused them to make reference in connection with their opinion to the subject matter of the disagreement.

The Company provided KPMG with a copy of this disclosure and requested KPMG to furnish it with a letter addressed to the Securities Exchange Commission stating whether it agrees with the above statements. A copy of that letter dated May 24, 2001 was filed as Exhibit 16.1 to a current report filed with the Securities and Exchange Commission on Form 8-K as amended.
(c)the Registrant engaged the accounting firm of Ernst & Young LLP (“Ernst & Young”), on May 21, 2001, as the independent auditors to audit the Registrant’s financial statements. Neither the Registrant nor anyone acting on its behalf had previously consulted Ernst & Young for any purpose, within the last two most recent fiscal years or any subsequent interim period.
Item 7.    Financial Statements and ExhibitsIndependent Registered Public Accounting Firm
(c)Exhibit 16.1 Letter from KPMG to the Securities Exchange Commission dated May 24, 2001.

19


PART III
ITEM 10.    DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT
The information required by this item will be included under the caption “Directors and Executive Officers of the Registrant” in the Registrant’s Proxy Statement for the 2003 Annual Meeting of Stockholders and is incorporated herein by reference.
ITEM 11.    EXECUTIVE COMPENSATION
The information required by this item will be included under the caption “Executive Compensation” in the Registrant’s Proxy Statement for the 2003 Annual Meeting of Stockholders and is incorporated herein by reference.
ITEM 12.    SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The information required by this item will be included under the caption “Security Ownership of Certain Beneficial Owners and Management” in the Registrant’s Proxy Statement for the 2003 Annual Meeting of Stockholders and is incorporated herein by reference.
ITEM 13.    CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
The information required by this item will be included under the caption “Certain Relationships and Related Transactions” in the Registrant’s Proxy Statement for the 2003 Annual Meeting of Stockholders and is incorporated herein by reference.

20


PART IV
ITEM 14.    EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND REPORTS ON FORM 8-K
(A)
1.    FINANCIAL STATEMENTS
The financial statements listed in the accompanying index to the consolidated financial statements are filed as part of this report.
2.
FINANCIAL STATEMENT SCHEDULES
The financial statement schedule listed in the accompanying index to the consolidated financial statements is filed as part of this annual report. Schedules not included have been omitted because they are not applicable or the information required is included in the financial statements and notes thereto.
(B)
EXHIBITS
23.1Consent of KPMG LLP, Independent Auditors
23.2Consent of Ernst & Young LLP, Independent Auditors
(C)
REPORTS FORM 8-K
The following filing on Form 8-K was filed during the fourth fiscal quarter, of the fiscal year reported herein, ended June 30, 2002:
The Company filed a Form 8-K on May 23, 2002 to announce the receipt of
approximately $2.4 million from a settlement with certain defendants in the
Vitamin Antitrust Litigation.

21


NATURAL ALTERNATIVES INTERNATIONAL, INC. AND SUBSIDIARIES
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
AND FINANCIAL STATEMENT SCHEDULE
JUNE 30, 2002
Independent Auditors’ Report23
Independent Auditors’ Report24
Consolidated Balance Sheets as of June 30, 2002 and 200125
Consolidated Statements of Operations and Comprehensive Income (Loss)
For the years ended June 30, 2002, 2001 and 2000
26
Consolidated Statements of Stockholders’ Equity for the years ended June 30, 2002, 2001 and 200027
Consolidated Statements of Cash Flows for the years ended June 30, 2002, 2001 and 200028
Notes to Consolidated Financial Statements29
Schedule II—Valuation and Qualifying Accounts for the years ended June 30, 2002, 2001 and 200045

22


Independent Auditors’ Report
The Board of Directors and Stockholders

Natural Alternatives International, Inc.

We have audited the accompanying consolidated balance sheets of Natural Alternatives International, Inc. as of June 30, 20022005 and 2001,2004, and the related consolidated statements of operationsincome and comprehensive income, (loss), stockholders’ equity, and cash flows for each of the three years then ended.in the period ended June 30, 2005. Our audits also included the financial statement schedule listed in the Indexindex at Item 14 (a)(2) for each of the two years in the period ended June 30, 2002.15(2). These financial statements and schedule are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements and schedule based on our audits.

We conducted our audits in accordance with auditingthe standards generally accepted inof the United States.Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. We were not engaged to perform an audit of the Company’s internal control over financial reporting. Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includesstatements, assessing the accounting principles used and significant estimates made by management, as well asand evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of Natural Alternatives International, Inc. at June 30, 20022005 and 2001,2004, and the consolidated results of theirits operations and theirits cash flows for each of the three years thenin the period ended June 30, 2005, in conformity with accounting principlesU.S. generally accepted in the United States.accounting principles. Also, in our opinion, the related financial statement schedule, when considered in relation to the basic financial statements taken as a whole, presents fairly in all material respects the information set forth therein.

/s/ Ernst & Young LLP

San Diego, California

August 9, 2002

5, 2005

23


Independent Auditors’ Report
The Board of Directors and Stockholders
Natural Alternatives International, Inc.
We have audited the consolidated statements of operations and comprehensive loss, stockholders’ equity, and cash flows of Natural Alternatives International, Inc. and subsidiaries for the year ended June 30, 2000. In connection with our audit of the consolidated financial statements, we have also audited the financial statement schedule for the year ended June 30, 2000. These consolidated financial statements and financial statement schedule are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements and financial statement schedule based on our audit.
We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated results of operations and cash flows of Natural Alternatives International, Inc. and subsidiaries for the year ended June 30, 2000, in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the related financial statement schedule, when considered in relation to the basic consolidated financial statements taken as a whole, presents fairly, in all material respects, the information set forth therein.
KPMG LLP
San Diego, California
October 9, 2000

24


Natural Alternatives International, Inc.

Consolidated Balance Sheets

As of June 30

(Dollars in thousands, except share and per share data)

   
2002

   
2001

 
Assets
          
Current assets:          
Cash and cash equivalents  $640   $499 
Restricted cash   1,500    —   
Accounts receivable—less allowance for doubtful accounts of $105 at June 30, 2002 and $470 at June 30, 2001   3,536    3,331 
Inventories, net   7,871    6,201 
Income tax refund receivable   701    —   
Prepaid expenses   271    481 
Deposits   168    33 
Other current assets   165    172 
   


  


Total current assets   14,852    10,717 
   


  


Property and equipment, net   12,439    13,798 
   


  


Other assets:          
Related parties notes receivable   118    451 
Other noncurrent assets, net   101    102 
   


  


Total other assets   219    553 
   


  


Total assets  $27,510   $25,068 
   


  


Liabilities and Stockholders’ Equity
          
Current liabilities:          
Accounts payable and accrued liabilities  $4,927   $4,149 
Accrued compensation and employee benefits   482    320 
Line of credit   —      242 
Income taxes payable   131    72 
Current portion of long-term debt and capital lease   587    889 
   


  


Total current liabilities   6,127    5,672 
Long-term debt and capital lease, less current portion   1,576    3,567 
Long-term pension liability   199    225 
   


  


Total liabilities   7,902    9,464 
   


  


Commitments and contingencies          
Stockholders’ equity:          
Preferred stock; $.01 par value; 500,000 shares authorized; none issued or outstanding   —      —   
Common stock; $.01 par value; 8,000,000 shares authorized, issued and outstanding 6,073,179 at June 30, 2002 and 6,048,106 at June 30, 2001   61    60 
Additional paid-in capital   11,362    11,307 
Retained earnings   9,488    5,609 
Treasury stock, at cost, 272,400 shares at June 30, 2002 and 262,500 shares at June 30, 2001   (1,303)   (1,283)
Accumulated other comprehensive loss   —      (89)
   


  


Total stockholders’ equity   19,608    15,604 
   


  


Total liabilities and stockholders’ equity  $27,510   $25,068 
   


  


   2005

  2004

 

Assets

         

Current assets:

         

Cash and cash equivalents

  $1,916  $7,495 

Accounts receivable - less allowance for doubtful accounts of $221 at June 30, 2005 and $132 at June 30, 2004

   10,834   8,889 

Inventories, net

   12,987   12,863 

Deferred income taxes

   421   1,010 

Other current assets

   1,012   633 
   


 


Total current assets

   27,170   30,890 
   


 


Property and equipment, net

   16,507   11,380 

Other assets:

         

Deferred income taxes

   276   —   

Other noncurrent assets, net

   185   198 
   


 


Total other assets

   461   198 
   


 


Total assets

  $44,138  $42,468 
   


 


Liabilities and Stockholders’ Equity

         

Current liabilities:

         

Accounts payable

  $7,973  $7,567 

Accrued liabilities

   1,923   2,078 

Accrued compensation and employee benefits

   1,351   2,626 

Income taxes payable

   664   320 

Current portion of long-term debt

   861   831 
   


 


Total current liabilities

   12,772   13,422 

Long-term debt, less current portion

   2,979   3,841 

Deferred income taxes

   —     717 

Deferred rent

   1,264   220 

Long-term pension liability

   206   140 
   


 


Total liabilities

   17,221   18,340 
   


 


Commitments and contingencies

         

Stockholders’ equity:

         

Preferred stock; $.01 par value; 500,000 shares authorized; none issued or outstanding

   —     —   

Common stock; $.01 par value; 20,000,000 shares authorized at June 30, 2005 and 8,000,000 at June 30, 2004, issued and outstanding 6,064,467 at June 30, 2005 and 5,970,992 at June 30, 2004

   61   60 

Additional paid-in capital

   11,494   10,864 

Accumulated other comprehensive loss

   (137)  (96)

Retained earnings

   15,792   13,593 

Treasury stock, at cost, 61,000 shares at June 30, 2005 and June 30, 2004

   (293)  (293)
   


 


Total stockholders’ equity

   26,917   24,128 
   


 


Total liabilities and stockholders’ equity

  $44,138  $42,468 
   


 


See accompanying notes to consolidated financial statements.

25


Natural Alternatives International, Inc.

Consolidated Statements Of OperationsIncome And Comprehensive Income (Loss)

For the Years Ended June 30

(Dollars in thousands, except share and per share data)

   
2002

   
2001

   
2000

 
Net sales  $50,037   $42,158   $47,827 
Cost of goods sold   39,068    33,970    44,152 
   


  


  


Gross profit   10,969    8,188    3,675 
Selling, general & administrative expenses   10,684    8,848    8,670 
Loss on abandonment of leased facility   —      —      1,729 
Loss on impairment of intangible assets acquired   —      1,544    —   
   


  


  


Income (loss) from operations   285    (2,204)   (6,724)
   


  


  


Other income (expense):               
Interest income   16    92    139 
Interest expense   (665)   (755)   (399)
Equity in loss of unconsolidated joint venture   —      (38)   (62)
Foreign exchange gain (loss)   (68)   15    74 
Proceeds from vitamin antitrust litigation   3,410    298    116 
Other, net   259    73    (45)
   


  


  


    2,952    (315)   (177)
   


  


  


Income (loss) before income taxes   3,237    (2,519)   (6,901)
Provision for (benefit from) income taxes   (642)   2,370    (2,429)
   


  


  


Net income (loss)  $3,879   $(4,889)  $(4,472)
   


  


  


Unrealized loss on investments   —      (28)   (1)
   


  


  


Comprehensive income (loss)  $3,879   $(4,917)  $(4,473)
   


  


  


Net income (loss) per common share:               
Basic  $0.67   $(0.85)  $(0.78)
   


  


  


Diluted  $0.67   $(0.85)  $(0.78)
   


  


  


Weighted average common shares outstanding:               
Basic shares   5,787,712    5,769,585    5,756,705 
Diluted shares   5,798,453    5,769,585    5,756,705 

   2005

  2004

  2003

 

Net sales

  $91,492  $78,534  $55,962 

Cost of goods sold

   73,095   59,964   42,781 
   


 


 


Gross profit

   18,397   18,570   13,181 

Selling, general & administrative expenses

   14,605   15,188   12,012 
   


 


 


Income from operations

   3,792   3,382   1,169 

Other income (expense):

             

Interest income

   21   24   57 

Interest expense

   (280)  (274)  (252)

Foreign exchange gain (loss)

   (137)  57   12 

Proceeds from vitamin antitrust litigation

   —     —     225 

Other, net

   13   (165)  (59)
   


 


 


    (383)  (358)  (17)
   


 


 


Income before income taxes

   3,409   3,024   1,152 

Provision for income taxes

   1,210   24   47 
   


 


 


Net income

  $2,199  $3,000  $1,105 
   


 


 


Unrealized gain resulting from change in fair value of derivative instruments, net of tax

   8   —     —   

Additional minimum pension liability, net of tax

   (49)  (96)  —   
   


 


 


Comprehensive income

  $2,158  $2,904  $1,105 
   


 


 


Net income per common share:

             

Basic

  $0.37  $0.51  $0.19 
   


 


 


Diluted

  $0.34  $0.48  $0.18 
   


 


 


Weighted average common shares outstanding:

             

Basic shares

   5,949,212   5,843,241   5,809,140 

Diluted shares

   6,464,714   6,304,167   6,021,155 

See accompanying notes to consolidated financial statements.

26


Natural Alternatives International, Inc.

Consolidated Statements Of Stockholders’ Equity

For the Years Ended June 30

(Dollars in thousands)

   
Common Stock

  
Additional Paid-in
Capital

  
Retained
Earnings

   
Treasury
Stock

     
Accumulated Other
Comprehensive
(Loss)

   
Total

 
   
Shares

  
Amount

            
Balance, June 30, 1999  6,002,375  $60  $11,237  $14,970   $(1,116)    $(60)  $25,091 
Issuance of common stock for employee stock purchase plan  22,005   —     35   —      —        —      35 
Treasury stock purchased  —     —     —     —      (167)     —      (167)
Net unrealized loss on investments  —     —     —     —      —        (1)   (1)
Net loss  —     —     —     (4,472)   —        —      (4,472)
   
  

  

  


  


    


  


Balance, June 30, 2000  6,024,380   60   11,272   10,498    (1,283)     (61)   20,486 
Issuance of common stock for employee stock purchase plan  23,726   —     35   —      —        —      35 
Net unrealized loss on investments  —     —     —     —      —        (28)   (28)
Net loss  —     —     —     (4,889)   —        —      (4,889)
   
  

  

  


  


    


  


Balance, June 30, 2001  6,048,106   60   11,307   5,609    (1,283)     (89)   15,604 
Issuance of common stock for employee stock purchase plan and stock option exercises  25,073   1   53   —      —        —      54 
Treasury stock purchased  —     —     —     —      (20)     —      (20)
Compensation expense related to stock options granted to employees  —     —     2   —      —        —      2 
Net realized loss on disposal of investments  —     —     —     —      —        89    89 
   
  

  

  


  


    


  


Net income  —     —     —     3,879    —        —      3,879 
   
  

  

  


  


    


  


Balance, June 30, 2002  6,073,179  $61  $11,362  $9,488   $(1,303)    $—     $19,608 
   
  

  

  


  


    


  


   Common Stock

  

Additional
Paid-in

Capital


  

Retained

Earnings


  

Treasury

Stock


  

Accumulated
Other

Comprehensive

(Loss)


  

Total


 
   Shares

  Amount

       

Balance, June 30, 2002

  6,073,179  $61  $11,362  $9,488  $(1,303) $—    $19,608 

Issuance of common stock for employee stock purchase plan and stock option exercises

  14,353   —     33   —     —     —     33 

Compensation expense related to stock options

  —     —     31   —     —     —     31 

Net income

  —     —     —     1,105   —     —     1,105 
   

 


 


 

  


 


 


Balance, June 30, 2003

  6,087,532   61   11,426   10,593   (1,303)  —     20,777 

Issuance of common stock for employee stock purchase plan and stock option exercises

  94,860   1   327   —     —     —     328 

Cancellation of treasury stock

  (211,400)  (2)  (1,008)  —     1,010   —     —   

Compensation expense related to stock options

  —     —     119   —     —     —     119 

Additional minimum pension liability, net of tax

  —     —     —     —     —     (96)  (96)

Net income

  —     —     —     3,000   —     —     3,000 
   

 


 


 

  


 


 


Balance, June 30, 2004

  5,970,992   60   10,864   13,593   (293)  (96)  24,128 

Issuance of common stock for employee stock purchase plan and stock option exercises

  93,475   1   427   —     —     —     428 

Compensation expense related to stock options

  —     —     72   —     —     —     72 

Compensation expense related to the acceleration of stock options

  —     —     131   —     —     —     131 

Unrealized gain resulting from change in fair value of derivative instruments, net of tax

  —     —     —     —     —     8   8 

Additional minimum pension liability, net of tax

  —     —     —     —     —     (49)  (49)

Net income

  —     —     —     2,199   —     —     2,199 
   

 


 


 

  


 


 


Balance, June 30, 2005

  6,064,467  $61  $11,494  $15,792  $(293) $(137) $26,917 
   

 


 


 

  


 


 


See accompanying notes to consolidated financial statements.

27


Natural Alternatives International, Inc.

Consolidated Statements Of Cash Flows

For the Years Ended June 30

(Dollars in thousands)

   
2002

   
2001

   
2000

 
Cash flows from operating activities
               
Net income (loss)  $3,879   $(4,889)  $(4,472)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:               
Provision for uncollectible accounts receivable   (58)   286    (142)
Increase in inventory reserve   1,535    —      2,000 
Write-off of notes receivable   —      89    80 
Depreciation and amortization   2,407    2,487    2,182 
Impairment charge on intangible assets   —      1,216    —   
Deferred income taxes   —      2,293    (907)
Non-cash compensation   2    —      —   
Pension expense, net of contributions   (26)   (192)   7 
(Gain) loss on disposal of assets   (54)   32    162 
Loss on investments   89    37    63 
Loss on abandonment of leased facility, net of amounts paid   —      (50)   (2,384)
Foreign exchange gains on foreign debt   —      —      (86)
Changes in operating assets and liabilities:               
Accounts receivable   (147)   373    3,560 
Inventories   (3,205)   1,426    249 
Tax refund receivable   (701)   1,500    729 
Prepaid expenses   210    154    420 
Deposits   (135)   37    875 
Accrued interest on related parties notes receivable   —      (53)   (64)
Other current assets   7    (109)   —   
Other noncurrent assets   1    12    393 
Accounts payable   778    (302)   (3,883)
Income taxes payable   59    72    —   
Accrued compensation and employee benefits   162    (35)   (431)
   


  


  


Net cash provided by (used in) operating activities   4,803    4,384    (1,649)
   


  


  


Cash flows from investing activities
               
Proceeds from sale of property and equipment   82    —      54 
Capital expenditures   (1,076)   (960)   (5,161)
Issuance of notes receivable   —      (100)   (826)
Repayment of notes receivable   313    17    78 
Investment purchases   —      —      (100)
Increase in intangible assets   —      (11)   —   
   


  


  


Net cash used in investing activities   (681)   (1,054)   (5,955)
   


  


  


Cash flows from financing activities
               
Net (payments) borrowing on lines of credit   (242)   (2,561)   2,833 
Borrowings on long-term debt and capital leases   —      1,708    5,455 
Payments on long-term debt and capital leases   (2,293)   (2,828)   (800)
Increase in restricted cash   (1,500)   —      —   
Issuance of common stock   54    35    35 
Treasury stock acquisitions   —      —      (167)
   


  


  


Net cash (used in) provided by financing activities   (3,981)   (3,646)   7,356 
Net increase (decrease) in cash and cash equivalents   141    (316)   (248)
Cash and cash equivalents at beginning of year   499    815    1,063 
   


  


  


Cash and cash equivalents at end of year  $640   $499   $815 
   


  


  


Supplemental disclosures of cash flow information
               
Cash paid during the year for:               
Interest  $394   $676   $365 
Income taxes refunded   —      (1,497)   (2,252)
   


  


  


Disclosure of non-cash activities:               
Net unrealized gains (losses) on investments  $—     $(28)  $(1)
   


  


  


Supplemental schedule of non-cash activities
               
Related parties notes receivable  $20   $855   $—   
Investments   —      150    —   
Accounts receivable   307    107    —   
Inventory   1,500    64    —   
Accounts payable   —      29    —   
   


  


  


   $1,827   $1,205   $—   
   


  


  


   2005

  2004

  2003

 

Cash flows from operating activities

             

Net income

  $2,199  $3,000  $1,105 

Adjustments to reconcile net income to net cash provided by operating activities:

             

Provision for uncollectible accounts receivable

   89   105   (46)

Depreciation and amortization

   2,559   2,676   2,477 

Deferred income taxes

   (404)  (293)  —   

Non-cash compensation

   203   119   31 

Pension benefit (expense), net of contributions

   17   (77)  (78)

Loss on disposal of assets

   20   86   10 

Changes in operating assets and liabilities:

             

Accounts receivable

   (2,034)  (3,326)  (2,086)

Inventories

   (124)  (5,018)  26 

Tax refund receivable

   —     —     701 

Other assets

   (427)  71   (175)

Accounts payable and accrued liabilities

   1,351   3,758   1,180 

Income taxes payable

   344   274   (85)

Accrued compensation and employee benefits

   (1,275)  1,909   235 
   


 


 


Net cash provided by operating activities

   2,518   3,284   3,295 
   


 


 


Cash flows from investing activities

             

Proceeds from sale of property and equipment

   —     —     109 

Capital expenditures

   (7,706)  (3,322)  (977)

Repayment of notes receivable

   13   7   89 
   


 


 


Net cash used in investing activities

   (7,693)  (3,315)  (779)
   


 


 


Cash flows from financing activities

             

Borrowings on long-term debt

   —     4,055   2,500 

Payments on long-term debt

   (832)  (2,339)  (1,707)

Increase in restricted cash

   —     —     1,500 

Issuance of common stock

   428   328   33 
   


 


 


Net cash provided by (used in) financing activities

   (404)  2,044   2,326 
   


 


 


Net increase (decrease) in cash and cash equivalents

   (5,579)  2,013   4,842 

Cash and cash equivalents at beginning of year

   7,495   5,482   640 
   


 


 


Cash and cash equivalents at end of year

  $1,916  $7,495  $5,482 
   


 


 


Supplemental disclosures of cash flow information

             

Cash paid during the year for:

             

Taxes

  $1,075  $44  $—   

Interest

  $280  $243  $252 
   


 


 


Disclosure of non-cash activities:

             

Treasury stock cancelled

  $—    $1,010  $—   

Net unrealized gains resulting from change in fair value of

derivative instruments

  $8  $—    $—   

Additional minimum pension liability

  $49  $96  $—   
   


 


 


See accompanying notes to consolidated financial statements.

28


NATURAL ALTERNATIVES INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

A. Organization and Summary of Significant Accounting Policies

Organization

Natural Alternatives International, Inc. manufactures

We provide private label contract manufacturing services to companies that market and distribute vitamins, micronutrientsminerals, herbs, and relatedother nutritional supplements, as well as other health care products, to consumers both within and provides innovative private-label products for specialized corporate, institutionaloutside the United States. We also develop, manufacture and commercial accounts worldwide. The Company operatesmarket our own products. We operate in a single segment, nutritional supplements.

International Subsidiary

On January 22, 1999, Natural Alternatives International Europe, SA (“NAIE”),NAIE was incorporatedformed as aour wholly-owned subsidiary, of the Company, based in Manno, Switzerland, which is adjacent to the city of Lugano. In September 1999, NAIE opened its new manufacturing facility to provide manufacturing capability in encapsulation and tablets, finished goods packaging, quality control laboratory testing, warehousing, distribution and administration. Upon formation, NAIE obtained from the Swiss tax authorities a five-year Swiss federal and localcantonal income tax holiday ending in fiscalthat ended June 30, 2005.

Principles of Consolidation

The consolidated financial statements include the accounts of Natural Alternatives International, Inc.NAI and itsour wholly-owned subsidiary, NAIE Natural Alternatives International Europe, SA (“Company”).NAIE. All significant intercompany accounts and transactions have been eliminated. The functional currency of the Company’sour foreign subsidiary is the United States dollar. The financial statements of the subsidiaryNAIE have been translated at either current or historical exchange rates, as appropriate, with gains and losses included in the consolidated statements of operations.

income.

Cash and Cash Equivalents

The Company considers

We consider all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.

Inventories

Inventories

Our inventories are recorded at the lower of cost (first-in, first-out) or market (net realizable value). Such costs include raw materials, labor and manufacturing overhead.

Property and Equipment

Property

We state property and equipment are stated at cost. Depreciation of property and equipment is provided using the straight-line method over their estimated useful lives, generally ranging from 31 to 39 years. LeaseholdWe amortize leasehold improvements are amortized using the straight-line method over the shorter of the life of the improvement or the expected term of the lease. In some locations, leasehold improvements are amortized over a period longer than the initial lease term as management believes it is more likely than not that the renewal option in the underlying lease will be exercised. Maintenance and repairs are expensed as incurred. Significant expenditures that increase economic useful lives are capitalized.

Impairment of Long-Lived Assets

Long-lived assets and certain identifiable intangibles are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of

29


NATURAL ALTERNATIVES INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceedexceeds the fair value of the assets. AssetsWe report assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.

Revenue Recognition

Revenue from sales of product,

We recognize revenue in accordance with SEC Staff Accounting Bulletin No. 101, “Revenue Recognition in Financial Statements” (SAB 101). SAB 101 requires that four basic criteria be met before revenue can be recognized: 1) there is evidence that an arrangement exists; 2) delivery has occurred; 3) the fee is fixed or determinable; and related cost of products sold,4) collectibility is reasonably assured. We recognize revenue upon determination that all criteria for revenue recognition have been met. The criteria are recognizedusually met at the time title passes to the customer, which usually occurs upon shipment. Customers generally do not haveRevenue from shipments where title passes upon delivery is deferred until the rightshipment has been delivered.

Additionally, we record reductions to returngross revenue for estimated returns of private label contract manufacturing products and direct-to-consumer products. The estimated returns are based upon the trailing six months of private label contract manufacturing gross sales and our historical experience for both private label contract manufacturing and direct-to-consumer product unless damaged or defective.

returns.

Cost of Goods Sold

Cost of goods sold includes raw material, labor and manufacturing overhead.

Research and Development Costs

As part of the services we provide to our private label contract manufacturing customers, we may perform, but are not obligated to perform, certain research and development activities related to the development or improvement of their products. While our customers typically do not pay directly for this service, the cost of this service is included as a component of the price we charge to manufacture and deliver their products.

Research and development costs are expensed when incurredincurred. Our research and were $821,000, $718,000 and $774,000development expenses for the last three fiscal years ended June 30 2002, 2001were $3.5 million for 2005, $2.8 million for 2004 and 2000, respectively.

$1.7 million for 2003.

Advertising Costs

Advertising

We expense advertising costs are expensed as incurred. During the years ended June 30, 2002, 2001 and 2000, the CompanyWe incurred and expensed advertising costs in the amountsamount of $679,000, $501,000$865,000 during the fiscal year ended June 30, 2005, $1.3 million during fiscal 2004 and $261,000, respectively.$1.5 million during fiscal 2003. These costs are included in selling, general and administrative expenses in the accompanying statements of operations.

income.

Income Taxes

The Company accounts

We account for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates, for each of the jurisdictions in which we operate, expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date.

Stock Option Plans

We do not record U.S. income tax expense for NAIE’s retained earnings that are declared as indefinitely reinvested offshore, thus reducing our overall income tax expense. The Company accountsamount of earnings designated as indefinitely reinvested in NAIE is based upon the actual deployment of such earnings in NAIE’s assets and our expectations of the future cash needs of our U.S. and foreign entities. Income tax laws are also a factor in determining the amount of foreign earnings to be indefinitely reinvested offshore.

It is our policy to establish reserves based upon management’s assessment of exposure for its stock-based employee compensation forcertain positions taken in previously filed tax returns that may become payable upon audit by tax authorities. The tax reserves are analyzed at least annually, generally in the fourth quarter of each year, and adjustments are made as events occur which warrant adjustments to the reserve.

Stock-Based Compensation

We have equity incentive plans under which we have granted nonqualified and incentive stock options usingto employees, non-employee directors and consultants. We also have an employee stock purchase plan. We account for stock-based awards to employees, including shares issued pursuant to the intrinsic value method prescribed byemployee stock purchase plan, in accordance with Accounting Principles Board Opinion No. 25, “Accounting for Stock Issued to Employees” (APB 25), and related interpretations, as allowed underinterpretations. We have adopted the disclosure-only alternative of Statement of Financial Accounting Standards No. (“SFAS”) 123. Accordingly, compensation cost123, “Accounting for Stock-Based Compensation” (SFAS 123), as amended by SFAS No. 148, “Accounting for Stock-Based Compensation –Transition and Disclosure” (SFAS 148).

Pro forma information regarding net income and net income per common share is measuredrequired and has been determined as if we had accounted for our stock-based awards under the excess, if any,fair value method, instead of the guidelines provided by APB 25. We estimated the fair value of the stock option awards at the date of grant and employee stock purchase plan shares at the beginning of the offering period using the Black-Scholes option valuation model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable. Option valuation models require the input of highly subjective assumptions, including expected life and stock price volatility. Because our options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect fair value estimates, in the opinion of management, the existing models do not necessarily provide a reliable single measure of the fair value of our stock option awards.

Effective April 27, 2005, our Board of Directors approved the Company’sacceleration of the vesting of all outstanding and unvested options held by directors, officers and other employees under our 1999 Omnibus Equity Incentive Plan. As a result of the acceleration, options to acquire 827,932 shares of our common stock, which otherwise would have vested over the next 36 months, became immediately exercisable. This action was taken to eliminate, to the extent permitted, the transition expense that we otherwise would incur in connection with the adoption of SFAS 123R. Included in the options to acquire 827,932 shares of our common stock were options to purchase 545,992 shares with exercise prices greater than our closing stock price on the date of acceleration. Under the accounting guidance of APB 25, the accelerated vesting resulted in a charge for stock-based compensation of approximately $131,000, which was recognized in the fourth quarter of fiscal 2005. Additionally, our pro forma disclosure includes the effect of this accelerated vesting, as calculated under SFAS 123, of $1.8 million which would have otherwise been recognized in our consolidated statements of operations over the next three fiscal years, upon the adoption of SFAS 123R in the first quarter of fiscal 2006.

The per share fair value of options granted in connection with stock option plans and rights granted in connection with employee stock purchase plans reported below has been estimated at the date of grant with the grantfollowing weighted average assumptions:

   Employee Stock Options

  Employee Stock Purchase Plans

 
   Fiscal Years Ended June 30,

  Fiscal Years Ended June 30,

 
   2005

  2004

  2003

  2005

  2004

  2003

 

Expected life (years)

   4.0 – 8.0   4.0 – 8.0   4.0–6.0   0.5   0.5   0.5 

Risk-free interest rate

   3.4–3.8%  2.4–3.7%  4.0%  2.0%  1.0%  1.5%

Volatility

   54%  64%  71%  54%  64%  71%

Dividend yield

   0%  0%  0%  0%  0%  0%

Weighted average fair value

  $3.82  $3.21  $1.75  $2.36  $1.82  $1.10 

For purposes of pro forma disclosures, we have amortized the estimated fair value of our stock option awards to expense over the priceoptions’ vesting periods and the estimated fair value of our employee must pay to acquirestock purchase plan shares over the stock.

offering period. Our pro forma information under SFAS 123 and SFAS 148 is as follows (dollars in thousands, except per share data):

   Fiscal Years Ended June 30,

 
   2005

  2004

  2003

 

Net income - as reported

  $2,199  $3,000  $1,105 

Plus: Reported stock-based compensation

   203   119   31 

Less: Fair value stock-based compensation

   (2,658)  (718)  (299)
   


 


 


Net income (loss) - pro forma

  $(256) $2,401  $837 
   


 


 


Reported basic net income per common share

  $0.37  $0.51  $0.19 
   


 


 


Pro forma basic net income (loss) per common share

  $(0.04) $0.41  $0.14 
   


 


 


Reported diluted net income per common share

  $0.34  $0.48  $0.18 
   


 


 


Pro forma diluted net income (loss) per common share

  $(0.04) $0.38  $0.14 
   


 


 


Fair Value of Financial Instruments

The carrying amounts of certain of the Company’sour financial instruments, including cash and cash equivalents, accounts receivable, notes receivable, investments, accounts payable, line of credit and notenotes payable

30


NATURAL ALTERNATIVES INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

approximates approximate fair value due to the relatively short maturity of such instruments. The carrying amounts for long-term debt approximate fair value as the interest rates and terms are comparable to rates and terms that could be obtained currently for similar instruments.

Use of Estimates

Management of the Company

Our management has made a number of estimates and assumptions relating to the reporting of assets and liabilities, revenue and expenses, and the disclosure of contingent assets and liabilities to prepare these consolidated financial statements in conformity with accounting principlesUnited States generally accepted in the United States.accounting principles. Actual results could differ from those estimates.

Net Income (Loss) per Common Share

The Company computes

We compute net income (loss) per common share in accordance with SFAS 128, “Earnings Per Share.” This statement requires the presentation of basic income (loss) per common share, using the weighted average number of common shares outstanding during the period, and diluted income per common share, using the additional dilutive effect of all dilutive securities. The dilutive impact of stock options account for the additional weighted average shares of common stock outstanding for the Company’sour diluted net income per common share computation. BasicWe calculated basic and diluted net income (loss)per common share as follows (amounts in thousands, except per share are calculated as follows:

   
For the Years Ended June 30,

 
   
2002

  
2001

   
2000

 
   
(Dollars in thousands, except share data)
 
Numerator
              
Net income (loss)  $3,879  $(4,889)  $(4,472)
Denominator
              
Basic weighted average common shares outstanding   5,787,712   5,769,585    5,756,705 
Dilutive effect of stock options   10,741   —      —   
   

  


  


Diluted weighted average common shares outstanding   5,798,453   5,769,585    5,756,705 
   

  


  


Basic net income (loss) per share  $0.67  $(0.85)  $(0.78)
   

  


  


Diluted net income (loss) per share  $0.67  $(0.85)  $(0.78)
   

  


  


For the years ended June 30, 2002, 2001 and 2000, sharesdata):

   For the Years Ended June 30,

   2005

  2004

  2003

Numerator

            

Net income

  $2,199  $3,000  $1,105

Denominator

            

Basic weighted average common shares outstanding

   5,949   5,843   5,809

Dilutive effect of stock options

   516   461   212
   

  

  

Diluted weighted average common shares outstanding

   6,465   6,304   6,021
   

  

  

Basic net income per common share

  $0.37  $0.51  $0.19
   

  

  

Diluted net income per common share

  $0.34  $0.48  $0.18
   

  

  

Shares related to stock options of 137,000, 524,400,193,000 for the fiscal year ended June 30, 2005, 61,000 for fiscal 2004 and 313,000, respectively,74,000 for fiscal 2003, were excluded from the calculation of diluted lossnet income per common share, as the effect of their inclusion would be anti-dilutive.

Concentrations of Credit Risk

Financial instruments that subject the Companyus to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company places itsWe place our cash and cash equivalents with highly rated financial institutions. Credit risk with respect to receivables is concentrated with the Company’sour largest customers. These customers’customers, whose receivable balances collectively represent 71%represented 86% of gross accounts receivable at June 30, 20022005 and 85%73% at June 30, 2001.2004. Concentrations of credit risk related to the remaining accounts receivable balances are limited due to the number of customers comprising the Company’sour remaining customer base.

Reclassifications
Certain prior period amounts have been reclassified to conform with the current period presentation.

31


NATURAL ALTERNATIVES INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

B. Inventories

Inventories, net are comprisedconsisted of the following at June 30:

   
2002

  
2001

   
(Dollars in thousands)
Raw materials  $4,631  $2,758
Work in progress   1,754   2,196
Finished goods   1,486   1,247
   

  

   $7,871  $6,201
   

  

30 (dollars in thousands):

   2005

  2004

Raw materials

  $8,068  $7,915

Work in progress

   3,230   3,066

Finished goods

   1,689   1,882
   

  

   $12,987  $12,863
   

  

C. Property and Equipment

The following is a summary of property

Property and equipment at June 30:

   
Life Used for Depreciation

  
2002

   
2001

 
      
(Dollars in thousands)
 
Land  NA  $393   $393 
Building and building improvements  5–39 years   3,279    3,277 
Machinery and equipment  3–15 years   15,517    14,995 
Office equipment and furniture  5–7 years   4,054    3,813 
Vehicles  3 years   197    197 
Leasehold improvements  5–39 years   4,230    4,100 
      


  


Total property and equipment      27,670    26,775 
Less accumulated depreciation and amortization      (15,231)   (12,977)
      


  


Property and equipment, net     $12,439   $13,798 
      


  


D.    Investments
Asconsisted of June 30, 2001, the Company’s investments include equity securities classified as available for sale. These investments were carried at fair value, with unrealized gains and losses recorded in Accumulated Other Comprehensive Loss. Securities are valued at $-0- and $17,000 as of June 30, 2002 and 2001 and are included in other current assets in the accompanying balance sheet. The security portfolio includes gross unrealized losses, net of tax, of $0 and $89,000following at June 30 2002 and 2001, respectively.
(dollars in thousands):

   

Depreciable Life

In Years


  2005

  2004

 

Land

  NA  $393  $393 

Building and building improvements

  7 – 39   2,713   3,235 

Machinery and equipment

  3 – 12   18,470   17,345 

Office equipment and furniture

  3 – 5   3,280   4,038 

Vehicles

  3   204   204 

Leasehold improvements

  1 – 15   9,244   4,954 
      


 


Total property and equipment

      34,304   30,169 

Less: accumulated depreciation and amortization

      (17,797)  (18,789)
      


 


Property and equipment, net

     $16,507  $11,380 
      


 


E.D. Debt

On December 20, 2000, the Company replaced

We have a $12.0 million credit facility with a bank. The facility is comprised of an existing $9.0$8.0 million working capital line of credit with a $9.35and $4.0 million credit facility.in term loans. The financing consisted of a $7.0 million working capital line of credit a $1.6 million term note,expires in November 2006, is secured by our accounts receivable and an additional $750,000 term note facility for financingother rights to payment, general intangibles, inventory and equipment, purchases. The entire credit facility carriedhas an annual interest rate of primePrime Rate or LIBOR plus 0.5%1.75%, as elected by the Company from time to time, and borrowings are subject to eligibility requirements for current accounts receivable and inventory balances. The term loans consist of a $700,000 ten year term loan with a twenty year amortization, secured by our San Marcos building, at an effective interest rate of 7.25%LIBOR plus 2.25%; a $1.8 million four year term loan, secured by our accounts receivable and other rights to payment, general intangibles, inventory and equipment, at an interest rate of LIBOR plus 2.10%; and a $1.5 million five year term loan, secured by equipment, at an interest rate of LIBOR plus 2.10%. Monthly payments on the term loans are approximately $63,000 plus interest. As of June 30, 2001. Borrowings2005, the outstanding amount on the term loans was $3.2 million and we did not have an outstanding balance on the working capital line of credit. As of June 30, 2005, we had $7.7 million available under the line of credit, were collateralized by eligible accounts receivable and inventory, as defined innet of a $270,000 outstanding letter of credit issued to our landlord.

On February 1, 2005, we amended our credit facility with the agreement; proceeds were usedbank to support ongoing operating requirements.

In October 2001,increase the Company andlimitation on our capital expenditures for the lender amended the credit agreement to provide new debt covenant restrictions and waive default rights and remedies as offiscal year ended June 30, 2001. Under the amended agreement the

32


NATURAL ALTERNATIVES INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

working capital line2005 from $6.5 million to $8.0 million. All other terms and conditions of credit was reduced to $2.5 million and the interest rate was increased to prime plus 3.5%. The entireour credit facility including the term note, expired on July 1, 2002. The term note was to be repaidremain in monthly installments of approximately $26,700 with the balance due upon expiration of the agreement on July 1, 2002.
Effective July 1, 2002, the Companyfull force and lender amended the working capital line of credit agreement. Under the terms of the amended agreement, maximum borrowings remain at $2.5 million, the interest rate was decreased to prime plus 0.5% and existing financial covenants were removed. The amended agreement requires the Company to maintain a minimum cash balance of $1.5 million with the secured creditor. The minimum cash balance requirement was reflected as restricted cash in the accompanying balance sheet as of June 30, 2002. The amount outstanding under the working capital line of credit agreement is to be paid upon expiration of the agreement on October 31, 2002. The Company expects the working capital line of credit to be refinanced in the normal course of business. As of June 30, 2002 there was no amount outstanding.
On May 2, 1996, the Company entered intoeffect.

Additionally, we have a term noteloan agreement for $1.1 million, secured by aour San Marcos building, at an annual interest rate of 8.25%. The noteloan is due in June 2011 and provides for principal and interest payable in monthly installments of $10,800. As of June 30, 20022005, the outstanding amount on the loan was $813,000.

In March 2001, NAIE entered into a capital lease arrangement with a bank for CHF 182,000, or approximately $108,000. The lease provided for monthly payments of approximately $3,000 over its thirty six (36) month term. Proceeds were used to finance capital equipment. This obligation was fully repaid at June 30, 2002.
During fiscal 2002, NAIE’s line of credit agreement that permitted borrowings up to CHF 1.0 million at an annual interest rate of 5.5% was cancelled. Amounts outstanding under the line of credit were $-0- and $30,000 as of June 30, 2002 and 2001, respectively.
On November 9, 1999, the Company entered into a term note agreement for $2.5 million, secured by equipment, at an annual interest rate of 9.2%. The note has a five-year term that provides for principal and interest payable in monthly installments of $52,000. As of June 30, 2002 the outstanding amount was $1.4 million.
$602,000.

The composite interest rate on all of our outstanding debt was 5.18% at June 30, 20022005 and 2001 was 8.84% and 8.06%, respectively.

5.44% at June 30, 2004.

Aggregate amounts of long-term debt maturities as of June 30, 2002 are2005 were as follows (dollars in thousands):

2003  $587
2004   642
2005   332
2006   83
2007   90
Thereafter   429
   

   $2,163
   

33


2006

  $861

2007

   895

2008

   888

2009

   445

2010

   151

Thereafter

   600
   

   $3,840
   

NATURAL ALTERNATIVES INTERNATIONAL, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

F.E. Income Taxes

The provision (benefit) for (benefit from) income taxes for the years ended June 30 consisted of the following:

   
2002

   
2001

  
2000

 
   
(Dollars in thousands)
 
Current:              
Federal  $(701)  $—    $(1,525)
State   —      —     3 
Foreign   59    —     —   
   


  

  


    (642)   —     (1,522)
   


  

  


Deferred:              
Federal   —      1,992   (755)
State   —      378   (152)
Foreign   —      —     —   
   


  

  


    —      2,370   (907)
   


  

  


Provision (benefit) for income taxes  $(642)  $2,370  $(2,429)
   


  

  


The provision (benefit) for deferred income taxes for the years ended June 30 consists of the following:
   
2002

   
2001

   
2000

 
   
(Dollars in thousands)
 
Accrual for loss on lease obligation  $—     $—     $951 
Accelerated depreciation and amortization for tax purposes   826    91    21 
Increase (decrease) in valuation allowance   (2,377)   3,355    83 
Inventories   703    (90)   (697)
Bad debt expense   155    (51)   308 
Accrued vacation expense   (10)   (18)   (15)
Customer deposits   —      —      (80)
Credit carryforward   (313)   —      (126)
Investment loss carryforward   —      —      36 
Other, net   (1)   304    (102)
Net operating loss carryforward   1,017    (1,221)   (1,286)
   


  


  


   $—     $2,370   $(907)
   


  


  


34
following (dollars in thousands):


   2005

  2004

  2003

 

Current:

             

Federal

  $1,320  $175  $—   

State

   94   3   —   

Foreign

   109   139   47 
   


 


 


    1,523   317   47 
   


 


 


Deferred:

             

Federal

   (398)  1,045   (372)

State

   85   293   (163)

Change in valuation allowance

   —     (1,631)  535 
   


 


 


    (313)  (293)  —   
   


 


 


Provision for income taxes

  $1,210  $24  $47 
   


 


 


NATURAL ALTERNATIVES INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Net deferred tax assets and deferred tax liabilities as of June 30 arewere as follows:
   
2002

  
2001

   
(Dollars in thousands)
Deferred tax assets:        
Allowance for doubtful accounts  $29  $184
Accrued vacation expense   88   78
Tax credit carryforward   439   126
Allowance for inventories   517   1,220
Other, net   117   116
Net operating loss carryforward   1,439   2,456
   

  

Total gross deferred tax assets   2,629   4,180
Less valuation allowance   1,097   3,474
   

  

Net deferred tax assets   1,532   706
Deferred tax liabilities:        
Accumulated depreciation and amortization   1,532   706
   

  

Net deferred tax liabilities   1,532   706
   

  

Net deferred tax asset  $—    $—  
   

  

follows (dollars in thousands):

   2005

  2004

 

Deferred tax assets:

         

Allowance for doubtful accounts

  $85  $48 

Accrued vacation expense

   189   156 

Tax credit carryforward

   99   128 

Allowance for inventories

   659   414 

Other, net

   93   —   

Net operating loss carryforward

   31   264 
   


 


Total gross deferred tax assets

  $1,156  $1,010 

Deferred tax liabilities:

         

Accumulated depreciation and amortization

   (459)  (717)
   


 


Deferred tax liabilities

   (459)  (717)
   


 


Net deferred tax assets

  $697  $293 
   


 


At June 30, 2002, the Company has federal and2005, we had state tax net operating loss carryforwards of approximately $3,335,000 and $5,229,000, respectively.$530,000. The Federal and state tax loss carryforwards will begin to expire in 2019 and 2005, respectively,2007, unless previously utilized.

A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized. Based upon the historical operating losses and the uncertainty regarding sufficient near term taxable income, management believes that this evidence creates sufficient uncertainty regarding the realizability of the net deferred tax assets. Therefore, a full valuation allowance of $3,474,000 was established in the year ended June 30, 2001 and adjusted to a full valuation allowance of $1,097,000 in the fiscal year ended June 30, 2002.

NAIE obtained from the Swiss tax authorities a five year Federalfive-year Swiss federal and localcantonal income tax holiday ending in fiscalthat ended June 30, 2005. Following the expiration of our tax holiday, we anticipate NAIE’s effective tax rate for Swiss federal, cantonal and communal taxes will be approximately 23%. NAIE had net income of $1,163,000$1.0 million for the fiscal year ended June 30, 2002.

During the fiscal year, Federal tax legislation was enacted that allows operating losses to be carried back five years, rather than three years as allowed under the previous statute. As a result of the new legislation, the Company amended its 1996 tax return, resulting in a $701,000 income tax refund. This amount was recognized as a benefit for income taxes for the year ended June 30, 2002 in the accompanying statement of operations and is included in income tax receivable in the accompanying balance sheet as of June 30, 2002.

35
2005.


NATURAL ALTERNATIVES INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

A reconciliation of income taxes computed by applying the statutory federal income tax rate of 34% to earningsnet income before income taxes for the year ended June 30 is as follows:
   
2002

     
2001

     
2000

 
   
(Dollars in thousands)
 
Income taxes (benefit) computed at statutory federal income tax rate  $1,101     $(857)    $(2,346)
State income taxes (benefit), net of federal income tax benefit (expense)   128      (101)     (214)
Net operating loss carryback refund   (701)     —        —   
Increase (decrease) in valuation allowance   (863)     3,355      83 
Expenses not deductible for tax purposes   3      70      68 
Foreign tax holiday   (356)     (442)     57 
Other   46      345      (77)
   


    


    


Income taxes (benefit) as reported  $(642)    $2,370     $(2,429)
   


    


    


Effective tax rate   (19.8)%     94.1%     (35.2)%
   


    


    


follows (dollars in thousands):

   2005

  2004

  2003

 

Income taxes computed at statutory federal income tax rate

  $1,159  $1,029  $392 

State income taxes, net of federal income tax expense

   118   196   67 

Increase (decrease) in valuation allowance

   —     (1,631)  534 

Expenses not deductible for tax purposes

   53   69   12 

Foreign tax holiday

   (304)  (187)  (228)

Foreign tax withholding

   101   —     —   

Dividend tax

   131   —     —   

Prior year adjustments

   —     305   (668)

Transfer pricing adjustment

   —     264   —   

Other

   (48)  (21)  (62)
   


 


 


Income taxes as reported

  $1,210  $24  $47 
   


 


 


Effective tax rate

   35.5%  0.8%  4.1%
   


 


 


G.F. Employee Benefit Plans

The Company has

We have a profit sharing plan pursuant to Section 401(k) of the Internal Revenue Code of 1986, as amended (the “Code”), whereby participants may contribute a percentage of compensation not in excess of the maximum allowed under the Code. All employees with twelvesix months and at least one thousand hours of service during the twelve-month periodcontinuous employment are eligible to participate in the plan. The CompanyWe may make contributions to the plan at the discretion of itsour Board of Directors. Effective July 1, 2001, the plan was amended to require the Company tothat we match one half of the first 6% of a participant’s compensation contributed to the plan. DuringEffective January 1, 2004, the plan was amended to require that we match 100% of the first 3% and 50% of the next 2% of a participant’s compensation contributed to the plan. The total contributions under the plan charged to operations totaled $315,000 for the fiscal year ended June 30, 2002, the Company contributed $73,000 in matching contributions to the plan. Prior to July 1, 2001, Company contributions to the plan were made at the discretion of the Board of Directors. During the years ended June 30, 20012005, $200,000 for fiscal 2004, and 2000, the Company contributed $-0- and $117,000, respectively. Contributions to the plan are expensed and included in selling, general and administrative expenses in the accompanying statements of operations.

The Company has$79,000 for fiscal 2003.

We have a “Cafeteria Plan” pursuant to Section 125 of the Code, whereby health care benefits are provided for active employees through insurance companies. Substantially all active full-time employees are eligible for these benefits. The Company recognizesWe recognize the cost of providing these benefits by expensing the annual premiums, which are based on benefits paid during the year. The premiums expensed for these benefits totaled $342,000, $271,000$876,000 for the fiscal year ended June 30, 2005, $697,000 for fiscal 2004, and $348,000$492,000 for 2002, 2001, and 2000, respectively.

fiscal 2003.

In December 1999, the Companywe adopted an employee stock purchase plan that provides for the issuance of up to 150,000 shares of the Company’sour common stock. Beginning July 1, 2004, the number of shares available for purchase under the plan will increase by 25,000 each year on July 1 until determined otherwise by the Board of Directors. The plan is intended to qualify under Section 423 of the Internal Revenue Code and is for the benefit of qualifying employees, as designated by the Human Resource Committee of the Board of Directors.employees. Under the terms of the plan, participating employees are eligiblemay have up to have a maximum of 15% of their compensation withheld through payroll deductions to purchase shares of our common stock at the lower of 85% of (i) the fair market value atclosing sale price for the beginning of eachstock as quoted on the Nasdaq National Market on either the first or last trading day in the offering period, or (ii) the fair market value on predetermined dates.whichever is lower. As of June 30, 2002, 64,7272005, 129,544 shares of common stock have beenwere issued pursuant to this plan.

The Company sponsors

We sponsor a defined benefit pension plan, (the “Plan”), which provides retirement benefits to employees based generally on years of service and compensation during the last five years before retirement. Effective June 21, 1999, the Companywe adopted an amendment to freeze benefit accruals to the participants. At

36


NATURAL ALTERNATIVES INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

June 30, 2002, the amortized portion of the unfunded accrued liability for prior service cost, using a 30-year funding period, was approximately $199,000. This amount was accrued. The Company’s policy is to fund the net pension cost accrued. However, the Company will notWe contribute an amount not less than the minimum funding requirements of the Employee Retirement Income Security Act of 1974 ornor more than the maximum tax-deductible amount.

Disclosure of Funded Status

The following table sets forth the Plan’sdefined benefit pension plan’s funded status and amount recognized in the Company’sour consolidated balance sheets at June 30 after(dollars in thousands):

   2005

  2004

 

Change in Benefit Obligation

         

Benefit obligation at beginning of year

  $1,286  $1,102 

Interest cost

   73   72 

Actuarial loss

   139   118 

Benefits paid

   (10)  (6)
   


 


Benefit obligation at end of year

  $1,488  $1,286 
   


 


Change in Plan Assets

         

Fair value of plan assets at beginning of year

  $1,146  $937 

Actual return on plan assets

   83   139 

Employer contributions

   63   76 

Benefits paid

   (10)  (6)
   


 


Fair value of plan assets at end of year

  $1,282  $1,146 
   


 


Reconciliation of Funded Status

         

Benefit obligation in excess of fair value of plan assets

  $(206) $(140)

Unrecognized net actuarial loss

   241   96 
   


 


Net amount recognized

  $35  $(44)
   


 


Additional Minimum Liability Disclosures

         

Accrued benefit liability

  $(206) $(140)

The weighted-average rates used for the effect of curtailment:

   
2002

   
2001

 
   
(Dollars in thousands)
 
Change in Benefit Obligation          
Benefit obligation at beginning of year  $978   $988 
Interest cost   63    68 
Actuarial (gain)/loss   8    141 
Benefits paid   (16)   —   
Other   —      (219)
   


  


Benefit obligation at end of year  $1,033   $978 
   


  


Change in Plan Assets          
Fair value of plan assets at beginning of year  $768   $768 
Actual return on plan assets   84    18 
Employer contributions   21    201 
Benefits paid   (16)   —   
Other   —      (219)
   


  


Fair value of plan assets at end of year  $857   $768 
   


  


Reconciliation of Funded Status          
Funded status (under)/over funded  $(176)  $(210)
Unrecognized net actuarial (gain)/loss   (23)   (15)
   


  


Accrued benefit cost  $(199)  $(225)
   


  


Additional Minimum Liability Disclosures          
Accrued benefit liability  $(176)  $(210)
years ended June 30 in determining the projected benefit obligations for the defined benefit pension plan were as follows:

   2005

  2004

 

Discount rate

  5.50% 6.00%

Compensation increase rate

  N/A  N/A 

Net Periodic Benefit Cost

The Net Periodic Benefit Costcomponents included in the defined benefit pension plan’s net periodic benefit cost for the fiscal years endingended June 30 includeswere as follows (dollars in thousands):

   2005

  2004

  2003

 

Interest cost

  $73  $72  $67 

Expected return on plan assets

   (89)  (73)  (64)
   


 


 


Net periodic benefit cost (income)

  $(16) $(1) $3 
   


 


 


The weighted-average rates used for the following components:

   
2002

   
2001

   
2000

 
   
(Dollars in thousands)
 
Components of Net Periodic Benefit Cost               
Interest cost  $63   $68   $68 
Expected return on Plan Assets   (68)   (58)   (61)
Recognized net actuarial (gain)/loss   —      (6)   —   
Effect of special events (curtailment)   —      4    —   
   


  


  


Net periodic benefit cost (income)  $(5)  $8   $7 
   


  


  


37
years ended June 30 in determining the defined benefit pension plan’s net pension costs, were as follows:


   2005

  2004

  2003

 

Discount rate

  6.00% 6.00% 6.50%

Expected long term rate of return

  8.00% 8.00% 7.50%

Compensation increase rate

  N/A  N/A  N/A 

NATURAL ALTERNATIVES INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

AssumptionOur expected rate of return is determined based on a methodology that considers historical returns of multiple classes analyzed to develop a risk free real rate of return and Method Disclosures
   
2002

   
2001

   
2000

 
Discount rate  6.50%  6.50%  7.00%
Expected long term rate of return  7.50%  7.50%  7.50%
Amortization method  Straight-line   Straight-line   Straight-line 
risk premiums for each asset class. The overall rate for each asset class was developed by combining a long-term inflation component, the risk free real rate of return, and the associated risk premium. A weighted average rate was developed based on those overall rates and the target asset allocation of the plan.

Our defined benefit pension plan’s weighted average asset allocation at June 30 and weighted average target allocation were as follows:

   2005

  2004

  Target
Allocation


 

Equity securities

  62% 61% 60%

Debt securities

  30% 31% 32%

Real estate

  8% 8% 8%
   

 

 

   100% 100% 100%
   

 

 

The underlying basis of the investment strategy of our defined benefit pension plan is to ensure that pension funds are available to meet the plan’s benefit obligations when they are due. Our investment strategy is a long-term risk controlled approach using diversified investment options with a relatively minimal exposure to volatile investment options like derivatives.

H.G. Stockholders’ Equity

Treasury Stock

In FebruaryJanuary 1999, the Board of Directors approved a repurchase program of up to 500,000 shares of the Company’sour common stock. As of June 30, 2001, 262,500 shares were repurchased under this program. In fiscal 2002, 9,900 shares were repurchased from a former Vice President of the Company pursuant to a separation agreement.

Stock Option Plans
Effective June 5, 1992, the Company adopted the 1992 Incentive Stock Option Plan for which 500,000 common shares have been reserved for issuance to officers, directors, and key employees of the Company. The plan provides that no option may be granted at an exercise price less than the fair market value of the common stock of the Company on the date of grant.
Effective December 9, 1994,This program was terminated by the Board of Directors approvedin October 2002 after the 1994 Nonqualified repurchase of 272,400 shares. During March 2004, 211,400 shares of such repurchased common stock were cancelled and returned to the status of authorized but unissued shares of our common stock.

Stock Option Plan for which 500,000 common shares were reserved for issuance to officers, employees, and consultants of the Company.

Plans

On October 28, 1998, and as amended March 11, 1999, the Board of Directors adopted the 1998 Outside Director Compensation Plan that provides non-employee directors an annual grant of nonqualified stock options. Three options for 10,000 shares each, were granted on March 11, 1999, at a fair market value price of $5.75 per share, and one grant of 10,000 shares was subsequently forfeited. The Outside Director Compensation Plan was subsequently included with the 1999 Plan and ceased to exist as a separate stock option plan. Pursuant to the former Outside Director Compensation Plan and the 1999 Plan, each non-employee director receives an annual grant of a Non-Qualified Option to purchase 10,000 shares on the first day of March of each fiscal year. Each such option has an exercise price equal to the fair market value on the date of grant, a five-year term and vests over 3 years providing the non-employee director remains willing to serve as a non-employee director of the Company.

At the Company’s Annual Meeting held on December 6, 1999, the Stockholdersour stockholders approved the adoption of the 1999 Omnibus Equity Incentive Plan (the “1999 Plan”) and reserved a. A total of 500,000 shares of common sharesstock were initially reserved under the 1999 Plan for issuance to our directors, officers, directors,other employees, and consultantsconsultants. Under the terms of the Company. 1999 Plan, the aggregate number of shares of common stock that may be awarded is automatically increased on January 1st of each year, commencing January 1, 2000, by a number equal to the lesser of 2.5% of the total number of common shares then outstanding or 100,000 shares. The 1999 Plan increased by 100,000 common shares on each of January 1, 2000, 2001, 2002, 2003, 2004 and 2005. In addition, at our Annual Meetings of Stockholders held on January 30, 2004 and December 31, 2004, our stockholders approved amendments to the 1999 Plan to increase the number of shares of common stock available under the 1999 Plan by an additional 500,000 shares, for a total increase of 1,000,000 shares.

Grants under thisthe 1999 Plan can be either Incentive Stock Options, or Nonqualified Stock Options.

With the exception of the 1999 Plan; allincentive stock options under each of the plans have five-year terms and all options become fully vested between three and eight years of their grant date. Stock optionsor nonqualified stock options. Options granted under the 1999 Plan have either a five or a ten-year termterm.

Effective April 27, 2005, our Board of Directors approved the acceleration of the vesting of all outstanding and become fullyunvested options held by directors, officers and other employees under our 1999 Omnibus Equity Incentive Plan. As a result of the acceleration, options to acquire 827,932 shares of our common stock, which otherwise would have vested within three yearsover the next 36 months, became immediately exercisable. This action was taken to eliminate, to the extent permitted, the transition expense that we otherwise would incur in connection with the adoption of their grant date.

38
SFAS 123R. Included in the options to acquire 827,932 shares of our common stock were options to purchase 545,992 shares with exercise prices greater than our closing stock price on the date of acceleration. Under the accounting guidance of APB 25, the accelerated vesting resulted in a charge for stock-based compensation of approximately $131,000, which was recognized in the fourth quarter of fiscal 2005.


NATURAL ALTERNATIVES INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Stock option activity duringfor the periods indicated is summarized below:
   
1992 Incentive Plan

   
1994 Nonqualified Plan

   
1998
Outside Director Plan

   
1999 Plan

   
Total
All
Plans

   
Weighted Average Exercise Price

Outstanding at June 30, 1999  181,750   171,000   —     —     352,750   6.32
Forfeited  (38,750)  (171,000)  (10,000)  (30,500)  (250,250)  4.79
Granted  30,000   —     30,000   150,500   210,500   2.73
   

  

  

  

  

  
Outstanding at June 30, 2000  173,000   —     20,000   120,000   313,000   5.18
Forfeited  (8,000)  —     —     (13,600)  (21,600)  5.17
Granted  —     —     —     233,000   233,000   2.17
   

  

  

  

  

  
Outstanding at June 30, 2001  165,000   —     20,000   339,400   524,400   3.84
Exercised  —     —     —     (6,104)  (6,104)  2.02
Forfeited  (80,000)  —     —     (186,296)  (266,296)  2.51
Granted  —     —     —     274,800   274,800   2.01
   

  

  

  

  

  
Outstanding at June 30, 2002  85,000   —     20,000   421,800   526,800   3.58
   

  

  

  

  

  
Exercisable at June 30, 2002  85,000   —     20,000   120,840   225,840   5.59
   

  

  

  

  

  
Weighted-average remaining contractual life in years  .6   —     1.7   8.3   6.66    
Available for grant at June 30, 2002  215,000   —     —     72,096   287,096    
   

  

  

  

  

   
three years ending June 30, 2005 was as follows:

   1992
Incentive
Plan


  

1998

Outside
Director Plan


  

1999

Plan


  

Total

All

Plans


  Weighted
Average
Exercise
Price


Outstanding at June 30, 2002

  85,000  20,000  421,800  526,800  3.58

Exercised

  —    —    (6,199) (6,199) 2.17

Forfeited

  (85,000) —    (135,401) (220,401) 5.57

Granted

  —    —    285,000  285,000  3.08
   

 

 

 

 

Outstanding at June 30, 2003

  —    20,000  565,200  585,200  2.60

Exercised

  —    (20,000) (61,700) (81,700) 3.40

Forfeited

  —    —    (8,600) (8,600) 5.61

Granted

  —    —    774,800  774,800  6.26
   

 

 

 

 

Outstanding at June 30, 2004

  —    —    1,269,700  1,269,700  4.76

Exercised

  —    —    (49,945) (49,945) 2.86

Forfeited

  —    —    (20,955) (20,955) 5.82

Granted

  —    —    240,500  240,500  8.56
   

 

 

 

 

Outstanding at June 30, 2005

  —    —    1,439,300  1,439,300  5.45

Exercisable at June 30, 2005

  —    —    1,439,300  1,439,300  5.45
   

 

 

 

 

Weighted-average remaining contractual life in years

  —    —    3.71  3.71   

Available for grant at June 30, 2005

  —    —    536,752  536,752   
   

 

 

 

  

During fiscal 2002, the Companywe granted options to purchase 90,000 shares to employees at an exercise price below the fair market value of the stock on the grant date. The CompanyDuring fiscal 2004, we granted options to purchase 150,000 shares to an employee at an exercise price below the fair market value of the stock on the grant date. We recorded approximately $2,000$72,000 of compensation expense in fiscal 2002 related to these option grants.grants in fiscal 2005, $63,000 in fiscal 2004 and $31,000 in fiscal 2003. As a result of June 30, 2002, the Company expects to record approximately $86,000acceleration of vesting of all outstanding and unvested options on April 27, 2005, we expensed the unamortized deferred compensation associated with these options.

Additionally, during fiscal 2004 we recorded $56,000 of compensation expense over the vesting period of the related stockto options through fiscal 2005.

granted to a non-employee to purchase 15,000 shares.

The fair value of the option grants was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions for fiscal 2002, 2001 and 2000: risk-free interest rates of 4.40%, 6.0% and 6.0%, respectively; dividend yield rate of zero; expected life of four to nine years, four years, and three to six years, respectively, depending on option termination date; and volatility of 53%, 52% and 88%, respectively. The weighted average fair valueis a further breakdown of the options granted was $1.45, $2.17 and $1.61 per share, respectively.

As ofoutstanding at June 30, 2002, the range of stock option exercise prices was $1.80 to $10.50.

39
2005:


Range of

Exercise

Prices


  

Number

Outstanding


  

Weighted

Average

Remaining

Contractural

Life


  

Weighted

Average

Exercise

Price


  

Number

Exercisable


  

Weighted

Average

Exercise Price


$1.80 - $2.03

  166,800  4.64  $1.97  166,800  $1.97

$2.04 - $3.02

  245,400  2.34  $2.63  245,400  $2.63

$3.03 - $5.21

  310,000  3.49  $4.96  310,000  $4.96

$5.22 - $6.65

  407,600  3.56  $6.56  407,600  $6.56

$6.66 - $10.47

  309,500  4.71  $8.58  309,500  $8.58

  
  
  

  
  

$ 1.80 - $10.47

  1,439,300  3.71  $5.45  1,439,300  $5.45

  
  
  

  
  

NATURAL ALTERNATIVES INTERNATIONAL, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Pro forma Information for Stock Options
The Company applies APB Opinion No. 25 in accounting for its Plans and, accordingly, recognizes compensation cost based on the intrinsic value of the options on the date of grant. Had the Company determined compensation cost based on the fair value at the grant date for its stock options under SFAS No. 123, the Company’s net income (loss) would have been the pro forma amounts indicated below. These pro forma amounts are not necessarily representative of the effects on reported net income (loss) for future years.
   
2002

  
2001

   
2000

 
   
(Dollars in thousands)
 
Net income (loss), as reported  $3,879  $(4,889)  $(4,472)
Pro forma net income (loss)  $3,740  $(4,993)  $(4,750)
Basic net income (loss) per share, as reported  $0.67  $(0.85)  $(0.78)
Pro forma basic net income (loss) per share  $0.67  $(0.87)  $(0.83)
Diluted earnings net income (loss) per share, as reported  $0.67  $(0.85)  $(0.78)
Pro forma diluted net income (loss) per share  $0.67  $(0.87)  $(0.83)
I.H. Commitments
The Company leases part of its main facilities under leases that are non-cancelable operating leases.
The Company entered into two

We lease agreements during fiscal year 1999 for adjacent buildings located in Vista, California. The facilities are leased from an unaffiliated third party and consist of a total of 181,500 square feet of our manufacturing facilities from unaffiliated third parties under non-cancelable operating leases, including 162,000 square feet at our manufacturing facility in Vista, California and 19,500 square feet at our San Marcos, California facility. The leases on the San Marcos facility have various expiration dates through 2007. The lease on the Vista facility expires in March 2014.

On February 25, 2004, we entered into an agreement to sublet 42,000 square feet at our Vista, California facility. The sublease was for a term of seven months that began on April 1, 2004, and provided for monthly rental income equal to our rental expense for the space. The sublease agreement ended October 31, 2004. The space is currently being used for warehousing.

As required under the terms of our Vista lease, on May 11, 2004, we provided a letter of credit in the amount of $440,000 to the landlord. The amount of the letter of credit will be reduced by approximately 74,00033% each year. On April 1, 2005, we reduced our outstanding amount to $270,000.

NAIE leases facility space in Manno, Switzerland. The leased space totals approximately 38,000 square feet. The leaseWe primarily use the facilities for the first building commenced in August 1998 under a 5-year lease agreement and consists of approximately 54,000 square feet to be utilized as amanufacturing, packaging, warehousing and blending facility. The lease for the second building commenced in March 1999 under a 3.5-year lease agreement for the rental of approximately 20,000 square feet to be utilized as a packaging facility.

NAIE leases two units in Manno, a town adjacent to Lugano, Switzerland. Both units total approximately 22,000 square feet. The facilities are used primarily for the use of manufacturing, packaging and distribution ofdistributing nutritional supplement products for the European marketplace. The Company entered into a five-year lease agreementexpires in March 1999 for the initial unit containing 18,000 square feet, with the facility becoming fully operational for manufacturing operations in September 1999. The lease for the second unit (the term of which is the same as the first unit) was completed in March 2001, for an additional 4,000 square feet.
December 2015.

Minimum rental commitments (exclusive of property tax, insurance and maintenance) under all non-cancelable operating leases including the lease agreements referred to above, (withwith initial or remaining lease terms in excess of one year)year, including the lease agreements referred to above, are set forth below as of June 30, 2005 (dollars in thousands):

2003  $906
2004   375
2005   241
2006   108
   

   $1,630
   

2006

  $1,872

2007

   1,937

2008

   1,919

2009

   1,939

2010

   1,977

Thereafter

   8,961
   

   $18,605
   

Rental expense totaled $818,000, $780,000 and $647,000$1.7 million for the yearsfiscal year ended June 30, 2002, 20012005, $1.2 million for fiscal 2004, and 2000, respectively.

40
$947,000 for fiscal 2003. Rental expense was offset by sublease rental income in the amount of $137,000 for fiscal 2005, $68,000 in fiscal 2004 and zero in fiscal 2003.


I. Foreign Currency Instruments

NATURAL ALTERNATIVES INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

On August 9, 2004, we purchased ten monthly participating forward contracts designated and effective as cash flow hedges against the foreign currency exchange risk inherent in our forecasted transactions denominated in Euros. The participating forward contracts consisted of ten put options providing protection if the exchange rate of the United States dollar to the Euro decreased below our contracted strike price of $1.1892, and ten call options that offset the initial cost of the purchased put options. The call options obligated us to give up 50% of the foreign currency gain related to the forecasted transaction if the United States dollar/Euro exchange rate increased above our contracted strike price. The participating forward contracts had an initial notional amount of $1.5 million and a weighted average strike price of $1.1892. As of June 30, 2005, we had exercised all of the participating forward contracts.

On May 13, 2005, we purchased seven option contracts designated and effective as cash flow hedges to protect against the foreign currency exchange risk inherent in a portion of our forecasted transactions denominated in Euros. The seven options expire monthly beginning June 2005 and ending December 2005. The option contracts had a notional amount of $4.2 million, a weighted average strike price of $1.19, and a purchase price of $21,000. The risk of loss associated with the options is limited to premium amounts paid for the option contracts. As of June 30, 2005, we had not exercised any of the options and one of the options had expired.

For the fiscal year ended June 30, 2005, approximately $109,000 had been charged to income for option contracts outstanding during the year.

J. Related Party Transactions

Prior to fiscal 2001, the Company had sales to a customer in which directors, officers and employees previously had direct and indirect equity ownership. During fiscal 2000, the Company wrote off an account receivable and a note receivable from this customer of $34,000 and $50,000, respectively. During fiscal 2001, $65,000 was received from this customer and credited to other income as recovery of amounts previously written off.

During fiscal 1999, the Companywe made a 6% interest-bearing loansinterest bearing loan of $20,000 secured by Company common stock, to our Chief Scientific Officer. The note and interest due were being paid in biweekly payments of $550. The balance of the Vice President of Science and Technology, the former Vice President of Marketing, and a former Vice President of Operations. During fiscal 2000 an additional loan of $19,000, with interest at 6% and secured by a second deed of trust on his principal residence, was made to a former Vice President of Marketing. During fiscal 2000 the loan amount,note, including accrued interest, was paid in full in September 2004.

K. Economic Dependency

We had substantial net sales to the Vice President of Operations, was repaid upon termination of his employment. As of June 30, 2001, the notes receivable from the former Vice President of Marketing of $39,000 plus accrued interest of $4,000 were fully reserved as uncollectible. During fiscal 2001, certain notes and accrued interest receivable, totaling $61,216 from the Company’s Vice President of Science and Technology, which had been fully reserved in fiscal 1999, as uncollectible, were forgiven. During fiscal 2002, the note and accrued interest receivables from the former Vice President of Marketing, which had been fully reserved in fiscal 2001, were repaid as part of a separation agreement. During fiscal 2002, the Company made a non-interest loan for $14,000 to the Vice President of Science and Technology. The loan has a 13 month term and provides for monthly payments of $1,100.

During fiscal 2001 and 2000, the Company paid the brother and sister-in-law of the Chief Executive Officer approximately $25,000 and $58,000, respectively, in settlement of an existing consulting arrangement. As of June 30, 2001, the agreement expired.
During each ofcustomers during the fiscal years 2001 and 2000, the Company made non-interest loans to a former member of the Board of Directors in the amount of $50,000. Amounts owed on these loans, which are secured by proceeds from life insurance policies, were $350,000 and $300,000 at June 30, 2001 and 2000, respectively. During fiscal 2002, the loans were repaid from the insurance proceeds.
The balances of these notes receivables from related parties and employees as of June 30, including accrued interest are shown below (dollars in thousands).
   
2002

  
2001

Chief Executive Officer  $76  $71
Vice President of Science and Technology   42   27
Chairperson—Board of Directors   —     350
Other Current Employees   —     1
Other   —     2
   

  

   $118  $451
   

  

The Company accrued interest from related parties notes receivable of $5,600 and $4,000 for the years ended June 30 2002 and 2001, respectively.
K.    Joint Venture and Intangible Assets Acquired
In March 1999, the Company entered into a letter of intent to form a joint venture with FitnessAge Incorporated, a privately held development stage company based in San Diego, CA (“FitnessAge”). In connection therewith, on March 30, 1999 the Company purchased 300,000 shares of FitnessAge common stock

41


NATURAL ALTERNATIVES INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

for $150,000. On or about the same date, the Family Limited Partnership of the Chief Executive Officer and the former Chairperson of the Board of Directors and Secretary purchased 200,000 shares of common stock of FitnessAge for $100,000.
During fiscal 2000, the Company and FitnessAge formalized the joint venture by forming a new company named Custom Nutrition, LLC, (“Custom Nutrition”) in which the Company at formation had a 40% ownership from an initial capital contribution of $100,000.
Additionally, in November and December 1999, the Company loaned FitnessAge a total of $750,000 (the “Loan”). The principal together with all accrued and unpaid interest on the Loan was due beginning February 1, 2001.
FitnessAge did not meet its loan payment obligation on February 1, 2001. As a result, the Company notified FitnessAge on February 2, 2001 of its decision to accelerate the maturity of the Loan and its intention to retain the Loan collateral in satisfaction of FitnessAge’s obligations. As of February 23, 2001, the Company perfected its interest in the collateralized assets, as defined per the escrow agreement and the Uniform Commercial Code, and took full ownership and possession of Custom Nutrition LLC and the perpetual, irrevocable, nonexclusive, royalty-free worldwide license to FitnessAge’s proprietary physical assessment software technology. The Company retained its equity interest in FitnessAge by its ownership of common stock.
As of June 30, 2001, management and the Board of Directors determined based on their on-going evaluation of the various alternatives to commercialize the physical assessment software, that the Company would not dedicate the resources necessary to recover the carrying value of the asset. Management determined that the fair value of the asset was zero and therefore recorded a charge of $1,216,000 to write off the carrying value of the intangible asset. Additionally, in fiscal 2001 the Company incurred expenses of approximately $328,000 in its efforts toward commercializing the assets.
As of June 30, 2002, the net book value of the intangible asset was zero.
L.    Economic Dependency
The Company had substantial sales to three separate customers during one or more of the periods shown in the following table. The loss of any of these customers, or a significant decline in net sales or the growth rate of net sales to these customers could have a material adverse impact on the Company’s revenuesour net sales and earnings. Sales bynet income. Net sales to any one customer representing 10% or more of the respective year’s total net sales are shown belowwere as follows (dollars in thousands):
   
2002

   
2001

   
2000

 
   
Sales by Customer

   
%(a)

   
Sales by Customer

  
%(a)

   
Sales by Customer

   
%(a)

 
Customer 1  $23,975   48%  $21,889  52%  $20,818   44%
Customer 2   10,432   21%   4,242  10%   8,958   18%
Customer 3   (b)  —      4,219  10%   (b)  —   
   


  

  

  

  


  

   $34,407   69%  $30,350  72%  $29,776   62%
   


  

  

  

  


  


(a)Percent of total sales (b) Sales for the year were less than 10% of total sales.

   2005

  2004

  2003

 
   Net Sales by
Customer


  

% of Total

Net Sales


  Net Sales by
Customer


  % of Total
Net Sales


  Net Sales by
Customer


  % of Total
Net Sales


 

Customer 1

  $36,991  40% $31,182  40% $24,119  43%

Customer 2

   35,193  39%  23,464  30%  15,337  27%
   

  

 

  

 

  

   $72,184  79% $54,646  70% $39,456  70%
   

  

 

  

 

  

Accounts receivable from these customers totaled $2,528,000 and $2,817,000$9.5 million at June 30, 20022005, and 2001, respectively.

42
$6.6 million at June 30, 2004.


NATURAL ALTERNATIVES INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

The Company purchasesWe buy certain products it does not manufacture from a limited number of raw material suppliers. MannatechThe loss of any of these suppliers could have a material adverse impact on our net sales and net income. Carrington Laboratories Incorporated comprised 29%35% of our total raw material purchases for the year ended June 30, 2002.2005. Accounts payable to MannatechCarrington Laboratories Incorporated was $1.5 million$660,000 at June 30, 2002.2005. No other supplier comprised 10% or more of the Company’sour raw material purchases for the year ended June 30, 2002.
2005.

M.L. Contingencies

From time to time, we become involved in various investigations, claims and legal proceedings that arise in the ordinary course of our business. These matters may relate to product liability, employment, intellectual property, tax, regulation, contract or other matters. The Companyresolution of these matters as they arise will be subject to various uncertainties and, even if such claims are without merit, could result in the expenditure of significant financial and managerial resources. While unfavorable outcomes are possible, based on available information, we generally do not believe the resolution of these matters, including that discussed below, will result in a material adverse effect on our business, consolidated financial condition, or results of operation. However, a settlement payment or unfavorable outcome could adversely impact our results of operation. Our evaluation of the likely impact of these actions, including that discussed below, could change in the future and we could have unfavorable outcomes that we do not expect.

On February 10, 2005, a complaint was filed against NAI on behalf of Novogen Research Pty. Ltd. in the United States District Court, Southern District of New York alleging a cause of action for patent infringement of a Novogen patent by products manufactured by NAI. The parties are attempting to resolve the matter in an out-of-court settlement but if we are unable to do so we intend to vigorously defend the action.

We were a plaintiff in an anti-trust lawsuit against several manufacturers of vitamins and other raw materials purchased by the Company.that we purchased. Other similarly situated companies filed a number of similar lawsuits against some or all of the same manufacturers. The Company’sOur lawsuit was consolidated with some of the others and captionedIn re: Vitamin Antitrust LitigationLitigation., and is pending in U.S. District Court in Washington D.C. As of June 30, 2003, all of our claims under the vitamin antitrust litigation were settled. Settlement payments that we received by the Company of $3,410,000, $298,000$225,000 in fiscal 2003 and $116,000$3.4 million in fiscal 2002 are included in proceeds from vitamin antitrust litigation in the accompanying statements of operationsincome for fiscal 2003 and 2002, 2001as applicable.

M. Segment Information

Our business consists of one segment, the development, manufacturing, marketing and 2000, respectively. Subsequent todistribution of nutritional supplements. Our products are sold both in the United States and in markets outside the United States, including Europe, Australia and Japan. Our primary market outside the United States is Europe.

Net sales by geographic region, based upon the customers’ location, were as follows (dollars in thousands):

   Year Ended June 30

   2005

  2004

  2003

United States

  $67,784  $56,350  $41,838

Markets Outside the United States

   23,708   22,184   14,124
   

  

  

Total Net Sales

  $91,492  $78,534  $55,962
   

  

  

Products manufactured by NAIE accounted for 46% of net sales in markets outside the United States in fiscal 2005, 42% in fiscal 2004 and 51% in fiscal 2003.

No products manufactured by NAIE were sold in the United States during the fiscal years ended June 30, 2002,2005, 2004 and 2003.

Assets and capital expenditures by geographic region, based on the Company receivedlocation of the company or subsidiary at which they were located or made, were as follows (dollars in thousands):

2005


  Long-Lived
Assets


  Total
Assets


  Capital
Expenditures


United States

  $17,144  $40,470  $7,397

Europe

   1,053   3,668   309
   

  

  

   $18,197  $44,138  $7,706
   

  

  

2004


  

Long-Lived

Assets


  

Total

Assets


  

Capital

Expenditures


United States

  $10,833  $38,625  $3,138

Europe

   1,135   3,843   184
   

  

  

   $11,968  $42,468  $3,322
   

  

  

2003


  

Long-Lived

Assets


  

Total

Assets


  

Capital

Expenditures


United States

  $9,996  $26,724  $755

Europe

   1,362   4,000   222
   

  

  

   $11,358  $30,724  $977
   

  

  

SCHEDULE II

Natural Alternatives International, Inc.

Valuation And Qualifying Accounts

For The Years Ended June 30, 2005, 2004 and 2003

   (Dollars in thousands)

   Balance at Beginning
of Period


  Provision

  (Deductions)

  

Balance at End

of Period


Fiscal year ended June 30, 2005:

                

Inventory reserves

  $1,113  $1,529  $(827) $1,815

Allowance for doubtful accounts

  $132  $101  $(12) $221

Fiscal year ended June 30, 2004:

                

Inventory reserves

  $708  $965  $(560) $1,113

Allowance for doubtful accounts

  $27  $106  $(1) $132

Fiscal year ended June 30, 2003:

                

Inventory reserves

  $1,467  $19  $(778) $708

Allowance for doubtful accounts

  $105  $(46) $(32) $27

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.

ITEM 9A. CONTROLS AND PROCEDURES

We maintain certain disclosure controls and procedures. They are designed to help ensure that material information is: (1) gathered and communicated to our management, including our principal executive and financial officers, on a final settlement paymenttimely basis; and (2) recorded, processed, summarized, reported and filed with the SEC as required under the Securities Exchange Act of $225,000, as all of its claims under theVitamin Antitrust Litigation were settled.

The Company was a party to a lawsuit filed in January 2000 against its former President, Director1934.

Our Chief Executive Officer and Chief Financial Officer evaluated the effectiveness of our disclosure controls and others. In November 2001,procedures as of June 30, 2005. Based on their evaluation, they concluded that our disclosure controls and procedures were effective for their intended purpose described above. There were no changes to our internal controls during the parties mutually resolved their disputes with each other, dismissed all pending claims against one another and entered into a confidential settlement agreement.

The Company is involved in various claims and legal actions arising in the ordinary course of business. In the opinion of management, after consultation with its legal counsel, the ultimate disposition of these matters will not have a material adverse effect on the Company’s consolidated financial position, results of operations or liquidity.
N.    Segment Information
Prior to July 1, 1999 the Company operated solely within the United States. During the yearfourth quarter ended June 30, 20002005 that have materially affected, or that are reasonably likely to materially affect, our internal controls.

ITEM 9B. OTHER INFORMATION

None.

PART III

ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS

The information for this item is incorporated by reference to the Company opened its new wholly owned manufacturing subsidiarysections “Our Board of Directors,” “Our Executive Officers,” “Section 16(a) Beneficial Ownership Reporting Compliance,” and “Code of Ethics” in Switzerland. our definitive proxy statement for our Annual Meeting of Stockholders to be held on December 2, 2005, to be filed on or before October 28, 2005.

ITEM 11. EXECUTIVE COMPENSATION

The Company’s segment information for this item is incorporated by geographic areareference to the sections “Director Compensation” and “Executive Officer Compensation” in our definitive proxy statement for our Annual Meeting of Stockholders to be held on December 2, 2005, to be filed on or before October 28, 2005.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

The information for this item is incorporated by reference to the sections “Stock Holdings of Certain Owners and Management” and “Securities Authorized for Issuance Under Equity Compensation Plans” in our definitive proxy statement for our Annual Meeting of Stockholders to be held on December 2, 2005, to be filed on or before October 28, 2005.

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

The information for this item is incorporated by reference to the section “Certain Relationships and Related Transactions” in our definitive proxy statement for our Annual Meeting of Stockholders to be held on December 2, 2005, to be filed on or before October 28, 2005.

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES

The information for this item is incorporated by reference to the sections “Audit Fees,” “Audit-Related Fees,” “Tax Fees,” “All Other Fees” and “Pre-Approval Polices and Procedures” in our definitive proxy statement for our Annual Meeting of Stockholders to be held on December 2, 2005, to be filed on or before October 28, 2005.

PART IV

ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

The following documents are filed as part of this report:

(1)Financial Statements. The financial statements listed below are included under Item 8 of this report:

Consolidated Balance Sheets as of June 30, 2005 and 2004;

Consolidated Statements of Income and Comprehensive Income for the years ended June 30, 2002, 20012005, 2004 and 2000, respectively, is as follows (dollars in thousands):
2002

  
Sales

  
Long Lived Assets

  
Total Assets

  
Capital Expenditures

United States  $41,807  $11,450  $24,290  $720
Europe   8,230   1,527   3,220   356
   

  

  

  

   $50,037  $12,977  $27,510  $1,076
   

  

  

  

2001

  
Sales

  
Long Lived Assets

  
Total Assets

    
Capital Expenditures

United States  $34,639  $12,678  $22,674    $605
Europe   7,519   1,370   2,394     355
   

  

  

    

   $42,158  $14,048  $25,068    $960
   

  

  

    

2000

  
Sales

  
Long Lived Assets

  
Total Assets

  
Capital Expenditures

United States  $44,429  $14,560  $32,006  $3,742
Europe   3,398   1,267   2,869   1,419
   

  

  

  

   $47,827  $15,827  $34,875  $5,161
   

  

  

  

2003;

43Consolidated Statements of Stockholders’ Equity for the years ended June 30, 2005, 2004 and 2003;


NATURAL ALTERNATIVES INTERNATIONAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)Consolidated Statements of Cash Flows for the years ended June 30, 2005, 2004 and 2003; and

O.    Quarterly Data (unaudited)
The following is a summary of unaudited quarterly data:
   
Year Ended June 30, 2002

   
1st Quarter

   
2nd Quarter

  
3rd Quarter

  
4th Quarter

  
Total

   
(Amounts in thousands, except per share amounts)
Net sales  $9,887   $12,655  $12,843  $14,652  $50,037
Gross profit   2,024    2,706   2,887   3,352   10,969
Net income (loss)  $(658)  $64  $759  $3,714  $3,879
Net income (loss) per common share:                     
Basic  $(0.11)  $0.01  $0.13  $0.64  $0.67
Diluted  $(0.11)  $0.01  $0.13  $0.64  $0.67
   
Year Ended June 30, 2001

 
   
1st Quarter

  
2nd Quarter

  
3rd Quarter

   
4th Quarter

   
Total

 
   
(Amounts in thousands, except per share amounts)
 
Net sales  $10,223  $11,240  $10,341   $10,354   $42,158 
Gross profit   2,011   2,845   2,290    1,042    8,188 
Net income (loss)  $205  $443  $(234)  $(5,303)  $(4,889)
Net income (loss) per common share:                       
Basic  $0.04  $0.08  $(0.04)  $(0.93)  $(0.85)
Diluted  $0.04  $0.08  $(0.04)  $(0.93)  $(0.85)
Notes to Consolidated Financial Statements.

44
(2)Financial Statement Schedule. The following financial statement schedule is included under Item 8 of this report:


Schedule II
NATURAL ALTERNATIVES INTERNATIONAL, INC.
- Valuation and Qualifying Accounts
For The Years Ended for the years ended June 30, 2002, 20012005, 2004 and 2000
     
Allowance for doubtful accounts

     
Balance at beginning of period

  
Provision

     
(Deductions)

     
Balance at end of period

     
(Dollars in thousands)
2002    $470  $(58)    $(307)    $105
2001    $330  $286     $(146)    $470
2000    $472  $389     $(531)    $330
See accompanying independent auditors report.2003.

45
(3)Exhibits. The following exhibit index shows those exhibits filed with this report and those incorporated by reference:


EXHIBIT INDEX

Exhibit
Number


Description


Incorporated By Reference To


3(i)Amended and Restated Certificate of Incorporation of Natural Alternatives International, Inc. filed with the Delaware Secretary of State on January 14, 2005Exhibit 3(i) of NAI’s Quarterly Report on Form 10-Q for the quarterly period ended December 31, 2004, filed with the commission on February 14, 2005
3(ii)By-laws of Natural Alternatives International, Inc. dated as of December 21, 1990NAI’s Registration Statement on Form S-1 (File No. 33-44292) filed with the commission on December 21, 1992
4(i)Form of NAI’s Common Stock CertificateFiled herewith
10.11999 Omnibus Equity Incentive Plan as adopted effective May 10, 1999, amended effective January 30, 2004, and further amended effective December 3, 2004Exhibit 10.1 of NAI’s Quarterly Report on Form 10-Q for the quarterly period ended December 31, 2004, filed with the commission on February 14, 2005
10.21999 Employee Stock Purchase Plan as adopted effective October 18, 1999Exhibit B of NAI’s definitive Proxy Statement filed with the commission on October 21, 1999
10.3Management Incentive PlanExhibit 10.3 of NAI’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2003, filed with the commission on November 5, 2003
10.4Amended and Restated Employment Agreement dated as of January 30, 2004, by and between NAI and Mark ZimmermanExhibit 10.4 of NAI’s Annual Report on Form 10-K for the fiscal year ended June 30, 2004, filed with the commission on September 14, 2004
10.5Amended and Restated Employment Agreement dated as of January 30, 2004, by and between NAI and Randell WeaverExhibit 10.5 of NAI’s Annual Report on Form 10-K for the fiscal year ended June 30, 2004, filed with the commission on September 14, 2004
10.6Amended and Restated Employment Agreement dated as of January 30, 2004, by and between NAI and Mark A. LeDouxExhibit 10.6 of NAI’s Annual Report on Form 10-K for the fiscal year ended June 30, 2004, filed with the commission on September 14, 2004
10.7Amended and Restated Employment Agreement dated as of January 30, 2004, by and between NAI and John WiseExhibit 10.7 of NAI’s Annual Report on Form 10-K for the fiscal year ended June 30, 2004, filed with the commission on September 14, 2004
10.8Amended and Restated Employment Agreement dated as of January 30, 2004, by and between NAI and John ReavesExhibit 10.8 of NAI’s Annual Report on Form 10-K for the fiscal year ended June 30, 2004, filed with the commission on September 14, 2004
10.9Amended and Restated Employment Agreement dated as of January 30, 2004, by and between NAI and Timothy E. BelangerExhibit 10.9 of NAI’s Annual Report on Form 10-K for the fiscal year ended June 30, 2004, filed with the commission on September 14, 2004
10.10Amended and Restated Exclusive License Agreement effective as of September 1, 2004 by and among NAI and Dr. Reginald B. CherryExhibit 10.11 of NAI’s Annual Report on Form 10-K for the fiscal year ended June 30, 2004, filed with the commission on September 14, 2004

10.11Exclusive License Agreement effective as of September 1, 2004 by and among NAI and Reginald B. Cherry Ministries, Inc.Exhibit 10.12 of NAI’s Annual Report on Form 10-K for the fiscal year ended June 30, 2004, filed with the commission on September 14, 2004
10.12First Amendment to Exclusive License Agreement effective as of December 10, 2004 by and among NAI and Reginald B. Cherry Ministries, Inc.Exhibit 10.3 of NAI’s Quarterly Report on Form 10-Q for the quarterly period ended December 31, 2004, filed with the commission on February 14, 2005
10.13Lease of Facilities in Vista, California between NAI and Calwest Industrial Properties, LLC, a California limited liability company dated October 27, 2003Exhibit 10.10 of NAI’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2003, filed with the commission on November 5, 2003
10.14Credit Agreement dated as of May 1, 2004 by and between NAI and Wells Fargo Bank, National AssociationExhibit 10.11 of NAI’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2004, filed with the commission on May 17, 2004
10.15First Amendment to Credit Agreement dated as of February 1, 2005 by and between NAI and Wells Fargo Bank, National AssociationExhibit 10.1 of NAI’s Current Report on Form 8-K dated February 1, 2005, filed with the commission on February 7, 2005
10.16Form of Indemnification Agreement entered into between NAI and each of its directorsExhibit 10.15 of NAI’s Annual Report on Form 10-K for the fiscal year ended June 30, 2004, filed with the commission on September 14, 2004
10.17Amended and Restated Exclusive License Agreement effective as of February 5, 2003, by and among NAI, Chopra Enterprises, LLC, Deepak Chopra, M.D., and David Simon, M.D.Exhibit 10.16 of NAI’s Annual Report on Form 10-K for the fiscal year ended June 30, 2004, filed with the commission on September 14, 2004
10.18Lease of Facilities in Manno, Switzerland between NAIE and Mr. Silvio Tarchini dated May 9, 2005 (English translation)Exhibit 10.19 of NAI’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2005, filed with the commission on May 13, 2005
10.19Lease of Facilities in Manno, Switzerland between NAIE and Mr. Silvio Tarchini dated July 25, 2003 (English translation)Filed herewith
10.20Lease of Facilities in Manno, Switzerland between NAIE and Mr. Silvio Tarchini dated June 8, 2004 (English translation)Filed herewith
10.21Lease of Facilities in Manno, Switzerland between NAIE and Mr. Silvio Tarchini dated February 7, 2005 (English translation)Filed herewith
10.22License Agreement effective as of April 28, 1997 by and among Roger Harris, Mark Dunnett and NAIFiled herewith
10.23Amendment to License Agreement effective as of March 17, 2001 by and among Roger Harris, Mark Dunnett and NAIFiled herewith
21Subsidiaries of the CompanyFiled herewith
23.1Consent of Independent Registered Public Accounting FirmFiled herewith

31.1Rule 13a-14(a)/15d-14(a) Certification of Chief Executive OfficerFiled herewith
31.2Rule 13a-14(a)/15d-14(a) Certification of Chief Financial OfficerFiled herewith
32Section 1350 CertificationFiled herewith

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, Natural Alternatives International, Inc., the registrant, has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: September 8, 2005

NATURAL ALTERNATIVES INTERNATIONAL, INC.
(Registrant)
NATURAL ALTERNATIVES INTERNATIONAL, INC.
Date: September 20, 2002By: 

/s/ MARKMark A. LEDOUX        

LeDoux


  
(Mark A. LeDoux, Chief Executive Officer)
By:
/s/    RANDELL WEAVER        

(Randell Weaver, Chief Financial Officer)
Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant andNatural Alternatives International, Inc., in the capacities and on the dates indicated.

Signature


  

Title


 

Date


/s/ MARKMark A. LEDOUX        

LeDoux


(Mark A. LeDoux)

  

Chief Executive Officer and

Chairman of the Board of Directors

(principal executive officer)

 September 20, 20028, 2005

/s/ John R. Reaves


(John R. Reaves)

  
/s/    JOE E. DAVIS        

Chief Financial Officer

(Joe E. Davis)

Directorprincipal financial officer and

principal accounting officer)

 September 20, 20028, 2005

/s/ Joe E. Davis


(Joe E. Davis)

  
/s/    LEE G. WELDON        

(Lee G. Weldon)

Director

 September 20, 20028, 2005

/s/ Alan G. Dunn


(Alan G. Dunn)

  
/s/    J. SCOTT SCHMIDT        

(J. Scott Schmidt)

Director

 September 20, 20028, 2005

/s/ Alan J. Lane


(Alan J. Lane)

Director

September 8, 2005

/s/ Lee G. Weldon


(Lee G. Weldon)

Director

September 8, 2005

46

52